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There is convincing evidence that myocardial intracellular Na+ overload ([Na]i) and 
metabolic derangement are two important and interconnected pathophysiological 
features of heart failure. Whether [Na]i elevation plays a causative role in ATP supply-
demand mismatching in the heart is unknown. A number of mitochondrial enzymes are 
stimulated by mitochondrial calcium (Cam) during contraction thereby sustaining 
production of reducing equivalents to maintain ATP supply. It is postulated that this 
stimulation is perturbed when [Na]i is high due to increased Cam efflux and that this 
may be linked with derangement in ATP supply-demand matching. 
This thesis tests the hypothesis that [Na]i elevation alters intermediary metabolism and 
energetics in the isolated perfused heart from healthy rats. [Na]i elevation was induced 
by perfusion with the Na+/K+ ATPase (NKA) inhibitor, ouabain, and measured in real-
time using triple quantum filtered (TQF) 23Na nuclear magnetic resonance (NMR) 
spectroscopy. Blebbistatin was used to transiently uncouple inotropy to better elucidate 
[Na]i-dependent from inotropy-dependent effects on metabolism and energetics. Real-
time 31P NMR measurements showed a transient increase or decrease in both PCr and Pi 
that mirrored a transient increase or decrease in inotropy. However PCr levels returned 
to baseline at the end of the protocol while there was a strong negative correlation 
between [Na]i and [ATP] independent of inotropy. End-point metabolomics were 
assessed using high resolution 1H NMR and liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Malate (and more tentatively fumarate) were elevated, 




Increased 13C  incorporation from [U]-13C-glucose inferred higher TCA cycle activity in 
hearts with [Na]i overload in the absence of elevated inotropy. 
This thesis supports that [Na]i elevation can cause ATP supply-demand mismatching in 
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If you can keep your head when all about you 
Are losing theirs and blaming it on you, 
If you can trust yourself when all men doubt you, 
But make allowance for their doubting too; 
If you can wait and not be tired by waiting, 
Or being lied about, don’t deal in lies, 
Or being hated, don’t give way to hating, 
And yet don’t look too good, nor talk too wise: 
 
If you can dream—and not make dreams your master; 
If you can think—and not make thoughts your aim; 
If you can meet with Triumph and Disaster 
And treat those two impostors just the same; 
If you can bear to hear the truth you’ve spoken 
Twisted by knaves to make a trap for fools, 
Or watch the things you gave your life to, broken, 
And stoop and build ’em up with worn-out tools: 
 
If you can make one heap of all your winnings 
And risk it on one turn of pitch-and-toss, 
And lose, and start again at your beginnings 
And never breathe a word about your loss; 
If you can force your heart and nerve and sinew 
To serve your turn long after they are gone, 
And so hold on when there is nothing in you 
Except the Will which says to them: ‘Hold on!’ 
 
If you can talk with crowds and keep your virtue, 
Or walk with Kings—nor lose the common touch, 
If neither foes nor loving friends can hurt you, 
If all men count with you, but none too much; 
If you can fill the unforgiving minute 
With sixty seconds’ worth of distance run, 
Yours is the Earth and everything that’s in it, 
And—which is more—you’ll be a Man, my son! 
  
By Rudyard Kipling. 
 
 
In loving memory of Walter Nunn.
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Approximately 500,000 people are currently living with heart failure (HF) in the UK 
(Townsend et al., 2015). It is a life-threatening condition and, with an ageing 
population, incidence rates are likely to increase further. The identification of novel 
pharmacological approaches for HF remains an area of unmet need. There is convincing 
evidence that myocardial intracellular Na+ ([Na]i) overload and metabolic derangement 
are two important and interconnected pathophysiological features of this disease. 
Maintenance of both normal [Na]i and contractile function are energy requiring 
processes. Perturbations in ATP supply will subsequently lead to [Na]i elevation and 
contractile dysfunction, and eventually to loss of ionic homeostasis and cell death. 
However, the reverse relationship is less well understood. Whether [Na]i elevation also 
plays a causative role in ATP supply-demand mismatching in the heart has received 
increased interest over the past decade or so (Murphy and Eisner, 2009). The work 
presented here in the Langendorff perfused heart model investigates whether [Na]i 
elevation can lead to alterations in metabolism and ATP supply-demand matching 
independent of increased contractile demand and whether the tricarboxylic acid (TCA) 






1.2  Na transport & excitation-contraction coupling in the healthy heart. 
Maintaining intracellular Na+ homeostasis is imperative for normal functioning of the 
heart, particularly with respect to the cardiac action potential and excitation-contraction 
coupling. 
 
1.2.1 The cardiac action potential. 
Upon stimulation of the ventricles by an action potential, voltage-gated Na+ channels 
open and the sarcolemma depolarises from around -90mV to approximately +25mV. An 
influx of Ca2+ from the extracellular space into the cytoplasm occurs via sarcolemmal 
L-type Ca2+ channels which leads to the opening of intracellular Ca2+-gated calcium 
channels (ryanodine receptors) of the sarcoplasmic reticulum (SR), increasing the 
intracellular calcium concentration ([Ca]i) further. The forward mode of the 
sarcolemmal sodium-calcium exchanger (NCX) is subsequently activated and one Ca2+ 
ion is extruded in exchange for three Na+ ions. K+ ions are then extruded from the 
cytocosol via sarcolemmal K+ channels and the membrane potential falls to 
approximately -80mV.  This membrane potential is set by the K+ gradient which is 
maintained via the simultaneous extrusion of three Na+ ions and influx of two K+ ions 






1.2.2 Structure and regulation of NKA 
Under physiological conditions, NKA is the most important efflux pathway for [Na]i in 
the heart. NKA has quaternary structure encompassing an α-subunit (consisting of four 
isoforms: α1, α2, α3 and α4), a β-subunit (consisting of three isoforms: β1, β2 and β3) 
and a FXYD protein (phospholemman, PLM) (Kaplan, 2002, Sweadner, 1989, 
Sweadner and Rael, 2000). The α subunit spans the sarcolemma and houses binding 
sites for Na+, K+ and ATP as well as cardiotonic steroids which regulate NKA function 
(discussed in Section 1.2.5). The β subunit is required for trafficking of the protein to 
the sarcolemma following its synthesis (Geering, 1991). The isoform profiles of these 
subunits are species dependent. For example, α1 and α2 predominate in the rat (Hensley 
et al., 1992) whereas only α1 and α3 are present in canine (Sweadner et al., 1994). It is 
estimated that the human isoform stoichiometry is α1 (62%), α2 (15%) and α3 (23%) 
(Zahler et al., 1992). In recent years, there has been increased interest in the PLM 
subunit of NKA owing to its ability to regulate NKA catalytic activity (Figure 1.1). In 
the unphosphorylated form, PLM decreases NKA activity and this inhibition is negated 
following phosphorylation of PLM by protein kinase A (PKA) at Ser68 and by PKC at 
Ser63, Ser68 and Ser/Thr69. For an extensive review of cardiac NKA regulation 






Figure 1.1  Schematic linking the regulation of Na+/K+ ATPase (NKA) by 
phospholemman (PLM) to their structures. 
The NKA α subunit (green) has a lower capacity for [Na]i extrusion when PLM is in the 
unphosphorylated active form (left panel) compared with the inactive phosphorylated 
form (right panel). Image taken from Pavlovic et al. (2013a) 
 
 
1.2.3 Excitation-contraction coupling in the healthy heart. 
The functional consequence of the action potential is the triggering of myocardial 
contraction referred to as ‘excitation-contraction (EC) coupling’ (summarised in Figure 
1.2). Calcium-induced calcium release by the SR during the action potential elevates 






Figure 1.2  Schematic summary of cardiac excitation-contraction coupling.
The action potential involves numerous ion movements across the sarcolemma which 
lead to calcium-induced calcium release by the sarcoplasmic reticulum and increased 
myofilament contraction. During diastole, this excess systolic calcium is removed from 
the cytosol via SERCA (which is regulated by PLB), as well as by NCX and the 
mitochondrial uniporter (pink cylinder). Abbreviations: AP (action potential); 
sarcoendoplasmic reticulum Ca2+ ATPase (SERCA); sarcolemmal Na+/Ca2+ exchanger 
(NCX); sarcolemmal Na+/K+ ATPase (NKA); phospholamban (PLB); ryanodine receptor 
type 2 (RyR). Image taken from Bers (2002). 
 
 
dyadic cleft. This leads to elevated [Ca]i at the myofilaments, as well as in mitochondria 
(discussed in Section 1.6). Myofilament contraction (inotropy) during systole is 
dependent upon both Ca2+ binding to troponin C in order that cross-bridge cycling can 
occur (Hajjar et al., 2000) and on the release of free energy from adenosine triphosphate 





diastole, Ca2+ is mainly removed from the cytosol via the SR Ca2+-ATPase (SERCA), 
NCX and the mitochondrial Ca2+ uniporter. 
 
1.2.4 Other modes of Na+ transport in the healthy heart. 
Under physiological conditions, NKA is the only quantitatively significant efflux 
pathway of Na+ in the myocyte (NCX and Na+/HCO3-/Cl- symporter can, in principle, 
reverse and efflux Na+). However, there are numerous Na+ influx pathways. These 
include the Na+/H+ exchanger (NHE) and the Na+/K+/2Cl- symporter which are both 
electroneutral whereas the Na+/PO3- symporter, the Na+/glucose symporter, the 
Na+/HCO3-/Cl- symporter and the Na+/Mg2+ exchanger are all electrogenic. These 
proteins influx much smaller amounts of Na+ than NCX and Na+ channels (Despa and 
Bers, 2013, Gray et al., 2001, Yao et al., 1998, Cook et al., 1997) and are therefore 
generally deemed less important in EC coupling.  A schematic summary of cardiac Na+ 
transport is shown in Figure 1.3 with reference to EC coupling (Section 1.2.3), 
mitochondrial function (Section 1.3.2) and Na+ overload (Section 1.4). 
 
1.2.5 Regulation of cardiac contractility and [Na]i 
The heart has several mechanisms by which it can modulate its contractility in response 
to changes in the demand for blood supply, for instance, during exercise.  
The Frank-Starling effect is the primary mechanism for increasing contraction. There 






Figure 1.3  Schematic summary of the main cardiac Na+ transporters.
Na+ transport is tightly linked to Ca2+ and excitation-contraction coupling. Abbreviations: 
action potential duration (APD); Na+/bicarbonate symporter (NBC); sarcolemmal 
Na+/Ca2+ exchanger (NCX); Na+/H+ exchanger (NHE); Na+/K+/2Cl- symporter (Na/K/2Cl-
); sarcolemmal Na+/K+ ATPase (NKA); Na+/Mg2+ exchanger (Na-MgX); phospholamban 
(PLB); phospholemman (PLM); ryanodine receptor type 2 (RyR); sarcoendoplasmic 
reticulum Ca2+ ATPase (SERCA); sarcoendoplasmic reticulum (SR).  Image taken from 
Despa and Bers (2013). 
 
overlap and increased cross bridge-cycling availability (Huxley and Niedergerke, 1954, 
Huxley and Hanson, 1954), changes in troponin C Ca2+ affinity (Kobirumaki-
Shimozawa et al., 2014), β-arrestin modulation (Abraham et al., 2016) and PKG-





Sympathetic and parasympathetic activation are also important modulators of 
contractility, for example, via (de)phosphorylation of phospholamban (unphosphory-
lated form inhibits Ca2+ uptake by SERCA) (Mattiazzi et al., 2005), sensitisation of 
troponin-C to Ca2+ on the myofilaments (Haikala et al., 1995), (de)phosphorylation of 
L-type Ca2+ channels (phosphorylated form has increased Ca2+ permeability) 
(Trautwein and Hescheler, 1990) and the Anrep effect (increase in afterload increases 
inotropy). Interestingly, it has been suggested that the latter mechanism involves [Na]i 
elevation mediated by paracrine changes (reviewed by Cingolani et al., 2013). 
Increases in heart rate (chronotropy) lead to elevated inotropy via the Bowditch effect 
(Zhang et al., 2015). This is due to increased action potential frequency leading to an 
enhanced time-averaged Ca2+ in the cytosol and SR as NCX has less time to extrude the 
surplus [Ca]i (Figure 1.2). There is a second postulated mechanism for the Bowditch 
effect that is [Na]i-dependent and thought to be specific to the electrically-paced 
isolated heart preparation. That is, an increased action potential frequency leads to an 
elevated time-averaged [Na]i as NKA has less time to efflux the additional [Na]i. This 
decreases NCX forward mode thereby increasing the time-averaged [Ca]i and 
contractility. 
As the majority of isolated heart experiments are free of catecholamines in the perfusate 
this effect may only occur in the absence of β-receptor stimulation, thus it is unlikely 
that this mechanism occurs in vivo in which positive chronotropy only occurs during β-
receptor stimulation. This is supported by the work of Despa et al. (2008) using isolated 







Figure 1.4  Ouabain dose-response curves in isolated heart. 
(A) Rat. (B) Guinea pig. Experimental data is mean ± SEM (solid line is computational 







A more established in vivo example of the use of [Na]i elevation to increase contractility 
is the administration of cardiac glycosides to HF patients. These are steroidal-like 
compounds found endogenously under normal conditions and are elevated in patients 
with renal failure (Kolmakova et al., 2011) and HF (Kennedy et al., 2015). Examples 
include ouabain, digoxin and bufalin (Schoner, 2001). Their clinical use for HF is 
limited due to their proarrhythmic properties (Gonano et al., 2011, Ferrier, 1977) but are 
useful for elevating [Na]i in experimental models. Cardiac glycosides elevate [Na]i via 
direct NKA inhibition and their positive inotropic response can vary considerably 
between species, for example, in the rat versus the guinea pig (Figure 1.4). 
Cardiac [Na]i can also be elevated by several other factors. For example, by increased 
pH via enhanced NHE activity as seen, for example, following ischaemia-reperfusion 
injury (Murphy and Allen, 2009). Furthermore, Shattock (1984) showed that  
myocardial [Na]i is elevated during hypothermia. This is due to decreased NKA enzyme 
activity (and thereby reduced [Na]i efflux) at lower temperatures (Isenberg and 
Trautwein, 1975, Eisner and Lederer, 1980). 
In terms of increasing [Na]i efflux, sympathetic stimulation has been demonstrated to 
stimulate NKA α1 and α2 isoforms (Glitsch, 2001, Bossuyt et al., 2009) which increases 
the Na outward current thereby keeping [Na]i at baseline. Over the last decade, there has 
been an increased interest in the regulation of NKA activity by the protein, 
phospholemman (PLM) (reviewed by Fuller et al., 2013 and Pavlovic et al., 2013). 
Following β-adrenergic stimulation, protein kinase A (PKA) phosphorylates PLM 
which reduces its inhibition of NKA thereby increasing [Na]i efflux. PLM can also be 





demonstrated that this phosphorylation is increased by nitric oxide (Pavlovic et al., 
2013b). 
For a summary of measured cardiac [Na]i values in different species under physiological 
and pathophysiological conditions see Section 1.4 (Table 1.1). 
Throughout this thesis, inhibition of NKA is carried out using ouabain in order to 
elevate [Na]i. As discussed later, a key issue with this approach is that the associated 
positive inotropic effect leads to increased ATP demand (discussed in Section 1.3.1) 
which in turn may induce metabolic changes that are independent of a reduction in ATP 
supply due to [Na]i overload. This is an important example of the close relationship 
between [Na]i and metabolism in the heart and is a central concept in this thesis. 
 
1.3 ATP supply-demand matching in the healthy heart. 
1.3.1 ATP demand in the healthy heart. 
The heart has an immense requirement for ATP in order to sustain cardiac output and 
ion homeostasis. According to Gibbs (2003), 70-75% of ATP is used for force 
generation and work output with the remaining 25-30% being used for basal 
metabolism. With respect to force generation, it is estimated that the actomyosin 
ATPase accounts for 76% of ATP utilisation with SERCA accounting for 15% and 
NKA accounting for 9% (Schramm et al., 1994). Experiments in non-beating hearts 
permit the estimation of cardiac basal metabolism, which is significantly higher than 
that of other organs such as skeletal muscle (Gibbs, 2003). Under these conditions, it is 





the maintenance of the mitochondrial membrane potential and the remaining 70% is for 
mitochondrial ATP synthesis to fuel, for example, protein synthesis (20-25%), 
transmembrane Na+ homeostasis (20%) and Ca2+ homeostasis (5%) (Gibbs and Loiselle, 
2001). 
 
1.3.2 ATP supply in the healthy heart. 
In order to maintain ATP levels, the heart must constantly and dynamically produce and 
recycle vast quantities of this molecule (approximately 6 kg / day in the human heart 
and this is achieved by the regulation of a complex network of metabolic reactions 
(reviewed in Kolwicz et al., 2013). A summary of these metabolic pathways is shown in 
Figure 1.5. 
The heart has a high degree of substrate flexibility. Under normal conditions, the heart 
uses free fatty acids (FFAs), glucose and lactate as the main fuel substrates for 
cataplerosis (ATP generation) and typically in the ranges of 60-90%, 5-20% and 5-20%, 
respectively (Gertz et al., 1988, Stanley et al., 1997, Wisneski et al., 1985a, Wisneski et 
al., 1985b, Wisneski et al., 1990). These ranges are a reflection of the greater molar 
ATP yield per carbon atom of FAs compared with carbohydrates (Darvey, 1999).  
During increased exercise, however, glucose and lactate predominate over FAs as fuel 
substrates (Taegtmeyer et al., 1980) because they produce more moles of ATP per mole 
of oxygen uptake relative to FAs. On a theoretical basis, the ATP-to-oxygen ratios for 






Figure 1.5  Schematic summary of cardiac metabolism.  
Cardiac metabolism can be divided into three stages: 1) substrate utilisation: fuel 
substrates such as glucose and free fatty acids are transported into the cytosol and 
subsequently converted into acetyl-CoA in the mitochondrion thereby driving the 
tricarboxylic acid (TCA) cycle which produces the reducing equivalents, nicotinamide 
adenine dinucleotide (NADH) and flavine adenine dinucleotide (FADH2). 2) oxidative 
phosphorylation: NADH and FADH2 from the TCA cycle feed electrons into the respiratory 
chain (containing electron transport chain complex I-V) thereby generating a proton 
gradient across the inner mitochondrial membrane which drives the production of ATP by 
ATP synthase. 3.) creatine kinase (CK) energy shuttling: ATP leaves the mitochondrion via 
the adenine nucleotide transporter (ANT) or by mitochondrial CK (CKmito) thereby 
producing phosphocreatine (PCr). Intermyofibrillar CK (CKMM) converts this PCr into ATP 
which is hydrolysed to produce free energy for contraction. Abbreviations: GLUT (glucose 






This aligns with the work of Mjos (1971) showing that administration of triglycerides 
increases FA uptake in dog leading to increased myocardial oxygen consumption but no 
change in ATP or left ventricular pressure. The apparent opposing relationship between 
glucose and FAs in the heart is, in part, due to the Randle cycle. This involves the 
competition between FFA and glucose for intermediary substrates, whereby FFA-
derived cytosolic citrate and mitochondrial acetyl CoA inhibits glycolysis and pyruvate 
dehydrogenase (PDH), respectively (reviewed by Hue and Taegtmeyer, 2009). FFAs 
and carbohydrates are not the only fuel substrates available to the cardiomyocyte. 
Ketone bodies can also be absorbed from the bloodstream and converted into acetyl 
CoA when carbohydrate availability is very low (Forsey et al., 1987). 
The TCA cycle is a central component of intermediary metabolism in the heart and is 
vital to the generation of ATP (via the production of reducing equivalents). The heart 
uses other molecules in addition to acetyl CoA as a carbon source for the TCA cycle 
(for example, amino acids such as glutamate and aspartate) via the process of 
anaplerosis (Figure 1.6). The TCA cycle also plays a role in cataplerosis (biosynthesis) 
of amino acids and fats. Each turn of the TCA cycle produces three molecules of NADH 
and one molecule of FADH2 which feed electrons into the respiratory chain (the 
electron transport chain). Two molecules of CO2 are also produced which are converted 
to bicarbonate and removed as a by-product via the bloodstream. The respiratory chain 
consists of five protein complexes. Complexes I (NADH dehydrogenase) and II 
(succinate dehydrogenase) are reduced by NADH and FADH2, respectively. Protons are 
translocated into the intermembrane space to generate a proton gradient across the 





IV (cytochrome c oxidase). Complex IV transfers electrons to molecular oxygen 
supplied from the bloodstream to form H2O as a by-product of the respiratory chain. 
Complex V (F1F0 ATPase; ATP synthase) uses the proton gradient to produce ATP via 
the condensation of ADP, inorganic phosphate (Pi) and a proton. 
Mitochondrial respiration accounts for greater than 95% of ATP supply in the heart 
(Kolwicz et al., 2013). The remainder is synthesised during glycolysis in which there is 
a net gain of 2 molecules of ATP. The end products of glycolysis are pyruvate and 
lactate which exist in equilibrium, although this equilibrium can shift towards lactate 
production during increased workload (Goodwin et al., 1998).  
As the key sites of ATP utilisation are extramitochondrial (discussed in Section 1.3.1), 
the ATP is transported out of the mitochondrion in exchange for ADP by the adenine 
nucleotide translocator (ANT). Mitochondrial creatine kinase (CK) (which resides on 
the outside of the inner mitochondrial membrane and in close proximity to ANT) uses 
this ATP as a substrate in order to produce phosphocreatine (PCr) and ADP and 
cytosolic CK converts PCr back to ATP at the myofilaments (Guzun et al., 2015, 
Lipskaya, 2001). PCr is known to diffuse significantly faster through the cytosol than 
ATP (Wyss et al., 1992) and thus the CK shuttle accelerates the transfer of energy from 
the mitochondria to the sites of utilisation. Another phosphotransfer enzyme involved in 
ATP supply is adenylate kinase (interconversion of ATP + AMP  2ADP). The 
importance of this enzyme in the maintenance of ATP supply is highlighted by the work 







Figure 1.6  Schematic of the TCA cycle and converging metabolic pathways.  
Note that the diagram is not an exhaustive summary of intermediary metabolism. For 
example, fatty acid metabolism is not included. Image taken from Robinson (2015). 
 
 
1.3.3 Regulation of ATP supply-demand matching in the healthy heart. 
The regulation of cardiac metabolism has been extensively studied since the 1950s yet 
is still an area of active research. Indeed, it is widely accepted that the heart comprises 
several mechanisms by which it orchestrates metabolism in order to match ATP supply 
to demand. One of the early mechanisms to be suggested was positive feedback by ADP 





activate isocitrate dehydrogenase (IDH) (Vaughan and Newsholm, 1969, Nichols et al., 
1994). However, Balaban (2009) argues that the only mitochondrial enzyme regulated 
by ADP in vivo is ATP synthase which is via a direct interaction and only occurs in the 
presence of Pi.  
When Pi is added alone to cardiac mitochondria, there are increases in the concentration 
of NADH, the mitochondrial membrane potential and the activity of the electron 
transport chain (ETC). Bose et al (2003) suggested that this is due to the stimulation of 
α-ketoglutarate dehydrogenase (αKDH) (Rodriguez-Zavala et al., 2000), IDH 
(Hansford, 1972) and malate dehydrogenase (MDH) (Blonde et al., 1967) by Pi. 
Isolated enzyme experiments have revealed that PDH (Denton et al., 1972, Siess, 1972) 
and αKDH (McCormack and Denton, 1979) are activated by increased levels of Ca2+ in 
the physiological range (10-1000 nM). Ca2+ also reduced the Km of IDH in this study 
although there was no influence on the Vmax. Nonetheless, this may be a key Ca2+-
dependent point of regulation given that IDH is the rate limiting enzyme of the TCA 
cycle. In isolated mitochondria, an increase from sub-physiological to physiological 
Ca2+ caused marked increases in state 3 respiration (Moreno-Sanchez, 1985). Other 
postulated points of Ca2+ activation include ANT (Moreno-Sanchez, 1983), ATP 
synthase (Harris and Das, 1991), ETC (Murphy et al., 1990), ATP-Mg2+/Pi carrier (del 
Arco and Satrustegui, 2004, Nosek et al., 1990) and aspartate/glutamate exchangers 
(citrin and aralar) (Palmieri et al., 2001, Contreras et al., 2007, Marmol et al., 2009). 
The dependence of oxidative phosphorylation on Ca2+ has also been demonstrated ex 
vivo by Wu et al (1992) using Langendorff perfused rat hearts, oxygen probes and 





have an additive effect on oxidative phosphorylation. At present, the best evidence that 
Ca2+ partially regulates cardiac energetics is that perfusion of the rat heart with 
ruthenium red (which reduces Ca2+ entry into the mitochondrial matrix via inhibition of 
the mitochondrial Ca2+ uniporter) results in compromised concentrations of high energy 
phosphates (HEPs) measured by 31P NMR and are unable to maintain contractile 
function (Unitt et al., 1989). This study also demonstrated the short term (responsive) 
temporal regulation of cardiac energy metabolism. Following isoprenaline perfusion, 
[ADP] and [Pi] were significantly elevated and reached a maximum after 10-30 seconds, 
subsequently returning to baseline within 120 seconds and [ATP] was not significantly 
altered. However, this recovery period was significantly longer in hearts with perturbed 
[Ca]m uptake.  
The regulation of cardiac metabolism by Ca2+ is summarised in Figure 1.7. Longer-term 
regulation of cardiac metabolism is also regulated by signalling pathways (for example, 
insulin and CD36 for glucose and FA uptake, respectively) and transcriptional pathways 
such as those regulated by peroxisomal proliferator activated receptor (PPAR) leading 
to changes in mitochondrial function and biogenesis. These areas have been reviewed 
comprehensively by Lopaschuk et al  (2008) and Ventura-Clapier et al (2008) but are 







Figure 1.7  Mitochondrial transport of Ca2+ and its regulation of cardiac metabolism.  
Ca2+ enters the mitochondrial matrix via the mitochondrial calcium uniporter (MCU) and is 
extruded by the mitochondrial Na+/Ca2+ exchanger, which is linked to the Na+/H exchanger 
via Na+. Ca2+ positively regulates the glutamate (glut)/aspartate (asp) exchanger, the 
ATP/Pi exchanger, ATP synthase (complex V), pyruvate dehydrogenase (PDH), isocitrate 
dehydrogenase (ICD), α-ketoglutarate dehydrogenase (KDH) and cytochrome bc1 
(complex III). Abbreviations: succinyl coenzyme A synthetase (SCS); succinate 
dehydrogenase/complex II (SDH); malate dehydrogenase (MDH); citrate synthase (CS); 
aconitase (A); NADH dehydrogenase complex (complex I / DH); CoQ (coenzyme Q); 







1.4 Na+ handling is deranged in the hypertrophied/failing heart. 
A hallmark of cardiac hypertrophy and failure is an elevation of the intracellular Na+ 
concentration ([Na]i). There is an abundance of literature on this phenomenon although 
absolute values of measured [Na]i are often dissimilar, probably owing to 
methodological differences. Table 1.1 gives a summary of a selection of these studies 
and allows an approximation to be made of the [Na]i in the myocyte under both 
physiological and pathophysiological conditions across various mammalian species. It 
is known that the rat heart has a higher resting [Na]i than other species. Using SBFI-
loaded rat and rabbit cardiomyocytes, Despa et al (2002) have attributed this species 
difference to a higher Na+ influx due to greater activities of Na+ channels, NHE and 
NCX in the rat with consequential higher NKA activity in this species. 
 
1.4.1 Evidence for reduced Na+ efflux. 
There is strong agreement that Na+ efflux is perturbed in cardiac hypertrophy and HF. 
Semb et al (1998) and Louch et al (2010) used SBFI-loading to show that both the 
maximal activity of NKA and its affinity for [Na]i were reduced in failing 
cardiomyocytes. Moreover, Schwinger et al (1999) reported a decreased expression of 
NKA protein in myocardial samples from patients with heart failure. In a similar study, 
no change in the abundance of NKA RNA transcripts (Allen et al., 1992) was observed 
which may infer that post-transcriptional events occur to NKA that are specific to HF.  
In the failing rat heart, the α2 isoform of NKA was found to be significantly decreased 
whereas the more abundant α1 was unchanged reflecting that of the normal rat heart 





cardiomyocytes express both of these isoforms to a lesser extent than non-failing 
counterparts. The Bossuyt et al. (2005) study also demonstrated that PLM, which 
applies a tonic inhibition of NKA when in its unphosphorylated form (see Pavlovic et 
al., 2013a), exhibits lower overall expression in HF although the fraction of 
phosphorylated PLM was higher in HF. However, work by El-Armouche et al (2011) 
demonstrated a trend toward decreased PLM phosphorylation in failing left ventricular 
samples compared with non-failing controls. The discrepancy in the PLM 
phosphorylation data may be due to the use of different models of HF. That is, in the 
Bossuyt et al. (2005) study an unusual rabbit model of volume overload was utilised 
whereas El-Armouche et al (2011) used left ventricular myocardium from HF patients. 
Correll et al. (2014) reported that overexpression of NKA α2 attenuated cardiac 
hypertrophy, increased Ca2+ extrusion by NCX1 and reduced PLM expression and 
phosphorylation. Moreover, overexpression of PLM reduces NKA activity in failing 
myocytes (Zhang et al., 2006) while knockout of PLM in mice with myocardial 
infarction improves Ca2+ transients and contractile function (Mirza et al., 2012). The 
most convincing evidence thus far that reduced Nai efflux is a causal factor in the 
development of hypertrophy/HF is the work of Boguslavskyi et al (2014), which 
showed that NKA inhibition and cardiac hypertrophy were significantly increased in 
knock-in mice expressing PLM that was unphosphorylatable by protein kinases A and 
C. The potential of targeting PLM therapeutically for cardiac hypertrophy and HF has 







 Table  1.1A  Literature values of (patho)physiological cardiac [Na]i . 
Region measured Species/ Condition [Na]i (mM) Method Used Reference 
Bulk cytosolic Dog/Normal 8.9 Na
+-selective microelectrodes; Purkinje 
fibers at rest. 
Lee and Dagostino 
(1982) 
Bulk cytosolic Dog/Normal 10.4 Na
+-selective microelectrodes; Purkinje 
fibers at 1 Hz. 
Lee and Dagostino 
(1982) 
Bulk cytosolic Ferret/Normal 7.8 Na
+-selective microelectrodes; muscle 
strips at rest. 
Baudet et al. (1991) 
Bulk cytosolic Ferret/RVH1 8.0 Na
+-selective microelectrodes; muscle 
strips at rest2. 
Baudet et al. (1991) 
Bulk cytosolic Guinea-pig/Normal 7.3 Na
+-selective microelectrodes; muscle 
strips at rest. 
Gray et al. (2001) 
Bulk cytosolic Guinea-pig/Normal 6.4 23Na NMR; isolated perfused heart. Jelicks and Siri (1995) 
Bulk cytosolic Guinea-pig/Normal 5.1 SBFI-loaded myocytes at rest. Harrison et al. (1992) 
Bulk cytosolic Guinea-pig/Normal 5.2 SBFI-loaded myocytes at rest. Liu et al. (2008) 
Bulk cytosolic Guinea-pig/Normal 38.3 Flame atomic absorption spectroscopy; isolated perfused hearts, Radford et al. (1998) 
Bulk cytosolic Guinea-pig/Normal 7.5 Na
+-selective microelectrodes; muscle 
strips at rest. 
Wilde and Kleber (1986) 
Bulk cytosolic Guinea-pig/Normal ~6.3 Na
+-selective microelectrodes; muscle 
strips at rest. 
Schmied et al. (1991) 
Bulk cytosolic Guinea-pig/Normal 4.7 Na
+-selective microelectrodes; muscle 
strips at rest. 
Wang et al. (1993) 
Bulk cytosolic Guinea-pig/Normal 8.0 Na
+-selective microelectrodes; atrial 
muscle strips at rest. 
Wang et al. (1993) 
Bulk cytosolic Guinea-pig/Normal 5.8 Na
+-selective microelectrodes; atrial 
muscle strips at rest. 
Cohen et al. (1982) 
Bulk cytosolic Guinea-pig/Normal 7.9 Na
+-selective microelectrodes; atrial 
muscle strips at 0.5 Hz. 
Cohen et al. (1982) 
Bulk cytosolic Guinea-pig/LVH1 12.1 Na
+-selective microelectrodes; muscle 
strips at rest. 
Gray et al. (2001) 
Bulk cytosolic Guinea-pig/LVH1 12.8 23Na NMR; isolated perfused heart. Jelicks and Siri (1995) 
Bulk cytosolic Guinea-pig/Failing 16.8 SBFI-loaded myocytes at rest.  Liu et al. (2008) 
Bulk cytosolic Human/Normal 8.0 SBFI-loaded muscle trips paced at 0.25Hz Pieske et al. (2002) 
Bulk cytosolic Human/MVD 11.8 Na
+-selective microelectrodes; muscle 
strips at rest. 
Gray et al. (2001) 
Bulk cytosolic Human/LVH 14.2 Na
+-selective microelectrodes; muscle 
strips at rest. 
Gray et al. (2001) 
Bulk cytosolic Human/Failing 12.1 SBFI-loaded muscle trips paced at 0.25Hz Pieske et al. (2002) 
 





Table  1.1B  Literature values of (patho)physiological cardiac [Na]i (continued). 
Region measured Species/ Condition 
[Na]i 
(mM) Method Used Reference 
Bulk cytosolic Mouse/Normal 11.6 23Na NMR; isolated perfused heart. Eykyn et al. (2015) 
Bulk cytosolic Mouse/Normal 14 SBFI-loaded myocytes at rest. Boguslavskyi et al. (2014) 
Bulk cytosolic Mouse/LVH1 23 SBFI-loaded myocytes at rest. (Boguslavskyi et al., 2014) 
Bulk cytosolic Rabbit/Normal 7.2 Na
+-selective microelectrodes; muscle 
strips at 0.5 Hz. 
Shattock and Bers 
(1989) 
Bulk cytosolic Rabbit/Normal 4.5 SBFI-loaded myocytes at rest. Despa et al. (2002a) 
Bulk cytosolic Rabbit/Normal 3.8 SBFI-loaded myocytes at rest. Levi et al. (1994) 
Bulk cytosolic Rat/Normal 12.7 Na
+-selective microelectrodes; muscle 
strips at 0.5 Hz. 
Shattock and Bers 
(1989) 
Bulk cytosolic Rat/Normal 28 Na
+-selective microelectrodes; myocytes 
at rest. 
Szabo and Armstrong 
(1984) 
Bulk cytosolic Rat/Normal 30 Na
+-selective microelectrodes; myocytes 
at rest. 
Wasserstrom (1983) 
Bulk cytosolic Rat/Normal 8.5 Na
+-selective microelectrodes; myocytes 
at rest. 
Grupp et al. (1985) 
Bulk cytosolic Rat/Normal 11.1 SBFI-loaded myocytes at rest. Despa et al. (2002a) 
Bulk cytosolic Rat/Normal 10.9 SBFI-loaded myocytes at rest. Levi et al. (1994) 
Bulk cytosolic Rat/Normal 17.5 
23Na NMR; isolated perfused arrested 
hearts. Schepkin et al. (1998) 
Bulk cytosolic Rat/Normal 21 SBFI-loaded myocytes at rest. Donoso et al. (1992) 
Bulk cytosolic Rat/Normal 7.8 SBFI-loaded myocytes at rest. Harrison et al. (1992) 
Mitochondrial Rat/Normal 5.1 SBFI-loaded myocytes at rest. Donoso et al. (1992) 
Bulk cytosolic Sheep/Normal 6.4 Na
+-selective microelectrodes; Purkinje 
fibers at 1 Hz. 
Lee et al. (1980) 
Bulk cytosolic Sheep/Normal ~5 Na
+-selective microelectrodes; Purkinje 
fibers at rest. 
Eisner et al. (1984) 
Bulk cytosolic Sheep/Normal 5.8 Na
+-selective microelectrodes; muscle 
strips at rest. 
Cohen et al. (1982) 
Bulk cytosolic Sheep/Normal 7.9 Na
+-selective microelectrodes; muscle 
strips at rest. 
Cohen et al. (1982) 
 
1Induced by aortic or pulmomary artery constriction. 2Right ventricular tissue was used (left 
ventricular tissue was used if not specified).  Abbreviations: RVH (right ventricular 






Indeed, there are a number of papers reporting a variety of results on the roles of NKA 
and PLM in cardiac hypertrophy and HF in different models. However, the consensus 
appears to support the notion that NKA is either unchanged or down-regulated and that 
the ratio of PLM to NKA α-subunit increases under these conditions which aligns with 
the widely reported decrease in NKA activity. This is further exacerbated by the 
enhanced PLM inhibition of NKA due to a reduction in basal phosphorylation of PLM. 
 
1.4.2 Evidence for elevated Na+ influx. 
In addition to reduced Na+ efflux, increased influx of Na+ is also thought to contribute 
to [Na]i overload in the hypertrophied/failing heart. In failing myocytes from pressure-
overloaded and volume-overloaded rabbit hearts, blocking NKA induces a [Na]i 
elevation that is double that of healthy hearts mainly due to increased tetrodotoxin 
(TTX)-sensitive Na+ channels (Despa et al., 2002b) as well as NHE (Baartscheer et al., 
2003b). Furthermore, [Na]i elevation is reduced by the Na+ channel antagonist, 
ranolazine, leading to an improvement in diastolic function (Sossalla et al., 2008, 
Gremmler and Kisters, 2013) and cariporide, an antagonist of both the late Na+ channel 
and the NHE, delays the onset of HF (Baartscheer et al., 2008). Increased NCX 
expression and activity have also been associated with heart failure in patients 
(Reinecke et al., 1996) which may act as a compensatory mechanism for decreased 
SERCA activity in HF (Murphy and Eisner, 2009). Although NCX is known to operate 
mainly in the forward mode (Cai efflux/Na+ influx) under physiological conditions, 





cardiomyocytes due to the [Na]i elevation, as well as decreased SR [Ca2+] and a 
prolonging of the action potential (Weber et al., 2003). 
 
1.4.3 Consequences of deranged Na+ handling in the hypertrophied/failing heart. 
There is consensus that significant and sustained [Na]i overload is detrimental to the 
heart. The two most severe consequences of pathologic [Na]i elevation are a reduction 
in contractile function (both systolic and diastolic) and the increased risk of arrhythmias 
(Noble and Noble, 2006). These consequences are often attributed to [Ca]i overload and 
the toxicity that arises from this, such as an increased generation of reactive oxygen 
species (Viola and Hool, 2011). 
 
1.5 Metabolism is deranged in the hypertrophied/failing heart. 
In addition to [Na]i overload, derangement in energy metabolism is a common 
pathophysiological feature of cardiac hypertrophy and HF. The report by Herrmann et al 
(1939) was one of the first to explore the chemical nature of HF. Myocardial tissue 
samples from canine hearts following coronary occlusion exhibited reduced levels of 
glycogen, total creatine and creatinine. More recent studies have confirmed metabolic 
derangement in human HF. For example, Starling et al. (1998) showed that ATP and 
NAD(H) were significantly depleted in biopsies from patients with dilated 
cardiomyopathy compared with healthy control hearts. Advances in analytical 
technologies and understanding of metabolic mechanisms have added much weight to 





pathophysiological features of hypertrophy and HF. These alterations can be categorised 
into those related to substrate utilisation, intermediary metabolism and cardiac 
energetics. 
 
1.5.1 Evidence for changes in substrate utilisation during hypertrophy and HF. 
Cardiac hypertrophy and dilated cardiomyopathy induce a switch in substrate utilisation 
from mainly oxidation of FFAs towards mainly glucose oxidation, which is similar to 
the fetal heart (Schisler et al., 2015, Osorio et al., 2002). The onset of this switch (and 
thereby the stage at which it could potentially be targeted therapeutically) is currently 
debated. For example, pressure-overload in the rat heart led to a reduction in palmitate 
oxidation and an elevation in pyruvate oxidation in the early stages of hypertrophy 
(Akki et al., 2008). In contrast, Chandler et al (2004) suggest that this switch only 
occurs following end-stage HF and not during compensated HF. The review by Ritchie 
et al (2006) discussed the potential role that Ca2+ handling plays in the time-course of 
metabolic alterations during hypertrophy. One suggestion is that SERCA preferentially 
uses glycolytically-derived ATP over oxidative phosphorylation (supported by the work 
of Xu et al., 1995) and therefore the heart switches to a more glycolytic phenotype 
during hypertrophy in order to sustain adequate SERCA function and Ca2+ handling. 
This may also be the case for Na+ and/or K+ handling given that NKA is also thought to 
be preferentially fuelled by glycolysis (Sepp et al., 2014). Furthermore, Neubauer et al 
(2007) have highlighted the difficulty in separating the intrinsic alterations in metabolic 
pathways leading to substrate utilisation from those caused by the altered availability of 





temporal regulation of the substrate switch in HF is currently unclear, a recent study 
using transverse aortic constriction in mice showed that this switch can be reversed 
within one week of debanding (Byrne et al., 2016). This finding infers that it may be 
possible to reverse early metabolic alterations in HF but further work on the mechanism 
underlying this reversal is needed.  In spite of the substantial in vitro and pre-clinical 
evidence to support the targeting of the substrate switch therapeutically, there has been 
limited translational success into the clinic. For example, sodium dichloroacetate 
(inhibits PDH kinase thereby increasing pyruvate oxidation) administration (50 mg/kg) 
appeared to improve contractile performance in ten HF patients but a vehicle control 
group was not included in this study (Bersin et al., 1994, Bersin and Stacpoole, 1997). 
Trimetazadine is currently prescribed for longer term inhibition of FFA oxidation and 
has been shown to reduce angina and improve cardiac function in patients with dilated 
cardiomyopathy (Fragasso et al., 2006, Tuunanen et al., 2008) although these 
improvements were modest. Given the limited clinical success of targeting substrate 
utilisation to date, it is important to evaluate the potential of targeting other aspects of 
cardiac metabolism, such as intermediary pathways leading to ATP supply. 
 
1.5.2 Evidence for changes in intermediary metabolism and energetics during 
hypertrophy and HF. 
Several catabolic changes are known to occur downstream of acetyl CoA production in 
the hypertrophied or failing heart. Nemutlu et al (2015) recently carried out 
metabolomic profiling of plasma samples from control and HF patients using gas 





succinate and elevation in glutamate was found in the plasma of HF patients indicating 
decreased TCA cycle activity. However, concentrations of plasma metabolites may not 
truly reflect the myocardial situation. Furthermore, experimental animal models have 
allowed the controlled induction of hypertrophy and HF thereby giving robust 
metabolomics datasets in myocardial tissue. For example, the TCA cycle and oxidative 
phosphorylation were downregulated in a chronic aorto-caval fistula rat model 
(Melenovsky et al., 2011). This is supported by the findings of Lai et al (2014) in which 
the concentrations of α-ketoglutarate, fumarate and malate were reduced by transverse 
aortic constriction (TAC)-induced HF in C57BL/6J mice. However, succinate was 
increased and citrate was unchanged under these conditions. This was not explained by 
the authors but may be associated with the direct roles of these metabolites in the 
respiratory chain and fatty acid synthesis, respectively. Interestingly, this study also 
showed that succinate is uniquely decreased following physiological hypertrophy in 
which there is an increased ATP demand without metabolic derangement. The 
metabolomics investigation by Wang et al (2013) also reported downregulated TCA 
cycle activity driven mainly by a large reduction in the abundance of malate 
dehydrogenase. However, hearts in this study were from mini-pigs with chronic 
ischemic HF and therefore may not represent the metabolic alterations that occur in 
pressure-overload induced-HF that exhibit a demand ischaemia. Interestingly, a pacing-
induced model of HF in the dog demonstrated a 60% increase in α-KDH activity 
thereby inferring enhanced TCA cycle activity during HF (O'Brien et al., 1990). 
Alterations to metabolites involved in anaplerotic pathways have also been reported. 





hearts by 44% over 60 minutes of perfusion with acetoacetate is completely negated by 
perfusion with pyruvate. Sorokina et al (2007) utilised 13C tracing to show that pyruvate 
carboxylation, as well as glutamate anaplerosis producing α-ketoglutarate, are increased 
in pressure-induced hypertrophic hearts perfused in the Langendorff mode. This 
redirecting of carbon flux is thought to be less energy efficient than flux through actyl 
CoA and thus may contribute to ATP supply-demand mismatching. Pound et al (2009), 
Atherton et al (2011) and Carley et al (2015) demonstrated that partial reversal of 
pyruvate carboxylation improved contractile performance in the hypertrophic rat heart. 
Nguyen et al (2015) hypothesised that anaplerosis increases the channelling of TCA 
cycle into protein biosynthesis pathways thereby contributing to hypertrophy. 
Furthermore, glutamate oxidation exhibits a rise in the initial stages of HF but then 
declines concomitantly with contractile performance and ejection fraction (Gong et al., 
2003). As glutamate oxidation increases the concentration of αKG in mitochondria, this 
is possibly suggestive of an adaptive mechanism in which TCA cycle activity is 
maintained in the early stages of HF followed by a waning of activity with disease 
progression. Indeed, enhanced glutamate oxidation may infer elevated glutamate uptake 
in HF thereby contributing to altered substrate selection (discussed in Section 1.5.1). 
There have also been numerous studies inferring reduced activities and/or altered 
expression of the electron transport chain complexes, ATP synthase and adenine 
nucleotide translocase in both pre-clinical experimental models as well as in the clinic 
(summarised in Table 1.2). There is evidence for alterations in the Ca2+-dependent 
components (Complex III, V and ANT). Respirometry studies in permeabilised cardiac 






Table  1.2  Summary of studies showing reduced activities of the electron transport chain, ATP synthase and adenine nucleotide translocase. 
Experimental Condition 
Protein 
I II I-III III IV V ANT 
Human IDCM 
    
Jarreta et al (2000)A; 
Buchwald et al 
(1990)A 
 
Buchwald et al 
(1990) A; Quigley 
et al (2000)A; 
Arbustini et al 
(1998)A. 
  
Sylven et al (1993)T; 
Dorner et al (2006) A,I; 
Dorner et al (2000); 
Schultheiss et al (1985)E 
 
Human Miscellaneous Scheubel et al (2002)
A     Unverferth et al 
(1988)A 
 
Canine rapid pacing 








Marin-Garcia et al 
(2001a)A; Marin-
Garcia et al 
(2001b)A  




Moe et al (2004) 
A; McCutcheon 
et al (1992) A 
 
Rat aortic banding     Garnier et al  (2003)A 
  
Rat spontaneous arterial 
hypertension 
    Sparagna et al 
(2007)A 
  
Rabbit aortic banding Griffiths et al (2010)
 A Griffiths et al (2010)A      






(Sharov et al., 2000) and human (Sharov et al., 2000, Lemieux et al., 2011) perfused 
with malate, glutamate and/or succinate as substrates have revealed reduced rates of 
state 3 respiration. However, an important aspect of respirometry studies is the sub-
population of mitochondria that is used for the experiment. Rosca et al (2013) have 
discussed that subsarcolemmal mitochondria are more affected by HF than 
intermyofibrillar populations (potentially due to differences in ETC chain complexes) 
and this may explain inconsistencies in findings using this technique. 
A highly-cited study by Neubauer et al (1997) using in vivo 31P NMR found that the 
myocardial PCr-to-ATP ratio (PCr:ATP) is a reliable prognostic indicator of dilated 
cardiomyopathy (DCM). During a 2.5 year investigational period, 44% of DCM patients 
with a PCr:ATP of <1.6 died of cardiovascular causes whereas only 5% of DCM 
patients with a PCr:ATP of >1.6 died of cardiovascular causes. The decrease in this 
ratio with increasing severity of DCM was driven by reduced myocardial PCr levels 
although ATP was also reduced in end-stage HF (Figure 1.8). ATP levels are sustained 
during the early-stages of HF and decrease only during advanced stages of the disease 
by 30-40% (Starling et al., 1998, Beer et al., 2000, Shen et al., 1972). The heart 
therefore has the capacity to buffer its ATP pool given the integral importance of this 
molecule to cardiac function and survival. The CK shuttle (discussed in Section 1.3.2) is 
a key mechanism by which ATP levels are sustained and this has long been known to be 
deranged in the earlier stages of HF Herrmann et al (1939). Nascimben et al (1996) 
observed reduced CK activity in hearts from HF patients as well as an altered CK 
isoenzyme profile compared with non-failing control hearts (failing hearts exhibited 







Figure 1.8  31P nuclear magnetic resonance spectra of a healthy volunteer 
and three dilated cardiomyopathy (DCM) patients.  
PCr:ATP ratio appears to be inversely related to the severity of DCM and prognosis 
thereof. Abbreviations: magnetic resonance (MR); 2,3-diphosphoglycerate (2,3-
DPG); phosphocreatine (PCr); adenosine triphosphate (ATP, 3 peaks representing  
γ, α and β phosphates); phosphodiester (PDE). Taken from Neubauer et al (1997). 
 
were also significantly lower in failing hearts in this study. This is consistent with the 





compared with normal counterparts. It is speculated that this PCr reduction is, in part, 
due to reduced creatine transport (Neubauer et al., 1999, Ten Hove et al., 2005). The 
combined loss of PCr and ATP represent a significant reduction in energy reserve 
associated with HF which may precede contractile dysfunction (Liao et al., 1996). 
 
1.6 Is there a causal link between [Na]i overload and bioenergetic remodelling in 
the hypertrophied/failing heart? 
In spite of significant evidence to support the occurrence of both [Na]i overload and 
bioenergetic remodelling during cardiac hypertrophy and HF, there have been very few 
studies investigating the interaction between these pathophysiological events. 
Using isolated mitochondria from healthy rat heart, Iwai et al (2002) demonstrated that 
increasing extramitochondrial Na+ from physiological (12.5mM) to supraphysiological 
(≥25mM) concentrations significantly reduced state 3 respiration, inferring reduced 
mitochondrial ATP supply under these conditions (Table 1.3). The authors also 
measured mitochondrial membrane potential and found that this was also reduced by 
supraphysiological levels of extramitochondrial Na+. The authors did not investigate the 
mechanism underlying this effect of Na+ overload on metabolism.  
However, this has been elucidated in a series of studies focused on the mitochondrial 
transport of Na and Ca2+ and its relationship with mitochondrial ATP production. At the 
time of the Iwai et al (2002) study, there was much data to support the stimulation of 
mitochondrial ATP production by Ca2+ (discussed in Section 1.3.3) but Cam transport 





Table 1.3  Effect of increasing extramitochondrial Na+ concentration on state 
3 respiration. 
 
 Values denote mean ± SEM (n=4/condition).*P<0.05 vs control group. Taken  
 from Iwai et al (2002). 
 
Ca2+ uptake was driven mainly by the mitochondrial Ca2+ uniporter (MCU) and that the 
mitochondrial Na+/Ca2+ exchanger (NCLX) was the predominant mechanism for Ca2+ 
extrusion (Huser et al., 2000). However, it was equivocal whether Cam was altered on a 
beat-to-beat basis with large transients or over a slower time-period where beat-to-beat 
changes are small. 
With respect to the regulation of [Ca]m by [Na]i, Cox et al (1993) used the fluorophore, 
fura-2, to measure [Ca]m in isolated cardiac mitochondria from healthy rabbits. 
Mitochondria were incubated at increasing concentrations of extramitochondrial Na+ 
([Na]ex) using NaCl and measurements of NADH production and state 3 respiration 
were carried out in the absence or presence of various inhibitors of NCLX (from highest 






               
             
Figure 1.9  Effect of extramitochondrial [Na+] ([Na]ex) elevation and NCLX inhibition on 
[Ca]m, NADH formation and oxidative phosphorylation rate (OPR) in isolated mitochondria.  
(A) Time-course of mitochondrial calcium concentration ([Ca2+]m) with increasing [Na]ex. (B) 
NADH formation (D) and OXPHOS (F) with 10mM [Na]ex and increasing concentrations of 
various mitochondrial Na+/Ca2+ exchange (NCLX) inhibitors. NADH formation (C) and OPR (E) 
with fixed NCLX inhibitor (CGP-37157) concentration (10 and 20 µM respectively) and increasing 
[Na]ex. All experiments used 1 µM ruthenium red (mitochondrial calcium uniporter inhibitor). 








ruthenium red. Increasing [Na]ex in the physiological range reduced [Ca]m (Figure 1.9A), 
NADH production (Figure 1.9C) and oxidative phosphorylation (Figure 1.9E) in a dose- 
dependent manner (Figure 1.9A). Inhibition of NCLX substantially increased [Ca]m 
(Figure 1.9B), NADH production (Figure 1.9D) and oxidative phosphorylation (Figure 
1.9F) in a dose-dependent manner using all three inhibitors (in accordance with their 
relative potencies).  
This study supported the findings of Iwai et al (2002) and thus provided weight to the 
hypothesis that [Na]i overload deranges ATP supply-demand matching. However, this 
study did not provide information on the beat-to-beat kinetics of [Ca]m transport and its 
relation to mitochondrial energy production. Moreover, isolated mitochondria 
experiments should be treated with caution given the measurements are performed in 
the absence of important ATP sinks (myosin ATPase, NKA and SERCA) and substrate 
utilisation pathways (glycolysis and β-oxidation). 
More recently, Maack et al (2006) reported findings in isolated cardiomyocytes from 
healthy guinea pig heart. A novel method was developed to measure both [Ca]i and 
[Ca]m during systole and diastole in the same cell, thereby providing information on the 
beat-to-beat regulation of [Ca]m handling during conditions of increased workload and 
increased [Na]i in intact cells. NADH was also measured in these experiments using 
autofluorescence to give an indication of bioenergetic status under these conditions. As 
anticipated, isoproterenol increased systolic [Ca]i (Figure 1.10A) which decreased 
following washout and was slightly higher in the high [Na]i  group throughout the 
protocols although was not statistically significant. Diastolic [Ca]i was unaffected by 






Figure 1.10  Effect of [Na]i elevation on systolic and diastolic Ca2+, NADH and mitochondrial 
membrane potential in isolated cardiomyocytes.  
Isolated guinea pig cardiomyocytes were patch-clamped, paced at 3 Hz and (A) [Ca2+]c, (B) [Ca2+]m, 
(C)  mitochondrial membrane potential (ΔΨm) and (D) NADH were monitored using indo-1, rhod2-
acetoxymethyl ester, tetramethyl rhodamine and autofluorescence (λem=450nm), respectively. 
Symbols and error bars denote mean ± SEM (n=8-38 cells per measurement). White and black 
symbols represent 5 mM and 15 mM [Na]i in the pipette solution, respectively. *P<0.05, **P<0.01 vs 









systolic [Ca]i and appeared to be reduced at a much slower rate during the washout 
period than [Ca]i. Diastolic [Ca]m was also elevated during isoproterenol incubation 
with similarly slow kinetics. Both systolic and diastolic [Ca]m were significantly 
reduced by [Na]i elevation and this difference was sustained even by the end of the 
washout period. 
Correspondingly, the percentage of NAD(H) in the reduced form was maintained at 
around 62% in the control group (Figure 1.10C) but started to decline shortly after the 
addition of isoproterenol in the high [Na]i group. NADH was significantly lower in the 
high [Na]i group versus control and continued to decline even during the washout 
period. In spite of these changes in [Ca2+] and [NADH], [Na]i elevation did not affect 
the mitochondrial membrane potential (ΔΨm) (Figure 1.10D). Furthermore, NCLX 
inhibition by CGP-37157 was shown to significantly elevate diastolic [Ca]m. Using 
time-resolved fluorescence measurements, it was also demonstrated that high Na+ 
significantly reduced the amplitude and decay of [Ca]m and also increased the time to 
peak value. As these effects were not altered by ruthenium red inhibition of the MCU, it 
is likely a consequence of increased Cam extrusion via NCLX on a beat-to-beat basis. 
This series of experiments by Maack et al (2006) gave yet more strength to the 
argument that [Na]i is an important regulator of cardiac bioenergetics. However, it 
remains unclear whether this is truly reflective of a regulatory mechanism in the beating 






1.6.1 The need for a [Na]i-overloaded beating heart preparation. 
In order to elucidate the importance of the link between [Na]i and ATP supply-demand 
matching in the beating heart, a preparation is required in which a heart can be perfused 
under physiologically-relevant conditions and in which [Na]i elevation can be induced 
and reliably measured. It is also necessary to be able to quantify a wide-range of 
metabolites involved in energy homeostasis in these hearts. The model of choice in this 
thesis was the isolated rat heart in the Langendorff mode perfused with ouabain to 
induce [Na]i overload. Given the established importance of ATP demand to energy 
mismatching, this model can also be used in conjunction with electrical pacing or 
electromechanical uncouplers in order to assess the effects of altered workload. It can 
also be used in conjunction with NMR thereby permitting the real-time measurement of 
[Na]i  by 23Na NMR, cardiac energetics by 31P NMR, as well as end-point measurements 
of metabolites in myocardial tissue and coronary effluent using, for example, NMR and 
mass spectrometry. Indeed, many studies (particularly those of Denton and Maack) 
point toward an integral role of the TCA cycle in the sodium-dependent derangement of 
energy balancing in the heart. However, there have been no reports of specific 
measurements of its intermediates (nor any other intermediary pathway contributing to 
ATP supply) in any experimental model of elevated [Na]i. 
Therefore, this project combines powerful analytical and biochemical tools in order to 








Elevation of [Na]i causes alterations in the TCA cycle and cardiac energetics in the 
isolated perfused rat heart. This will lead to a mismatch of ATP supply and demand 
independent of altered contractility. 
 
1.8 Aims 
In order to test this hypothesis, this thesis aims to: 
- Investigate the dose-response relationship between ouabain concentration and 
[Na]i in both the beating and electromechanically-uncoupled perfused rat heart 
using 23Na NMR. 
 
- Ascertain the metabolomic profiles of beating and electromechanically-
uncoupled perfused rat hearts exhibiting [Na]i elevation using high-resolution 
NMR and mass spectrometry. 
 
- Monitor cardiac energetics in real-time during [Na]i elevation in the perfused rat 
heart using 31P NMR. 
 
- Measure the activity of the TCA cycle in [Na]i overloaded perfused rat hearts 







2.1 Langendorff Heart Perfusions 
2.1.1 General Principles 
The concept of using beating hearts ex vivo for studying cardiac physiology dates back 
to the 19th century, pioneered by Loebel, Ludwig and Cyon using the frog and later by 
Oscar Langendorff using retrograde perfusion of the mammalian heart (Zimmer, 1998). 
The Langendorff heart perfusion technique has become an integral method for the study 
of contractile and electrophysiological function, arrhythmias, coronary vasculature, 
metabolism and pathophysiological mechanisms, to name but a few. 
The technique involves arresting the heart in a cold cardioplegic solution followed by 
cannulation of the aorta and then perfusion with a crystalloid buffer closely resembling 
the ionic composition and pH of the blood, typically containing glucose as a fuel 
substrate and dissolved oxygen at 37 °C. It is crucial that the heart is ischaemic for as 
little time as practically possible during this process to avoid either preconditioning 
(Awan et al., 1999) or irreversible damage that may have bearing upon the experimental 
data subsequently obtained. Perfusing the heart retrogradely with a crystalloid buffer 
causes the aortic valve to close due to the exerted perfusion pressure. Perfusate is 
thereby directed through the coronary ostia of the aortic root into the coronary 
vasculature. Perfusate then flows into the coronary sinus via the coronary veins and out 
of the heart from the right atrium. The ventricles are therefore essentially fluid-free in 





immediately upon reperfusion as the cells return to normothermia and the supply of 
essential ions is resumed. 
The key advantages of the Langendorff perfused heart preparation include its relatively 
simple technical setup and perfusion buffer preparation, high reproducibility, intact 
autoregulatory mechanisms, isolation from neurohumoral effects that can confound 
several cardiac properties and the ease of carrying out pharmacological interventions 
dynamically with real-time functional measurements. A further advantage more specific 
to this thesis is that it can be used in conjunction with real-time nuclear magnetic 
resonance spectroscopy (NMR) measurements (discussed in Section 2.2). However, the 
isolated perfused heart is clearly far less physiological than the in vivo situation and 
therefore can exhibit effects that are specific to the ex vivo preparation. For example, 
coronary flows are substantially higher ex vivo in order to compensate for the reduced 
ability to carry oxygen (due to lack of haemoglobin) and changes in the viscosity of the 
perfusion medium. Moreover, the Langendorff preparation does not carry out “work” 
and thus ATP demand is lower than that in the isolated working heart preparation or in 
vivo (Wengrowski et al., 2014). Notwithstanding the limitations of the Langendorff 
heart, it provides a reliable means by which to compare cardiac function, ion 
homeostasis and metabolism between control and treatment groups under tightly 
controlled and near-physiologic conditions. 
 
2.1.2 Setup 





   
Figure 2.1  Schematic of a generic Langendorff heart perfusion setup.  
See text for full details. Abbreviations: thermocouple (T); perfusion pressure 
transducer (PP); developed pressure transducer (DP); left ventricular balloon (LVB). 






perfusion rig used for the hearts that were not subjected to NMR measurements 
consisted of the following: steel cannula (~3mm diameter; made in house), pressure 
transducer (Cat # 682021, BD Bioscience) to monitor perfusion pressure, left-
ventricular water-filled balloon (consisting of a plastic 16 G x 2” intravenous Argyle 
Medicut™ cannula (Covidien, USA), approximately 2cm2 piece of cling film wrap and 
approximately 300μL distilled water at maximal inflation) attached to a pressure 
transducer (Cat # 682021, BD Bioscience), water-jacketed delivery tube, Minipuls 3 
peristaltic pump (Gilson Inc, USA) with STH Pump Controller (ADInstruments, 
Australia) to permit switching between constant flow and constant pressure (Shattock et 
al., 1997), three water-jacketed glass reservoirs (~500mL) for perfusion fluid with 
sintered base and sintered glass gassing sticks. Perfusion fluid was gassed continuously 
with carbogen (95% O2 and 5% CO2) and plastic tubing clips were located close to the 
aortic cannula to either direct the KH into the heart or re-circulate when not in use 
negating undesired switching effects on the heart. All water-jacketed apparatus were 
connected to a C-85A water circulator (Techne, UK) set to 38°C giving a perfusate 
temperature of 37°C. Both pressure transducers were calibrated at the beginning of each 
day using a sphygmomanometer, as was coronary flow rate by the collection of 
perfusate into a measuring cylinder for one minute. The pressure transducers were fixed 
at an identical height to the heart to ensure accurate pressure recordings. These 
transducers (ADInstruments, Australia) were connected via Bridge Amps (4 kHz 
sampling rate) to a PowerLab 8/30 (ADInstruments, Australia) interface 






2.1.3 Perfusion buffers 
All water used was ultrapure (>18MΩ) using an Elga Purelab Option-Q system. Unless 
otherwise stated in the chapter-specific methods section, all perfusates were based upon 
Krebs-Heinseleit buffer (KH) and consisted of the following: 118.5 mM NaCl, 1.4 mM 
CaCl2.2H2O, 25.0 mM NaHCO3, 1.19 mM MgSO4.7H2O, 1.75 mM KCl and 11 mM 
glucose (all from ThermoFisher, UK) dissolved in ultrapure distilled water which had 
been pre-gassed with carbogen for 20 minutes (hereafter referred to as ‘KH’). This was 
filtered using a Buchnor flask with a 5.0μm Whatman pre-filter (cat# 7195-004) and 
0.2μm Whatman filter (cat# 1820-047). KH was phosphate-free to allow comparisons to 
be made between data from 31P NMR experiments (in which phosphate must be absent 
from KH to avoid interference with the measurement of endogenous inorganic 
phosphate) and other experiments. 
 
2.1.4 Animals 
Male Wistar rats weighing ~300 g (Envigo, UK) were used for all heart perfusion 
experiments. Animals were able to access drinking water and a standard diet ab libitum. 
All experiments were performed in accordance with the Home Office guidance in the 
Operation of the Animals (Scientific Procedures) Act 1986. Animals were anaesthetised 
by intraperitoneal injection of approximately 170 mg/kg Pentoject pentobarbitone 
sodium (Animalcare Limited, UK) per kg body weight and approximately 160U heparin 






2.1.5 Excision and perfusion setup 
Using surgical scissors (Fine Science Tools, Heidelberg), a large incision was made 
across the abdomen of a rat and then through each side of the rib cage until the clavicles 
were reached. The diaphragm was incised and the rib cage was inverted, revealing the 
thoracic cavity. The pericardium was subsequently incised and the beating heart was 
gently moved away from the thoracic cavity by hand, the lungs were pared away and the 
heart was released via a single incision of the great vessels and then placed into an 
arresting solution (KH at 4°C) which was rapidly weighed using a TE162 balance 
(Sartorious, UK) thus giving the wet weight of the heart. Within one minute of arrest, 
the heart was revived by cannulation of the aorta and perfusion with carbogenated KH 
at ~37 °C in the Langendorff mode at 10 mL/min constant flow. The aorta was secured 
to the cannula using a silk suture and non-myocardial tissue was carefully removed 
before making a small incision in the pulmonary artery to aid the extrusion of effluent 
from the preparation. A Traceable™ thermocouple probe (Fisher Scientific, UK) was 
carefully inserted into the right ventricle via the pulmonary artery to confirm a 
temperature of 36.5-37.2 °C. A deflated intraventricular balloon (IVB) was carefully 
inserted through the mitral valve via the left atrium and then into the left ventricle. The 
IVB was slowly inflated by addition of ~100-150 µL ddH2O to give a left ventricular 
end-diastolic pressure (LVEDP) of 3-10 mmHg to reflect the in vivo range (Fletcher et 
al., 1981).  The setup was then changed to constant pressure mode (73-74 mmHg) 
which was maintained throughout the entirety of the perfusion protocol. The heart was 
then positioned in the centre of an organ bath, covered with a piece of parafilm and a 
clamp was tightened slightly around the exit tubing of the organ bath. This helped to 





perfusion protocols included an initial stabilisation period of at least 20 minutes with 
standard KH to assess whether the heart was acceptable for use in the final dataset based 
on pre-determined exclusion criteria. 
 
2.1.6 Exclusion Criteria 
Hearts were excluded from the final dataset if they exhibited a mean LVDP of less than 
80 mmHg with LVEDP set between 3 and 10 mmHg, a mean coronary flow of less than 
7 mL/min or a mean heart rate of less than 250 BPM. Furthermore, hearts were 
immediately excluded if ventricular fibrillation occurred at any point during the 
stabilisation period. 
 
2.1.7 Electrical pacing 
Electrical pacing was used in experiments that required artificial control of heart rate. 
Bipolar pacing was via an active fine silver-wire electrode impaled into the apex of the 
left-ventricular referenced to the stainless steel aortic cannula. The cannular and pacing 
wire were connected to a Multistim System-D330 (Digitimer, UK), a Powerlab™ 
interface (ADInstruments, Australia) and Labchart software version 7 (ADInstruments, 
Australia). Square step pulses of 5 msec duration were applied to the frequencies 





2.1.8 Electrocardiogram (ECG) 
In studies where an ECG recording was made, these were recorded using similar 
electrode placements to those used for pacing. That is an apical silver wire recording 
electrode was referenced to the stainless steel aortic cannula. The ECG was recorded via 
a Bioamp and Powerlab™ running LabChart (v.7) (ADInstruments, Australia) and 
sampled at 4 kHz. 
 
2.1.9 Snap-freezing of perfused hearts 
At the end of perfusion, the IVB (and pacing/ECG wires if applicable) were carefully 
removed from the heart. Exempting the aorta, all non-ventricular tissue was rapidly 
excised from the beating heart using surgical scissors (Fine Science Tools, Germany) 
and the ventricles were then snap-frozen in situ using Wollenberger clamps pre-cooled 
in liquid nitrogen for five minutes. The clamps were then carefully pulled away from 
the perfusion cannula thereby separating the ventricles from the aorta and residual aortic 
tissue and frozen perfusion buffer were rapidly excised from the ventricles. The 
ventricles were stored at -80°C until analysis. The process described above was 
completed within one minute. 
 
2.1.10 Data acquisition and processing 
All perfusion data were acquired using LabChart software Version 7 (ADInstruments, 





pressure (LVP), perfusion pressure, coronary flow, peak systolic pressure (PSP; derived 
from LVP), heart rate (derived from LVP), LVEDP (derived from LVP) and left 
ventricular developed pressure (LVDP, Equation 2.1) were acquired for all hearts. 
LVDP was used as an indicator of contractile “effort”. 
     
    LVDP = PSP − LVEDP   Equation 2.1 
where,   LVDP = left ventricular developed pressure (mmHg) 
   PSP = peak systolic pressure (mmHg) 
   LVEDP = left ventricular end-diastolic pressure (mmHg) 
 
All perfusion parameters were averaged into five minute time windows using MS Excel. 
For ECG recordings, the time from the onset of activation to 90% recovery of 
repolarization (QT90%) values of the final five complexes in each treatment period 
were manually determined from the ECG trace and averaged for each heart. Heart rate 
from ECG recording was calculated automatically using the ECG analysis feature of 
LabChart and averaged into five minute time windows using MS excel. All averaged 
data were plotted as mean ± standard error of the mean (SEM) using GraphPad Prism 






2.2 Assessment of cardiac metabolism and [Na]i by nuclear magnetic resonance 
spectroscopy (NMR). 
NMR is a powerful tool for the real-time assessment of ion homeostasis and cardiac 
energetics in the Langendorff perfused heart (reviewed in Singhal et al., 2009). In this 
thesis, 23Na NMR and 31P NMR were used to measure [Na]i and high energy phosphates 
respectively under both control and high [Na]i conditions. 
 
2.2.1 General Principles of NMR 
Nuclei comprising an odd number of nucleons (protons and neutrons) exhibit net 
nuclear spin and thereby possess a magnetic moment. When placed into a magnetic 
field, these nuclei are quantised either in alignment with or in opposition to the external 
magnetic field. For a spin I = ½ nucleus such as 1H or 31P the different energy levels are 
populated according to the Boltzmann distribution (Equation 2.2). 
 
                 
Ni
Nj
= e(−ΔEkT)                 Equation 2.2 
where,  
Ni = Number of nuclei in upper energy state. 
 Nj = Number of nuclei  in lower energy state. 
∆E =Energy difference between nuclear spin states. 
 k  =  Boltzmann constant = 1.38 x 10-23 J K-1. 






The energy difference (ΔE) is small compared to the thermal energy (kT) and therefore 
lower or higher spin states have approximately equal populations (i.e, Ni/Nj ≈1). 
However, a small population difference exists which can be detected by NMR. 
Excitation of the spins with a radio frequency pulse causes them to be excited and then 
undergo precession which is quantified according to the Larmour Frequency (Equation 
2.3).  
 
        ω0 = γ · B0                                                 Equation 2.3 
where,  
 ω0 = Larmor frequency (MHz). 
 γ = Gyromagnetic ratio (magnetism:spin ratio, nucleus-specific, eg, 1H = 42.5 
        MHz T-1). 
           B0 = External Magnetic Field (T). 
 
 
When a radiofrequency (RF) pulse is applied (at the Larmour frequency of the nucleus 
of interest), resonance occurs exciting spins from the lower to the higher energy state. 
Upon removal of this radiofrequency pulse, the excited nuclei precess at their respective 
Larmor frequencies and return to their lower energy state via two relaxation processes: 
longitudinal recovery (or spin-lattice decay, T1) or transverse recovery (spin-spin decay, 
T2). Importantly, the precessing magnetic moment of the nuclear spin induces a current 
in the receiver coil of the NMR probe known as the free induction decay (FID), the 





of the FID to an NMR spectrum using Fourier transformation permits integration of 
signals (peaks) from the nuclei of interest. For nuclei within molecules, different 
chemical shifts of the peaks arise due to differences in electron shielding within the 
molecule. The area (integral) of a peak is proportional to the abundance (concentration) 
of that nucleus within the sample. In order to maximise signal-to-noise (S:N) of the 
analytes of interest, multiple ‘scans’ of the sample are summed, where one scan 
encompasses one RF pulse sequence in which nuclei are excited and then allowed to 
relax. For n number of scans, the signal increases according to n and the noise by n1/2, 
thus the S:N increases by n1/2 (for example, 100 scans of a sample increases S:N by 10-
fold). Comparing the areas of an NMR peak in a control and treatment sample (be it a 
solution or whole organ) gives a semi-quantitative measure of the relative change in the 
concentration of that analyte due to the treatment. An internal standard can be added to 
the sample in order to quantify absolute concentrations of metabolites. 
Two modes of NMR were used in this thesis: real-time NMR measurements of isolated 
perfused hearts (discussed in sections 2.2.2) and high-resolution NMR of aqueous 
metabolite extracts from snap-frozen myocardial tissue (discussed in Section 2.4.3). 
 
2.2.2 NMR measurements of the isolated perfused heart (setup) 
The setup for 23Na NMR and 31P NMR measurements was identical other than different 
RF coils being used. The Langendorff perfusion rig setup was identical to that used for 
non-NMR studies but with the following alterations: four glass perfusion reservoirs; a 
long (~2 m) water-jacketed piece of plastic tubing between the peristaltic pump and 





perfusate temperature of 37 °C at the aortic cannula; the heart was placed into an NMR 
tube rather than an organ bath; an exhaust line was connected to a second peristaltic 
pump so that there was a constant and steady removal of coronary effluent from the 
NMR tube throughout perfusion. 
After setting up the isolated perfused heart preparation (as detailed in 2.1.5), the heart 
was carefully placed into a 15 mm NMR tube (OD 15 mm) (Wilmad, UK) and secured 
with a silicon cap through which the aortic cannula, tubing connecting the IVB to the 
LVP pressure transducer and exhaust sipper line were fixed. This NMR tube was then 
centred within an RF coil (either 1H/23Na or 1H/31P dual-tune coil) (Figure 2.2A) within 
a microimaging probe (Figure 2.2B). A Bruker Avance III 400 MHz (9.4T) wide-bore 
spectrometer (Bruker, Germany) (Figure 2.2C) with triple-axis gradients (kept at a 
constant temperature of ~313K using a second water circulator) was used for all real-
time perfused heart NMR measurements. The resonance frequency was then optimised 
for the particular nuclei being measured by adjusting the tune and match controls on the 
appropriate channel of the probe. Magnetic homogeneity was optimised by fine tuning 
the shimming gradients in the z, z2, z3, x and y planes thus maximising S:N. 
 
2.2.3 Assessment of [Na]i by triple quantum-filtered (TQF) 23Na NMR. 
The real-time measurement of [Na]i in the beating heart under near-physiological 
conditions is challenging. This is mainly because the Larmor frequency of the 
intracellular [Na]i and extracellular [Na]e pools is identical and, also, [Na]i is 
























Figure 2.2  Photographs of the NMR perfusion setup.  
(A) Isolated perfused rat heart. (B) Nuclear Magnetic Resonance (NMR) birdcage 
radiofrequency coil. Ruler units are centimetres. White arrow indicates the position at 
which the heart was centred. (C) NMR microimaging probe. 1: Inflow and exhaust lines; 
2: 15 mm NMR tube centred in RF coil using rubber O-ring; 3: RF coil (Figure 2.2B) 












overlapped by a large [Na]e signal in the NMR spectrum and thus neither of these 
populations can be integrated under these circumstances. At present, there are two key 
approaches used to distinguish these populations: the use of shift reagents and triple 
quantum filtering. 
NMR shift reagents, such as Tm(DOTP) (Buster et al., 1990), are labile anions that are 
unable to cross the sarcolemma and therefore bind only to [Na]e but not [Na]i. The 
unpaired electron density of the paramagnetic shift reagent interacts with the magnetic 
dipole of Na+ (known as the dipolar hyperfine mechanism) thereby shifting the Larmor 
frequency of [Na]e but not [Na]i. This separates the spectral signals of [Na]e and [Na]i 
thereby permitting their quantification. The key issue with shift reagents is that, as 
anions, they are efficient chelators of Ca2+ and thereby alter contractile and 
electrophysiological properties of the heart (often inducing toxicity) and reduce the 
physiological relevance of the preparation. 
Multiple quantum filtered 23Na NMR permits less invasive and more physiological 
measurements of [Na]i in the absence of shift reagents. This approach relies on the 
differences in physicochemical environment of [Na]e and [Na]i. The majority of [Na]i is 
bound to macromolecular structures (such as those in the sarcolemma or cytoskeleton) 
whereas the majority of [Na]e is in isotropic solution. As 23Na is a spin 3/2 system, 
multiple quantum coherences can be induced and detected (Figure 2.3). Triple quantum 
filtered (TQF) and double quantum filtered (DQF) NMR pulse sequences both filter out 
the bulk isotropic signal leaving only anisotropic Na+ signals; TQF giving rise mainly to 
intracellular Na+ bound to macromolecules while DQF is selective for Na+ bound to 






Figure 2.3  Multiple quantum coherences in 23Na. 
Spin 3/2 nuclei can exist in one of four energy states. Single quantum (SQ) transitions 
(black arrows) occur between neighbouring energy levels whereas double quantum (DF; 
blue arrows) and triple quantum (TQ; red arrow) transitions occur when nuclei skip one 
and two energy levels respectively. Image taken from Gottwald et al. (2016). 
 
There have been numerous reports of this technique being utilised in conjunction with 
the isolated perfused rat heart (Payne et al., 1990, Dizon et al., 1996, Tauskela et al., 
1997, Schepkin et al., 1998). The technique has previously been developed in our lab in 
the perfused mouse heart (Eykyn et al., 2015) showing that [Na]i contributes 
approximately 68% of the TQF signal and does not contribute to the smaller DQF 
signal. Therefore, assuming that [Na]e is constant then the TQF signal will be 









Figure 2.4  Correlation plot of [Na]i measured by 23Na NMR with shift reagent vs 
TQF NMR signal in isolated perfused rat heart.  
Baseline [Na]i is 17.5 mM according to the shift reagent experiments. a = normal; b = 
200 µM ouabain with washout; c = stop-flow ischemia; d = 200 µM ouabain; e = K+-free; 






In a similar study by Schepkin et al (1998), [Na]i was elevated to different extents 
(using stop-flow ischaemia, K+-free KH, ouabain, Ca2+-free KH and K+/Ca2+-free KH) 
in the Langendorff rat heart preparation and was measured using atomic absorption 
spectroscopy (AAS) as well as TQF. It was found that there was a very strong positive 
correlation (r = 0.995) between [Na]i measured by AAS and the TQF signal with a slope 
of 0.35 ± 0.015 mM/% and an intercept of 50 ± 5% (Figure 2.4). [Na]i was 17.5 mM in 
the normal heart under baseline conditions. These observations, combined with the 
technique previously implemented in our lab, formed the basis of the TQF 
measurements in this thesis. Therefore, the absolute [Na]i values reported in this thesis 
are derived using the Schepkin et al (1998) study. 
In terms of 23Na NMR data acquisition, alternating TQF and DQF measurements were 
performed in an interleaved fashion in order to assess [Na]i and [Na]e in real-time, 
respectively. The acquisition duration of each TQF and DQF spectrum was 
approximately 1.3 minutes and acquisition parameters were identical to those described 
in Section 2.3 of Eykyn et al (2015). Representative spectra from isolated perfused rat 
hearts under baseline conditions and perfused with increasing concentrations of ouabain 
are displayed in Figures 2.5A and 2.5B, respectively. Each TQF and DQF spectrum was 
magnitude-corrected and then baseline-corrected. Peak integration was performed 
automatically using TopSpin software (Bruker, Germany) and all peaks were integrated 
on the same scale to permit relative comparisons. Baseline integrals were averaged and 
then incorporated into Equation 2.4 to give an estimation of [Na]i at each time point. 
Correcting for differences in baseline measurements between hearts is important as the 







Figure 2.5 Representative 23Na TQF and DQF NMR spectra of isolated rat 
hearts at baseline and perfused with ouabain.  
(A) TQF (large blue peak) and DQF (small red peak) at baseline perfusion. (B) TQF 
signals increasing in height and area due to increasing ouabain concentration in the 
perfusate. From smallest to largest: baseline/0 µM ouabain (blue peak); 50 µM ouabain 







heart within the active region of the RF coil, which can both differ between 
experiments. ‘Normalised TQF’ and ‘normalised DQF’ herein refer to the measured 
signal normalised to its respective baseline value. 
 [Na]e was assumed to be linearly related to DQF and thus the reliability of Equation 2.3 
was confirmed by an absence of change in the DQF signal over the time course of the 
experiment, as Schepkin et al (1998) showed that 50% of the TQF is attributable to 
[Na]e.                          
                            
          [𝑁𝑁𝑁𝑁]𝑖𝑖 = �� 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇x̅�������  x 100� − 50%� x 0.35              Equation 2.3 
where, 
 [Na]i = Derived intracellular Na+ (mM). 
 TQF = Integral of triple quantum filtered (TQF) 23Na NMR signal at a particular 
  time-point. 
 TQFx̅ = Mean integral of TQF 23Na NMR signal during stabilisation period. 
 50% = Contribution of extracellular Na+ to TQF 23Na NMR signal. 
 0.35 = Slope of relationship between [Na]i and TQF 23Na NMR signal in mM/%. 
 
2.2.4 Assessment of cardiac energetics by 31P NMR 
The use of real-time 31P NMR for the assessment of energetics in muscle dates back to 
the 1970s and is now widespread tool in cardiovascular research. Any metabolite 
containing 31P at a concentration of at least ≈600 µM is detectable using this technique 






Figure 2.6  Representative 31P NMR spectrum of an isolated perfused rat heart under 
normal baseline conditions. 
As ADP and NAD contribute to the γ-ATP and α-ATP signals, respectively, only the β-ATP 
signal was used as a determinant of ATP concentration in the heart. The chemical shift 
difference of Pi and PCr in this example is 4.8ppm equating to an intracellular pH of 7.1. 
Abbreviations: intracellular inorganic phosphate (Pi); phosphocreatine (PCr). 
 
(PCr) and ATP which are imperative to cardiac function and survival. Under certain 
conditions, monophosphate esters can be observed as well as glycolytic intermediates 
such as glucose-6-phosphate during hypoxia. This approach also permits the 
determination of intracellular pH which is linearly proportional to the difference in 
chemical shift between the Pi and PCr signals. In contrast to the measurement of [Na]i 
by 23Na NMR, using 31P NMR to assess Pi, phosphocreatine (PCr) and ATP does not 









frequencies of these metabolites are different. However, given that 31P is less NMR 
sensitive than 23Na due to lower concentrations of these metabolites, longer acquisition 
times are required when measuring the former thereby reducing temporal resolution in 
order to give an acceptable S:N.   
31P NMR acquisition parameters were as per Wilder et al (2016) with the only 
difference being that each spectrum was obtained using 73 scans over a five minute 
period. Each spectrum (Figure 2.6) was phased and baseline-corrected and each peak 
was then integrated manually using the same scaling. To correct for differences in heart 
size/mass and position within the RF coil active region, each integral for all measured 
metabolites was divided by the mean PCr integral during the stabilisation (baseline) 
period. This also permitted direct comparison between the relative concentrations of 
PCr, ATP and Pi. Intracellular pH was calculated using Equation 2.4. 
 
      pHi = 6.72 + log δPi−3.175.72− δPi              Equation 2.4 
where,                                                                                                    (Sidell et al., 2002)
 pH = Intracellular pH. 
 δPi = Chemical shift difference between intracellular inorganic phosphate peak 







2.3 Lactate analysis of coronary effluent 
Elevated extrusion of lactate from the myocardium is indicative of increased glycolytic 
activity and is a classic marker of metabolic stress (Becker et al., 2013, Mansor et al., 
2016, Trueblood et al., 2000). Quantification of the lactate efflux rate in the isolated 
perfused heart is therefore a convenient way in which to gain an insight into the 
metabolic status of the beating myocardium under control and high [Na]i conditions 
without the need for challenging NMR protocols. 
The 2300 STAT Plus (YSI, USA) is an enzyme-based electrode technique capable of 
quantifying lactate down to 1 µM in biological matrices. At the beginning of each day 
of analysis, the instrument was flushed thoroughly with YSI cleaning buffer (cat# 2357) 
and the current was allowed to stabilise. The instrument was then calibrated using 5 mM 
lactate calibration solution (cat# 2747). Coronary effluent samples were collected on ice 
and analysed immediately using 25 µL sample volume. Absolute lactate concentrations 
(mM) were incorporated into Equation 2.5 to give lactate efflux rate from each heart. 
 
      Lactate efflux = [Lac] x 1000 x � CFTime� 
Wet wt                  Equation 2.5 
where, 
 Lactate efflux = Efflux of lactate from the heart (nmol/min/g wet weight) 
 [Lac] = Lactate (mM) in coronary effluent according to 2300 STAT Plus. 
 CF = Coronary flow (mL/min) during collection of coronary effluent. 
 Time = Duration of coronary effluent collection (mins). 





2.4 Metabolomic Profiling 
2.4.1 General principles 
Metabolomics (also known as metabonomics, metabolic profiling and metabolic 
fingerprinting) is becoming an increasingly important tool in several areas of research 
such as cardiovascular (Marcinkiewicz-Siemion et al., 2016), drug discovery 
(Cuperlovic-Culf and Culf, 2016, Wishart, 2016) and cancer (Mikkonen et al., 2016). 
Developments in the field of analytical chemistry have provided powerful tools 
(particularly NMR and mass spectrometry) for the simultaneous quantification of 
multiple metabolites in a single biological sample. Historically, mainly enzymatic/ 
spectrophotometric assays were used for this purpose but these are slowly being 
replaced by metabolomics approaches as its advantages are realised. There are two key 
modes of metabolomic analysis. ‘Untargeted metabolomics’ involves semi-
quantitatively assessing hundreds or thousands of metabolites in order to identify 
potential biomarkers of, for example, a particular disease state. This is often used in the 
early stages of research and is useful for hypothesis generation. A more focused 
approach is known as ‘targeted metabolomics’ whereby a smaller number of known 
metabolites are measured with respect to a specific hypothesis on the role of a pre-
selected metabolic pathway under a particular condition.  
In this thesis, semi-targeted metabolomic evaluation of energy metabolism was 
achieved using NMR. In addition, mass spectrometry was utilised for targeted 






2.4.2 Dual-phase extraction of metabolites. 
The three key techniques used for the isolation of polar metabolites in biological 
matrices are dual-phase extraction, acetonitrile extraction and perchloric acid extraction 
(full methodological details can be found for each of these in Beckonert et al., 2007). 
The dual-phase extraction technique has also more recently been described by Chung et 
al. (2016). All three methods were trialled using snap-frozen tissue from perfused 
control rat hearts. Following reconstitution of lyophilised extracts, it was found that 
extracts from the acetonitrile and perchloric acid procedures were not translucent 
indicative of the presence of undesired lipid species. However, extracts derived from the 
dual-phase technique were translucent and NMR analysis did not detect the presence of 
lipid species in these solutions but was positive for several polar metabolites relevant to 
energy metabolism. The dual-phase extraction technique was therefore utilised for all 
metabolomic investigations in this thesis. 
In brief, snap frozen rat heart was ground under liquid nitrogen, an aliquot (500-800 
mg) was electromechanically homogenised in ice-cold methanol (2 mL/g tissue) 
followed by addition of water (total = 2.85 mL/g tissue) and chloroform (total = 2 mL/g 
tissue) with vortexing. Suspensions were centrifuged at 3600 RPM for one hour at 4°C. 
Three layers were formed: an upper aqueous layer containing small, polar entities; a 
middle solid layer containing protein and cell debris; and a lower lipophilic layer 
containing lipid species. For NMR analysis, the upper aqueous phase was subsequently 
added to a fresh Falcon tube containing 20-30 mg chelex-100 which was vortexed and 
centrifuged at 3600 RPM for 1 minute at 4°C. The supernatant was then added to a fresh 





lyophilisation. For mass spectrometry analysis, the chelex-100 and universal indicator 
steps were omitted. Lyophilised extracts were stored at -80°C until analysis. 
 
2.4.3 High resolution 1H NMR of metabolite extracts 
High resolution 1H NMR provides a means by which to simultaneously quantify several 
organic entities within a single sample with high degree of precision and accuracy. Any 
molecule containing proton is detectable by this technique but NMR has relatively low 
sensitivity and often overlapping signals thus its applicability is limited to the more 
abundant metabolites in the heart. A key advantage, however, is that a single proton-
containing internal standard can be used for the reliable quantification of all metabolites 
with an appropriate S:N. 
1H NMR was used to obtain a semi-targeted metabolomic profile. That is, some of the 
metabolites measured by this technique were directly relevant to the pre-defined 
hypothesis (perturbation of the TCA cycle and ATP production) whereas others were 
indirectly relevant (such as amino acid anaplerosis). Furthermore, 1H NMR was only 
able to measure two TCA cycle intermediates (succinate and fumarate) with a generally 
poor S:N. 
Lyophilised, dual-phase-extracted metabolites were reconstituted in 600 µL deuterium 
oxide (containing 8 g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HPO4, 0.2 g/L KH2PO4 and 
0.0075% w/v trimethylsilyl propanoic acid (TSP)) and adjusted to pH ≈6.5 using 1 M 
hydrochloric acid and/or 1M sodium hydroxide (<5 µL of each) prior to vortexing. The 





using a Bruker Avance III 400 MHz (9.4 T) wide-bore spectrometer (Bruker, Germany) 
with a high-resolution broadband spectroscopy probe at 298 K. A NOESY 1D pulse 
sequence was used with 152 scans and an acquisition duration of 20 minutes. Using 
TopSpin software version 2.1 (Bruker, Germany), each FID was Fourier-transformed to 
give a 1H NMR spectrum (Figure 2.7) which was then phased, baseline-corrected and 
chemical shifts were normalised by setting the TSP signal to 0 ppm. Peaks of interest 
(Table 2.1) were initially integrated automatically using a pre-written integral text file 
and integration regions were manually adjusted where required (this was particularly 
important for the taurine signal as its chemical shift is highly pH-dependent). All 
metabolite integrals were scaled to the TSP integral. Peak assignments were confirmed 
using Chenomx NMR Profiler Version 8.1 (Chenomx, Canada). The concentration of 
each metabolite of interest in each sample was determined by incorporating the integrals 
of the metabolite and TSP into Equation 2.6. 
 
              [Metabolite] = [TSP] × �IMet nMet ⁄ ��ITSP nTSP ⁄ �
Wet wt   Equation 2.6 
where, 
[Metabolite] = Concentration of metabolite in sample (nmol/g wet weight of heart). 
[TSP] = Concentration of TSP internal standard in sample (nmol). 
IMet = Integral of metabolite peak relative to TSP peak integral. 
nMet = Number of protons giving rise to the metabolite peak. 
ITSP = Integral of TSP peak. 











Figure 2.7  Representative 1H NMR spectrum of an isolated perfused rat heart 
under normal baseline conditions. 
When multiple peaks arose from a single metabolite, only the peak with the highest 
signal-to-noise ratio and least interference from neighbouring peaks was used for 
integration of that metabolite. See Table 2.1 for peak assignments. 
 
 







 Table 2.1 1H NMR chemical shift values of peaks used for metabolite 
 integrations. 
 






































2.4.4 High performance liquid chromatography tandem mass spectrometry (LC-
MS/MS) of metabolite extracts. 
Given the central importance of the TCA cycle to the thesis hypothesis, it was important 
to use a method that permitted robust measurements of as many of the TCA cycle 
intermediates as possible. Quantification of multiple TCA cycle intermediates in a 
single analysis is challenging due to their relatively low concentrations in muscle and 
similar chemical structures and properties (particularly citrate and isocitrate). As the 
TCA cycle intermediates are all weak acids they can be separated using ion exchange 
chromatography as demonstrated by Lu et al (2003). However, this method was only 
able to quantify malate and citrate due to issues with S:N of (and interference with) the 
other intermediates and encompassed lengthy acquisition times using gradient elution. 
An alternative method developed by Bylund et al (2007) involved high performance 
liquid chromatography tandem mass spectrometry (LC-MS/MS) in ion exclusion mode. 
Owing to its high selectivity and sensitivity, LC-MS/MS is an ideal method for targeted 
metabolomics. LC-MS/MS combines the separation powers of HPLC with the high 
sensitivity of multiple reaction monitoring (MRM) using triple quadrupole mass 
spectrometry instrumentation. MRM involves the measurement of multiple pre-defined 
MS transitions during different and specific time-points of a chromatographic 
separation. During each MS transition, quadrupole 1 (Q1) is used to filter-out all non-
parent ions, Q2 acts as a collision cell in which the parent ion is fragmented into a 
daughter ion and Q3 detects and quantifies the abundance of this daughter ion.  
An adaptation of the Bylund et al (2007) LC-MS/MS method was used for the 













Figure 2.8  Representative LC-MS/MS chromatograms of metabolite extracts from isolated 
perfused rat heart.  
(A) A single full scan experiment of mixed standard solution (in this example a guard column was not 
used hence peaks generally eluted earlier than those in ‘B-I’ for which a guard column was used). 
For studies, two separate chromatographic runs were performed in order to maximise resolution and 
signal-to-noise (this full scan image is for presentation purposes only and was not used for studies). 
MRM was carried out for each metabolite during their particular retention times: (B) α-ketoglutarate; 
(C) pyruvic acid; (D) citric acid; (E) isocitric acid; (F) malic acid; (G) fumaric acid; (H) succinic acid; (I) 
lactic acid. Y-axis = Raw counts; X-axis = minutes. Signal at 0-9.5 mins is due to background. 
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lactate, in myocardial samples from perfusion studies. 
 
Lyophilised aqueous metabolite extracts were reconstituted in 350µL ultrapure water. A 
series of mixed external standards were prepared in ultrapure water containing 0.0025-
50 µM of each metabolite. Representative chromatograms are shown in Figure 2.8. 
An Agilent 1100 HPLC system (Agilent Technologies, USA) consisting of an 
autosampler, a binary pump, a degasser unit and a column oven coupled to an Applied 
Biosystems Sciex API 3000 mass spectrometer with Turbo Ionspray interface (MDS 
Sciex, Canada) were used for LC-MS/MS analysis. Chromatograpic separation was 
achieved using a Supelcogel C610-H column (300 mm x 7.7 mm) with a Supelcogel H 
guard column (50 mm x 4.6 mm) (Supelco, USA) with an isocratic flow (0.4 mL/min) 
of mobile phase consisting of 0.01% v/v formic acid and methanol (90:10) and an 
injection volume of 100µL. The HPLC eluate was split (4:1) just before the Turbo 
Ionspray interface resulting in a flow of 0.1 mL/min into the mass spectrometer. The 
mass spectrometer acquisition parameters were exactly as described in Bylund et al 
(2007). In order to eliminate peak to peak interference, two separate acquisitions were 
performed for each sample and standard. Acquisition 1 included α-ketoglutarate 
(145>101 m/z), citrate (191>87 m/z), isocitrate (191>155 m/z), fumarate (115>71 m/z) 
and lactate (89>43 m/z) while Acquisition 2 included pyruvate (87>43 m/z), malate 
(133>115 m/z) and succinate (117>73 m/z).  Data were acquired using Analyst software 
(version 1.4.2) and metabolite concentrations in the samples were interpolated using 
calibration curves of each metabolite as per Bylund et al (2007). These concentrations 







   Met = [Met] x 0.00035 x 1000
Wet wt              Equation 2.7 
where, 
 Met = Metabolite content of heart (nmol/ g wet wt) 
 [Met] = Metabolite concentration in reconstituted extract according to  
   LC-MS/MS (µM). 
 0.00035 = Dilution factor (350µL used for reconstitution) 
 1000 = Conversion factor (µmolnmol) 
 Wet wt = Wet weight of tissue used for LC-MS/MS (g). 
 
2.4.5 Gas chromatography tandem mass spectrometry (GC-MS) of metabolite 
extracts 
An alternative means by which to quantify the TCA cycle intermediates in myocardial 
tissue is GC-MS (Guo et al., 2016, Shibayama et al., 2015, Atherton et al., 2006). In 
summary, the metabolite extract is dissolved in a volatile diluent and is injected into a 
heated source thereby vapourising the extract. The sample is carried by an inert gas 
through a column lined with a suitable stationary phase within a heated oven. 
Analogous to LC-MS/MS, the time of elution into the detector (retention time) of a 
given metabolite depends upon its partitioning between the stationary phase which is 
governed by its physicochemical properties (particularly boiling point). The majority of 
GC-MS method use electron impact ionisation which involves electron bombardment of 
the sample leading to a loss of an electron and generation of an M+ parent ion of the 





(such as the TCA cycle intermediates) is the necessity for increasing their volatility 
using derivatisation with, for example, N-tert-Butyldimethylsilyl-N-methyltrifluoro-
acetamide (MTBSTFA). The addition of the derivitisation agent to the analyte increases 
its molecular mass which is taken into account when interpreting the mass spectra. An 
adaptation of the method used by Mamer et al. (2013) was used in Chapter 6 for the 
measurement of TCA cycle intermediates as well as metabolites involved in anaplerosis 
(alanine, aspartate and glutamate) and glycolysis (dihydroxyacetone phosphate (DHAP), 
pyruvate and lactate). 
 
Metabolites were isolated from 20-40 mg of myocardial tissue by the addition of 1.5 mL 
ice-cold methanol and 10 μL D3-methylmalonic acid internal standard (1 mg/mL) 
followed by homogenisation using a TissueLyser II (Qiagen, Germany) at 30 Hz for 
five minutes. Homogenates were then centrifuged for 10 minutes at 3500 RPM. The 
supernatant was evaporated to dryness under nitrogen. The extracts were heated at 80 
°C for 15 minutes in 30 μL methyldroxyalmine hydrochloride (20 mg/mL in pyridine) 
to methoxymate the α-ketoacids thereby improving their stability. Upon cooling, 
MTBSTFA (30 μL) and hexane (70 μL) were added followed by brief vortexing and 
heating at 80 °C for 30 minutes. The solution was then transferred into an injection vial 
with a crimped septum cap to minimise sample loss due to evaporation. 
GC-MS was performed using a 6890 gas chromatograph (Agilent Technologies, USA) 
with 7683 autosampler (Agilent Technologies, USA) and 122-5532UI DB-5ms 30 m x 
0.25 mm internal diameter capillary column with 0.25 μm film thickness (Agilent 





was kept at 1.0 mL/min. The column oven was held at an initial temperature of 50 °C 
for one minute which was increased at a rate of 10 °C/ minute and held at a final 
temperature of 320 °C for 10 minutes. The injection volume was 1.00 μL. Each sample 
was analysed twice. The first injection was split 1:10 for the measurement of 
metabolites with a relatively high signal:noise ratio (pyruvate, lactate, alanine, 
succinate, malate, aspartate and glutamate) whereas the second splitless injection 
permitted the measurement of metabolites with lower signal-noise (fumarate, 
oxaloacetate, αKG, DHAP, citric and isocitric). The effluent was carried into a 5973 
mass selective detector (single quadrupole) mass spectrometer (Agilent Technologies, 
USA) via an MSD transfer line maintained at 280 °C and fragmented using an electron 
beam of 70eV. Detection of analytes in selected ion monitoring mode was started after a 
solvent delay of 8.60 minutes. MSD ChemStation D.02.00 software was used for GC-
MS data analysis. Peaks of interest were integrated automatically or manually where 
appropriate. Peak assignments were confirmed using a derivatised mixed standard 
solution containing all metabolites of interest. Addition of MTBSTFA to samples 
resulted in tert-butyldimethylsilylation of hydroxyl groups which was reflected in the 
mass ions observed. Representative GC-MS chromatograms are displayed in Figure 2.9. 
The integral for each isotopologue of these metabolites were used to calculate mean 13C 
enrichment and mass distribution vector (MDV) in Chapter 6. Representative GC-MS 
spectra of 13C-labelled and unlabelled myocardial extracts are displayed in Figure 2.10 
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Figure 2.9  Representative GC-MS chromatograms of metabolite extracts from isolated 
perfused rat heart.  
(A) Dihydroxyacetone phosphate. (B) Pyruvate. (C) Lactate. (D) Oxaloacetate. (E) Citrate (larger 
peak at 22.75 minutes) & isocitrate (smaller peak at 22.85 minutes). (F) α-ketoglutarate. (G) 
Succinate. (H) Fumarate (I) Malate. (J) Alanine. (K) Aspartate. (L) Glutamate. Arrow indicates 
metabolite of interest where multiple peaks are present. 
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Figure 2.10  Representative GC-MS spectra of malate isotopologues from isolated perfused 
rat heart. 
(A) Perfused with [U]-12C-glucose. (B) Perfused with [U]-13C-glucose. Hearts had elevated [Na]i due 
to ouabain. 




































































All calculations were performed using Microsoft Excel. GraphPad Prism Version 5 
(Graphpad Software Inc., USA) was used for all statistical analyses and graphs. Data 
were expressed as mean ± SEM unless otherwise stated. Two-tailed, unpaired Student’s 
t-test was used unless otherwise stated (P<0.05 was considered statistically significant). 
All metabolomics datasets were subjected to outlier detection and removal using the 
median absolute deviation method (± 2.5 threshold) (Leys et al., 2013). 
  




3 INVESTIGATING THE EFFECTS OF OUABAIN ON 
[Na]i AND METABOLISM IN THE ISOLATED 
PERFUSED RAT HEART. 
3.1 Introduction 
In order to investigate the relationship between [Na]i elevation and altered metabolism 
in the beating heart, it is necessary to develop and optimise a Langendorff preparation in 
which [Na]i can be elevated to a significant level and measured in real-time. Previous 
studies have used modified ion compositions in KH to increase [Na]i such as those free 
of K+, Ca2+ or Mg2+ (Eykyn et al., 2015, Schepkin et al., 1998). However, these buffers 
alter electrophysiology and lead to functional impairment in isolated perfused hearts. 
Other methods known to elevate [Na]i include electrical pacing. For example, 3 Hz (or 
180 ‘BPM’) has been shown to increase [Na]i by up to ~30% in isolated ventricular 
myocytes and muscle strips versus unpaced controls (Cohen et al., 1982, Despa et al., 
2002b). However, this does not appear to reflect the response of the intact heart. Simor 
et al. (1997) showed that increasing pacing rate from 4.2 Hz (250 BPM) to 8.3 Hz (500 
BPM) elevated [Na]i by only 9%. Furthermore, increasing heart rate by pacing reduces 
developed pressure due to the negative force frequency relationship in the rat (Schouten 
and ter Keurs., 1991) and therefore any metabolic changes driven by [Na]i may also be 
subject to changes in contractile function. A more suitable approach is to use a 
pharmacological agent in order to either inhibit [Na]i efflux or enhance [Na]e influx. As 
discussed in Section 1.2.3, NKA is the only quantitatively important efflux pathway for 




[Na]i under physiological conditions whereas there are numerous influx pathways for 
this ion. Therefore, the most widely used approach is inhibition of NKA with real-time 
23Na NMR measurements to assess the rise in [Na] (detailed in Section 2.3.3). 
The use of ouabain to elevate [Na]i and measurements employing 23Na NMR have 
previously been implemented in our laboratory in the mouse heart (Eykyn et al., 2015) 
and elsewhere in the rat heart (Schepkin et al., 1998). Ouabain was therefore used to 
elevate [Na]i while simultaneously measuring [Na]i using 23Na NMR in the Langendorff 
rat heart preparation. Schepkin et al (1998) used 1 mM ouabain, resulting in cardiac 
arrest and [Na]i of approximately 40 mM (Figure 2.4), whereas previous measurements 
in the perfused mouse heart using 50 µM ouabain increased [Na]i from 16 mM to 26 
mM (Eykyn et al., 2015). In addition, Koomen et al (1984) and Maixent (1998) showed 
that hearts perfused with 100µM ouabain do not exhibit arrest and Peng et al (1996) 
demonstrated that ouabain does not affect myocyte viability at or below 100 µM but 
does above this concentration. Initial studies in this chapter investigated the dose 
response relationship for 50-100 µM ouabain to establish the most suitable 
concentration to elevate [Na]i in the perfused rat heart. 
Following these initial dose-response experiments, a single concentration was chosen to 
investigate possible metabolomics changes associated with ouabain treatment in both an 
unpaced group of hearts with baseline heart rate and a group with an elevated heart rate 
using electrical pacing where ATP demand is elevated. End-point metabolomics 
measurements were performed using a semi-targeted 1H NMR approach. Lactate efflux 
was measured throughout the perfusion protocols to assess whether glycolytic flux was 
altered in response to ouabain. 





The aims of the studies described in this chapter were: 
1. To determine a dose-response relationship between ouabain concentration and 
[Na]i in the perfused rat heart. 
 
2. To determine whether a semi-targeted metabolomics approach using 1H NMR 
probes alterations in metabolism in response to ouabain in unpaced or paced 
hearts. 
 
3.3 Establishing dose-response between [ouabain] and [Na]i 
This study investigated the dose-response of 50-100 µM ouabain and [Na]i in the 
perfused rat heart. 
 
3.3.1 Experimental methods 
Hearts were blinded and randomised into either control group (n=6) or treated groups 
with three different concentrations of ouabain (50, 75 & 100µM; n=6/group) and were 
perfused in Langendorff mode within the NMR magnet as described in Sections 2.2 and 
2.1.2. Ouabain octahydrate was obtained from Sigma (UK). 
Hearts were stabilised for 30 minutes with standard KH (Section 2.1.3) and then 
perfused with treatment KH (control or ouabain) for 25 minutes. Derived [Na]i was 
monitored throughout the protocols using TQF 23Na NMR interleaved with DQF 23Na 




NMR (Section 2.2.3). Left ventricular developed pressure (LVDP), heart rate and 
coronary flow were monitored throughout all experiments. 
 
3.3.2  Results - Ouabain induces a dose dependent elevation of [Na]i  
All perfusion parameters remained constant during the stabilisation period, according to 
previously defined exclusion criteria (detailed in Section 2.1.6) and were not 
significantly different between any of the groups. Mean baseline LVDP (Figure 3.1A) 
was 97±10 mmHg in the control group. In the 50 µM, 75 µM and 100 µM ouabain 
groups, LVDP was elevated by a maximum of 15, 28 and 38 mmHg at 40 minutes 
respectively versus their baseline values. However, LVDP returned to baseline values in 
all groups by the end of perfusion. There were no significant differences in LVDP 
between any of the four groups at any point of the perfusion protocol. Heart rate in the 
control group (Figure 3.1B) did not deviate from baseline values (302±6 BPM) at any 
point of perfusion. 50, 75 and 100 µM ouabain decreased heart rate by a maximum of 
52, 56 and 59 BPM versus baseline values, respectively. The time at which maximum 
bradycardia was reached differed between these ouabain groups (45, 55 and 50 minutes, 
respectively). End-point heart rate at 55 minutes was not significantly different to 
control (312±8 BPM) in the 50µM and 75µM ouabain groups however was significantly 
lower (211±23 BPM, P<0.01) in the 100µM ouabain group at this time. Coronary flow 
(Figure 3.1C) averaged 10±1 mL/min for all hearts in this study with no significant 
differences (P>0.05) between any of the groups. 
  




           










   
  
 
Figure 3.1  Dose response studies, ex vivo functional parameters recorded 
during stabilisation and control, 50uM, 75uM and 100uM ouabain treatment 
periods.  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary Flow. 













































































Figure 3.2  Dose-response studies using real-time 23Na NMR during stabilisation 
and control, 50uM, 75uM and 100uM ouabain treatment periods. 
(A) Normalised TQF signal as a function of time (left axis) and corresponding derived 
[Na]i (right hand axis). (B) End-point derived [Na]i for control and treatment groups. 
(C) Normalised DQF signal as a function of time. (D) Dose-response curve of end-
point derived [Na]i values as a function of ouabain concentration. Curve fitting 
constraints were applied: bottom=17.71 mM; top=38.59mM; slope=0.05. 
EC50=45.8μΜ (NB. 20μM ouabain datapoint was acquired in another study using the 
same protocol (see Appendix 8.3). Data are displayed as mean±SEM (n=6/group). 
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The 23Na TQF (Figure 3.2A) remained constant throughout the stabilisation period (0-
30 minutes) in all groups and also remained constant throughout the entire protocol in 
the control group (30-55 minutes) with a calculated [Na]i of 17±0.8 mM (using the 
calibration curve of Schepkin et al., 1998). During the treatment period, the initial slope 
of derived [Na]i elevation was the same in all ouabain groups between 30 and 37 
minutes reaching 25±0.9 mM. Following this, the TQF elevation of the 50 µM ouabain 
group plateaued earlier than the other ouabain groups, while the 75 µM and 100 µM 
ouabain groups showed almost identical 23Na TQF profiles throughout the entirety of 
the protocol. At the end of perfusion (55 minutes), all treatment groups exhibited 
significantly elevated [Na]i (Figure 3.2B) than control (control = 17±1.1 mM; 50 µM = 
31±1.5 mM, P<0.01 vs control; 75 µM = 39±3.5 mM; P<0.001 vs control; 100 µM = 
38±3.5 mM, P<0.001 vs control). The 23Na DQF signal (Figure 3.2C) did not markedly 
deviate from baseline (1.0±0.1 arbitrary units) at any point of perfusion in any of the 
groups, although this had a lower signal-to-noise ratio than the 23Na TQF 
measurements. The dose-response relationship (Figure 3.2D) between [ouabain] and 
[Na]i was sigmoidal with a calculated EC50 of 45.8 µM ouabain. 
 
3.4 A semi-targeted metabolomics study of ouabain response in the perfused rat 
heart 
To assess whether ouabain induces metabolic alterations in the perfused rat heart, a 
single concentration of 50µM ouabain was used for further investigation as it was 
shown in the previous study to induce significant and sustained [Na]i elevation without 
observable toxicity. Two bench protocols were performed, either an unpaced group 




allowed to free-run at the intrinsic heart rate or a paced group where heart rate and 
therefore ATP demand were elevated. These protocols were not conducted in the NMR 
magnet but on a separate isolated heart perfusion rig. End-point metabolomics was 
assessed in a semi-targeted fashion using 1H NMR. Lactate efflux was monitored 
throughout the protocols. 
 
3.4.1 Experimental methods 
Hearts were perfused with either control or 50 µM ouabain KH in a randomised and 
blinded fashion (n=6/group). Unpaced hearts were stabilised for 30 minutes with 
standard KH (Section 2.1.3) and then perfused with either control KH or ouabain for a 
further 20 minutes followed by snap-freezing (Section 2.1.9). In the paced study, hearts 
were stabilised for 20 minutes with standard KH perfusion (Section 2.1.3) during which 
they were paced (Section 2.1.7) at 3.35 Hz (320 BPM). Between 20 and 80 minutes, 
hearts were perfused with either control KH or 50 μM ouabain and subsequently paced 
at higher rate (9.16 Hz; 550 BPM) followed by snap-freezing (Section 2.1.9) at 80 
minutes. In both groups aqueous metabolites were extracted (Section 2.4.2) and 
quantified by high-resolution 1H NMR (Section 2.4.3). Coronary effluent was taken at 
five minute intervals throughout the perfusion and analysed using the 2300 STAT Plus 
giving lactate efflux rate (Section 2.3). Left ventricular developed pressure (LVDP), 
heart rate, left ventricular end diastolic pressure (LVEDP) and coronary flow were 
monitored throughout all experiments. 
 




3.4.2 Results – 50 μM ouabain induces metabolomic changes in the unpaced 
heart. 
All perfusion parameters remained constant during the stabilisation period according to 
predefined exclusion criteria (detailed in Section 2.1.6). Baseline LVDP (Figure 3.3A) 
was 151±4 mmHg (average) in the control group and did not significantly deviate from 
this between 30 and 50 minutes (average=143±5 mmHg). In the ouabain group, LVDP 
was elevated to a maximum of 184±5 mmHg at 40 minutes (after 10 minutes of 
perfusion with 50µM ouabain) and remained significantly elevated at 55 minutes 
(177±2 mmHg, P<0.001) versus control (140±3 mmHg). Mean control heart rate during 
stabilisation was 289±14 BPM (Figure 3.3B). Coronary flow and LVEDP averaged 
15±1 mL/min and 5.6±0.7 mmHg respectively for all hearts in this study with no 
significant differences (P>0.05) between any of the groups. 
Lactate efflux rate during the stabilisation period (Figure 3.4) averaged 348±45 
nmol/min/g for all hearts with no significant differences between the two groups 
(P>0.05) and reached steady-state within 30 minutes. Lactate efflux increased to a 
maximum of 673±61 nmol/min/g after 5 minutes of 50 µM ouabain perfusion and 
remained significantly elevated at the end of perfusion (504±37 nmol/min/g) versus 
control (229±49 nmol/min/g, P<0.01). 
High resolution 1H NMR permitted the quantification of numerous metabolites in a 
semi-targeted metabolomics approach (Figure 3.5). Metabolites were categorised into 
pathways related to ATP supply (including glycolysis, the TCA cycle, acetyl carnitine 
shuttling, anaplerosis and energetics) and those that were less important to ATP supply 












Figure 3.3 Perfusion measurements (unpaced ouabain bench study).  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary flow. (D) 
Left ventricular end diastolic pressure (LVEDP). Symbols and error bars represent 
mean±SEM of five minute time windows (n=6/group). Hearts were snap-frozen at 50 
minutes. P-values represent unpaired student’s t-test of area under the curve between 

























































































Figure 3.4  Lactate efflux (unpaced ouabain bench study).  
Symbols and error bars represent mean±SEM of five minute time windows (n=6/group). 
Significant p-values are shown (unpaired student’s t-test of area under the curve 
between 30 and 50 minutes). 
 
Figure 3.5  1H nuclear magnetic resonance spectroscopy metabolomic profile of 
myocardium (unpaced ouabain bench study). 
Hearts were snap-frozen at 50 minutes. Bars and error bars represent mean fold 
change ± propagated SEM (n=4-6/metabolite/group). A fold change of ‘1.0’ represents 
zero change vs control. The y-axis scale has been matched to that of the paced 
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(‘other’). Figure 3.5 shows fold change of metabolite concentrations in treated versus 
control. 
50 µM ouabain lead to increased fumarate by 64% (P<0.05), acetyl carnitine by 74% 
(P<0.001) and an 88% elevation in the acetyl carnitine-carnitine ratio (P<0.001). The 
trend towards an increase in alanine by 51% did not reach statistical significance 
(P>0.05). All other metabolites were unaltered following 50µM ouabain treatment. Full 
details of the unpaced metabolomics dataset are shown in Appendix 8.1. 
 
3.4.3 Results – 50 μM ouabain induces metabolomic changes in the paced heart. 
Perfusion parameters were stable according to predefined exclusion criteria (detailed in 
Section 2.1.6) except LVDP (Figure 3.6A) which was elevated at the start of the 
perfusion (control = 169±10 mmHg; ouabain = 178±6 mmHg) and took 40 minutes to 
reach steady-state (116±4 mmHg) in the control group. There was no difference 
(P>0.05) in LVDP between the control and ouabain group in the first 20 minutes during 
which all hearts were paced at 320 BPM in the absence of ouabain. LVDP was higher in 
the ouabain group versus control throughout the treatment period (20-80 minutes) and 
was significantly higher at the end of perfusion (control = 72±1 mmHg; ouabain = 91±2 
mmHg; P<0.0001). Following increased pacing rate from 320 BPM to 550BPM (Figure 
3.6B), LVDP significantly decreased in both groups (control = 113±5 to 81±2 mmHg, 
P<0.0001; ouabain = 136±7 to 89±9 mmHg, P<0.001). Coronary flow (Figure 3.6C) 
was not significantly altered (P>0.05) by ouabain or pacing. There was a trend towards 
increased LVEDP (Figure 3.6D) with high pacing rate (control = 6±1 to 14±4 mmHg;  
  










Figure 3.6 Perfusion measurements (paced ouabain bench study).  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary flow. (D) 
Left ventricular end diastolic pressure (LVEDP). Symbols and error bars represent 
mean±SEM of five minute time windows (n=6/group). Hearts were snap-frozen at 80 
minutes. Significant p-values are shown (unpaired student’s t-test of area under the 
































































































Figure 3.7  Lactate efflux (paced ouabain bench study).  
Symbols and error bars represent mean±SEM of five minute time windows (n=6/group). 
Significant p-values are shown (unpaired student’s t-test of area under the curve 
between either 20 and 50 minutes or 50 and 80 minutes). 
 
 
Figure 3.8 1H nuclear magnetic resonance spectroscopy metabolomic profile of 
myocardium (paced ouabain bench study).  
Hearts were snap-frozen at 80 minutes. Bars and error bars represent mean fold 
change ± propagated SEM (n=4-6/metabolite/group). A fold change of ‘1.0’ represents 
zero change vs control. The y-axis scale has been matched to that of the unpaced 
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ouabain = 7±1 to 17±4 mmHg) although this was only significant in the ouabain group 
(P<0.05). 
Rates of lactate efflux during the stabilisation period (Figure 3.7) were the same in the 
control (1014±124 nmol/min/g) and ouabain groups (958±145 nmol/min/g). There was 
a decline in the lactate efflux rate during this period (control = -24 nmol/min/g; ouabain 
= -26 nmol/min/g). In the control group, steady-state was reached at 40 minutes from 
the start of perfusion. Lactate efflux was not significantly increased by elevating pacing 
rate from 320 BPM to 550 BPM (P<0.05) in either group. Lactate efflux was 200-500 
nmol/min/g higher in the ouabain group versus control throughout the treatment period 
and was significantly elevated  at the end of perfusion, 857±47 nmol/min/g and 524±64 
nmol/min/g (P<0.01), respectively. 
In the end-point metabolomics (Figure 3.8) from the two paced groups of hearts, 
treatment with 50µM ouabain resulted in increased lactate (101%; P<0.05), fumarate 
(211%; P<0.05), succinate (88%; p<0.01), acetyl carnitine (132%; P<0.001), acetyl 
carnitine-carnitine ratio (119%; P<0.0001), creatine (Cr) (50%; P<0.01) and choline 
(48%; P<0.05). The increased Cr resulted in a reduction in the phosphocreatine PCr:Cr 
ratio  (-39%; P<0.05). All other metabolites were unaltered following 50 µM ouabain 
treatment. Full details of the paced metabolomics dataset are shown in Appendix 8.2. 
 





3.5.1 Dose response between derived [Na]i and ouabain. 
Ouabain caused a dose-dependent elevation in TQF signal in the absence of any change 
in DQF, giving confidence in the 23Na NMR methodology used to assess intracellular 
and extracellular pools of Na+ in the perfused rat heart. 
The peak elevation in derived [Na]i induced by 50 µM ouabain (31±1 mM) was two-
fold higher than the baseline value (17±1 mM), which is in agreement with the relative 
changes seen by Lotan et al. (1992) using a similar protocol. The derived [Na]i value 
using this concentration of ouabain was similar to that previously measured in the 
mouse (26±5 mM, Eykyn et al., 2015). Perfusion with 50-100 μM ouabain gave rise to a 
dose response that was similar to that observed by Koomen et al. (1984) (Figure 1.4). In 
further agreement with the literature (Koomen et al., 1984, Maixent et al., 1998, Peng et 
al., 1996), perfusion with ouabain up to 100 µM gave rise to a positive inotropic effect 
in the absence of functional impairement. The ouabain dose-response measurements 
carried out in this chapter will act as a guide for increasing [Na]i to desired levels in the 
perfused rat heart in subsequent chapters of this thesis. 
 
3.5.2 Lactate efflux 
Lactate efflux was significantly increased in both paced (Figure 3.7) and unpaced 
(Figure 3.4) hearts during perfusion with 50µM ouabain. Lactate is extruded by the 
sarcolemmal monocarboxylate transporter (MCT) (Zhu et al., 2013) and therefore likely 




suggests an elevation in anaerobic glycolysis, possibly due to increased inotropy. The 
isolated rat heart is known to release a relatively small amount of lactate under basal 
conditions (approximately 0.5 μmol/min/g, Allen et al., 1986) which aligns with the 
values shown in Figure 3.4. Lactate efflux is known to be elevated during increased 
contractile demand (Allen et al., 1986) and following ischaemia (Wilder et al., 2016) 
but the effect of [Na]i elevation on lactate efflux has not been previously reported. 
 
3.5.3 Metabolomics 
Figure 3.5 revealed that perfusion of unpaced rat hearts with 50 µM ouabain was 
associated with significant elevations in fumarate but not succinate, while paced rat 
hearts revealed an elevation in both these metabolites in response to ouabain suggesting 
a possible change in the TCA cycle. The acetyl carnitine-carnitine ratio is an indicator 
of the extent of shuttling of acetyl groups into the mitochondria for the production of 
acetyl CoA and was also significantly elevated by ouabain perfusion in both paced and 
unpaced hearts. Elevated acetyl carnitine levels have been reported previously in urine 
(Matsui et al., 1994) and plasma (Turer et al., 2009) from patients with contractile 
dysfunction although the role of [Na]i was not investigated in these studies. Despite the 
elevation in lactate efflux due to ouabain, the end-point myocardial levels of lactate 
were unaltered in unpaced hearts following ouabain perfusion. This is indicative of 
increased anaerobic glycolysis and increased extrusion of lactate. 
Figure 3.8 demonstrated that increased contractile demand via elevated pacing 
augmented the metabolic alterations induced by ouabain identified in unpaced hearts. 




Fumarate and acetyl carnitine-carnitine ratio were elevated to a greater extent than in 
unpaced hearts. Furthermore, some metabolites that were not significantly altered by 50 
µM ouabain in unpaced hearts were significantly increased by ouabain during elevated 
pacing. Increased succinate was observed in the paced group which, taken together with 
the elevation in fumarate, adds weight to the hypothesis that the TCA cycle is altered in 
these experiments, either due to increased [Na]i or increased inotropy. The rates of 
lactate efflux were similar at the end of perfusion in both unpaced and paced ouabain 
metabolomics studies, but myocardial lactate was elevated in the paced hearts 
suggesting that lactate efflux may become saturated at higher pacing rates leading to a 
build-up of intracellular lactate. Creatine also became elevated by ouabain in the paced 
group. As discussed in Section 1.3.2, creatine is essential for the creatine kinase reaction 
in order to maintain ATP supply instantaneously with increased contractile demand. 
However, PCr and total ATP+ADP were unaltered by ouabain suggesting unaltered 
energetic reserve. Taken together with the other metabolite elevations due to ouabain, 
this may reflect a shift of metabolism in order to sustain cardiac energetics during [Na]i 
elevation. Choline was also increased by ouabain in paced hearts. In vivo choline 
supplementation has been shown to sustain both systolic and diastolic contractile 
performance as well as reduce the release of brain natriuretic peptide (a biomarker of 
myocardial infarction) (Strilakou et al., 2013). Furthermore, increased choline release 
occurs following global ischaemia-reperfusion insult in the perfused rat heart (Bruhl et 
al., 2004) due to enhanced hydrolytic cleavage of membrane phosphocholine. 
The metabolomic changes induced by 50 µM ouabain in both unpaced and paced (550 
BPM) rat hearts are summarised in Table 3.1. 




Table 3.1  Summary of alterations due to 50 µM ouabain in unpaced and paced  hearts. 
Analyte 
Unpaced Paced 
% change  P-value % change P-value 
Acetylcarnitine  74 0.0009   132 <0.0001 
Fumarate  64 0.022    211 0.015 
Succinate N/A N/A   88 0.002 
Lactate N/A N/A   101 0.032 
Creatine N/A  N/A   50 0.003 
Choline N/A  N/A   48 0.013 
 
% changes are for unpaced control group vs unpaced 50µM ouabain group or high-rate 
paced control group vs high-rate paced 50µM ouabain ouabain group at the end of 
perfusion where ‘0%’ change represents no change from baseline. N = 6 per group. 
‘N/A’: These metabolites were unaltered by 50µM ouabain perfusion in unpaced hearts. 
 
3.5.4 The problem with ouabain: undesired inotropic effects. 
The studies described in this chapter have given an initial insight into the relationship 
between ouabain concentration, [Na]i and metabolism during ‘normal’ and ‘high’ ATP 
demand. Although several metabolites were observed to be altered by ouabain including 
two TCA cycle intermediates, the impact of the associated positive inotropic effect on 
these metabolites is unknown. Hence, the sensitivity of these metabolites to [Na]i per se 
remains obscure. Whereas there have been very limited studies on the effect of [Na]i 
elevation on metabolism, more is known about the effects of increased contractile work 




on metabolism. For example, acetyl carnitine concentration has been shown to increase 
in skeletal muscle upon prolonged exercise in humans (Sahlin et al., 1990) and elevating 
peak systolic pressure from 60 mmHg to 120 mmHg in the working rat heart increases 
creatine by 26% (Kobayashi and Neely, 1983). Also, an increase in myocardial lactate 
concentration was observed in a similar model reported by Goodwin et al (1998). The 
importance of choline to in vivo contractile performance in the rat heart has been 
demonstrated (Strilakou et al., 2013). It is therefore likely that many of the metabolic 
changes observed in these studies may simply reflect an increase in inotropy and hence 
energetic demand induced by elevated [Na]i. 
 
3.6 Summary 
In this chapter, studies were carried out in order to determine the effects of ouabain on 
[Na]i (derived using TQF 23Na NMR) and metabolism (using high resolution 1H NMR 
metabolomics of snap-frozen myocardium) in the Langendorff rat heart preparation at 
both intrinsic heart rate and elevated heart rate (using electrical pacing). The degrees of 
[Na]i elevation induced by 50, 75 and 100 µM ouabain were substantial and sustained. 
Acetyl carnitine and fumarate were significantly elevated by 50 µM ouabain in unpaced 
hearts and this was augmented by high pacing rate. Increasing contractile demand by 
pacing appeared to enhance the sensitivities of other metabolite concentrations to 50 
µM ouabain, which were significantly elevated in paced hearts but not in unpaced hearts 
including lactate, succinate, creatine and choline. However, it is unclear whether these 
metabolic alterations were in response to the [Na]i elevation induced by ouabain or its 




associated positive inotropic effect. It is therefore important to develop a method which 
allows this to be elucidated. Proceeding Chapters will therefore aim to establish 
methods to uncouple the effects of enhanced inotropy during [Na]i elevation and 
thereby unravel any metabolic changes that are due to [Na]i overload alone. 
 
  




4 ELECTROMECHANICAL UNCOUPLING TO 
NORMALISE OUABAIN-INDUCED INOTROPY. 
4.1 Introduction 
In Chapter 3, a number of metabolomic alterations were observed in response to 50 µM 
ouabain perfusion in both unpaced and paced perfused hearts. These potentially arose 
from those that are [Na]i-dependent as well as those that are inotropy-dependent. To 
compare control and treated groups where [Na]i is elevated, a technique is required to 
normalise differences in inotropy between hearts. Two techniques were evaluated.  
The first method involved the induction of a positive inotropy in the control group by 
increasing intraventricular balloon volume and stretch via the Frank-Starling effect 
thereby elevating left ventricular developed pressure (LVDP) to that of the 
corresponding ouabain group. However, the corresponding ouabain group did not 
exhibit a sustained elevation in [Na]i and thus this approach was not developed further. 
Full details of this protocol are given in Appendix 8.3. 
An alternative approach is the removal of inotropy using electromechanical uncoupling. 
Metabolomic alterations could then be assessed in a non-contracting control versus a 
non-contracting ouabain group in which [Na]i remained elevated but the positive 
inotropic response of ouabain was negated. Metabolic differences between these two 
groups would be considered [Na]i-dependent in the absence of inotropic differences. 




Electromechanical uncoupling is commonly used to remove motion artefacts in optical 
mapping studies of isolated perfused hearts (Lang et al., 2011). This usually involves 
the cessation of contraction using inhibitors of the myofilament myosin ATPase, for 
example, 2,3-butanedione monoxime (BDM, Figure 4.1A) and blebbistatin (Figure 
4.1B). BDM and blebbistatin are both reported to inhibit myosin ATPase by the same 
uncompetitive mechanism, Herrmann et al. (1992) and Kovács et al. (2004), 
respectively. In brief, BDM and blebbistatin bind allosterically to the myosin head with 
ADP and phosphate (Pi) bound to the substrate binding site. A conformational change 
induced by blebbistatin reduces the release of Pi from the active site thereby decreasing 
myosin-actin interaction (cross-bridge formation). IC50 values of force inhibition by 
BDM have been reported as 7.22 mM (Brixius et al., 2000) and 22±8 mM (Hebisch et 
al., 1993). BDM concentrations in the range 10-30 mM are often used for elimination of 
contractility in the Langendorff model (Kettlewell et al., 2004, Daly et al., 1987, Sill et 
al., 2009, Doumen et al., 1995, Hebisch et al., 1993, Yaku et al., 1993). Blebbistatin is 
enantiomeric and Shu et al. (2005) reported that racemic blebbistatin contains 59 % (-) 
and 41 % (+) and that a 100 % solution of (-)-blebbistatin inhibits myosin II ATPase 
with an IC50 of ~3-4 µM. This is similar to the IC50 value (1.2 µM)  reported by 
Limouze et al. (2004). 
 




                 
Figure 4.1  Chemical structures of 2,3-butanedione monoxime (BDM) and 
blebbistatin.  
(A) BDM (PubChem= 6409633). (B) (-)-blebbistatin (PubChem CID:3476986). 
In this chapter, experiments were performed in isolated rat hearts perfused with BDM 
(10-30 mM) or 5 µM (±)-blebbistatin (≈2.95 µM (-)-blebbistatin) to uncouple 
contraction in the absence or presence of ouabain. The protocols were carried out in 
conjunction with TQF 23Na NMR measurements to assess the dose-response 
relationship of [Na]i to ouabain in uncoupled preparations.  
In a separate bench perfusion study, ouabain was administered to blebbistatin treated 
non-contracting hearts to assess possible metabolomic changes using semi-targeted 
metabolomics (1H NMR) and lactate efflux measurements. 
 
4.2 Aims 
The aims of the studies described in this chapter are: 
1. To assess the [Na]i dose-response and contractile response to ouabain in the 
electromechanically uncoupled perfused rat heart treated with BDM (10-30 
mM). 
(A) (B) 




2. To assess the [Na]i dose-response and contractile response to ouabain in the 
electromechanically uncoupled perfused rat heart treated with 5 µM blebbistatin. 
 
3. To determine whether a semi-targeted metabolomics approach using 1H NMR 
probes alterations in metabolism in response to ouabain in the non-contracting 
perfused rat heart. 
 
4.3 Uncoupling contraction with 2,3-butanedione monoxime 
4.3.1 Experimental methods 
BDM was dissolved in standard KH (unless otherwise stated) to the required 
concentration (10, 20 and 30 mM) using sonication and vigorous mixing. Daly et al. 
(1987) showed that 30 mM BDM sequesters 1.3 mM Ca2+ and compensated for this by 
adding an extra 1.3 mM Ca2+ to their KH to a final concentration of 2.6 mM (giving a 
free Ca2+ concentration of 1.3 mM). Extra Ca2+ was added to the BDM solutions in this 
chapter based on the assumption that 30 mM BDM sequesters 1.3 mM Ca2+ and that this 
is a linear relationship across all BDM concentrations. Solutions of 10, 20 and 30 mM 
BDM were prepared with Ca2+ concentrations of 1.83, 2.27 and 2.70 mM, respectively, 
to give an estimated final free Ca2+ concentration of 1.4 mM. 
Rat hearts were perfused in Langendorff mode as described in Section 2.2. Hearts were 
stabilised for 20 minutes with standard KH (Section 2.1.3) followed by 12 minutes of 
BDM perfusion. Hearts were subsequently perfused for a further 20 minutes with the 
same concentration of BDM in the absence or presence of 100µM ouabain. Interleaved 




TQF and DQF 23Na NMR measurements (Section 2.2.3) were performed throughout all 
perfusions. LVDP, heart rate and coronary flow were monitored throughout all 
perfusions. 
A Vetscan® i-STAT®1 analyser with CG8+ cartridge (Abaxis UK) was used to 
determine the concentrations of Na+, K+ and Ca2+ in 20 mM BDM KH containing 2.27 
mM CaCl2 (as used in the BDM perfusion study) or 3.0 mM CaCl2 to assess whether 
increasing Ca2+ concentration affects any of the iSTAT measurements. 
To assess whether BDM alters the interaction of Na+ with protein (which gives rise to 
the TQF signal), solutions containing 145 mM NaCl, 10 mg/mL bovine serum albumin 
(BSA, obtained from Sigma, UK) in the absence or presence of BDM (5, 10, 15 or 20 
mM) were analysed by TQF 23Na NMR (Section 2.2.3). 
 
4.3.2 Results – Impact of BDM on functional parameters and [Na]i 
Isolated perfused hearts were initially perfused in a pilot study with 10, 20 and 30 mM 
BDM (n=1/group). 20 mM BDM was chosen for the main study (n=6/group) as it 
reduced contractility to a greater extent than 10 mM BDM and to the same extent as 30 
mM BDM (Figure 4.2A). All perfusion parameters (Figure 4.2) reached steady-state by 
the end of the stabilisation period (0-20 minutes), according to previously defined 
exclusion criteria (detailed in Section 2.1.6) and were not significantly different 
(P>0.05) between any of the groups. BDM induced an immediate and significant 
(P<0.0001) negative inotropy with LVDP values of 3.3±0.6 mmHg and 2.9±0.4 mmHg 
in the 20 mM BDM group and the 20 mM BDM+Oua group, respectively. A small but 




significant positive inotropic response occurred in the 20 mM BDM+Oua group during 
the ouabain treatment period that was sustained until the end of perfusion (P<0.05 vs 20 
mM BDM group at 50 minutes). BDM reduced heart rate in a dose-dependent manner 
(Figure 4.2B). The reductions from baseline heart rate at the end of perfusion were 17 
BPM (10 mM BDM), 69±13 BPM (20 mM BDM, P<0.05 vs baseline) and 187 BPM 
(30 mM BDM). Ouabain decreased heart rate further in the presence of 20 mM BDM 
(reduced by 115 BPM in the 20 mM BDM+oua group versus baseline; P<0.001). BDM 
reduced coronary flow (Figure 4.2C) by 4.8 mL/min (10 mM), 3.6±0.4 mL/min (20 
mM; P<0.0001) and 5.2 mL/min (30 mM) at the end of perfusion versus baseline. There 
was no difference (P>0.05) in end-point coronary flow between the 20 mM BDM group 
(6.0±0.3 mL/min) and 20 mM BDM+oua group (6.0±0.6 mL/min). 
Baseline derived apparent [Na]i (Figure 4.3A) was 18.0±0.4 mM in the 20 mM BDM 
group and was not different to that in the 20 mM BDM+Oua group (17.4±0.5 mM). 
BDM perfusion at 20 minutes resulted in an immediate decline in the normalised TQF 
signal and therefore derived [Na]i in both groups. After 10 minutes of perfusion with 
BDM, derived [Na]i was 11.8±0.4 mM in the 20 mM BDM group (P<0.001 vs baseline; 
paired t-test) and 12.6±0.4 mM in the 20 mM BDM+Oua group (P<0.01 vs baseline; 
paired t-test). This affect appeared to be dose dependent as the derived [Na]i in the 10 
mM and 30 mM were 14.0 mM and 7.55 mM respectively. The dose-dependent 
separation persisted until the end of perfusion with derived end-point [Na]i values for 
the 10mM, 20 mM and 30 mM BDM of 14.2, 12.3±0.6 and 8.4 mM, respectively. In the 
20 mM BDM+Oua group, there was an elevation in [Na]i after five minutes of ouabain   




   
     
   
Figure 4.2 Ex vivo functional parameters recorded during stabilisation, BDM and 
BDM+Ouabain (Oua).  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary Flow. 
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Figure 4.3  Effect of 2,3-butanedione monoxime (BDM) on TQF/DQF 23Na NMR measurements.  
(A) Normalised TQF signal as a function of time (left axis) and corresponding derived [Na]i (right 
hand axis). (B) Normalised DQF signal as a function of time. (C) End-point derived [Na]i for control 
and BDM group (***p<0.001 vs corresponding ouabain-free group). Data are displayed as 
mean±SEM (n=6/group). BDM-free data was from Section 3.3.2 (see Figure 3.1A for full [Na]i time 
profile of BDM-free control group). 
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treatment which reached a steady-state at 16 mM. This was sustained until the end of 
perfusion and was significantly higher than the 20 mM BDM group (P<0.01 at 50 
minutes). 
The normalised DQF signal (Figure 4.3B) did not markedly deviate from baseline 
(1.0±0.2) at any point of perfusion in any of the groups. Figure 4.3C displays the 
derived end-point [Na]i values from the 20 mM BDM study and the control study in 
Chapter 3. This data demonstrates that 20 mM BDM significantly decreased end-point 
apparent [Na]i  versus control hearts by 31% (P<0.05) and 56% (P<0.0001) in the 
absence and presence of ouabain, respectively. 
 
4.3.3 Results – Impact of BDM on free Na+ and TQF 23Na NMR signal in vitro. 
The mechanism underlying the apparent drop in 23Na TQF signal and therefore derived 
Na+ in the presence of BDM is worth further investigation and may reflect a change in 
the visibility of Na+ by TQF NMR rather than a real drop in [Na]i.  In vitro experiments 
were carried out in order to investigate a possible mechanism by which BDM reduces 
apparent observed [Na]i. Table 4.1 shows the measured values of Na+, K+ and ionised 
Ca2+ (iCa) for a 20 mM BDM solution. The apparent concentration of free Na+ was 
decreased by 30.3 % while the apparent concentration of free K+ increased by only 2.2 
% versus standard BDM-free KH. The measurement of free Na+ and K+ was not altered 
by different concentrations of added Ca2+. However, iCa could not be measured in these 
BDM solutions due to “chemical interference” (according to the iSTAT instrument). 




Nonetheless, the reduction in free Na+ indicate that BDM directly chelates Na+ with a 
stoichiometry of 2xNa+ per BDM molecule. 
 





+ (mM) iCa2+ (mM) 
20 mM BDM KH with 
2.27 mM CaCl2 101 4.6 
*Could not 
measure 
20 mM BDM KH with 




 *Due to chemical interference (according to the iSTAT instrument). Blebbistatin 
 (bleb); 2,3-butandione monoxime (BDM); ionised Ca2+ (iCa); KH (standard Krebs-
 Heinseleit buffer; see Section 2.1.3). 
 
 
Figure 4.4  Normalised triple quantum filtered (TQF) 23Na NMR intensity of NaCl 
solution with bovine serum albumin (BSA) and increasing concentrations of 2,3-
butanedione monoxime (BDM).  
    
    
 





























Concentrations of NaCl and BSA were 145 mM and 10 mg/mL respectively in all solutions 
(n = 1 solution / BDM concentration). 
Since BDM appeared to bind Na+ based on the iSTAT measurements it was also 
investigated whether BDM would sequester Na+ bound to protein and therefore change 
the visibility of Na+ measured using 23Na TQF NMR. The relationship between BDM 
concentration (0-20 mM) and normalised TQF intensity in solutions containing 145 mM 
Na+ and 10 mg/mL BSA (Figure 4.4) was investigated and showed an inverse sigmoid 
with an IC50 value of 13 mM and a plateau of 0.25 at 20 mM BDM. This suggests that 
binding of Na+ to BDM is able to sequester protein bound Na+ and reduce the 
observability of Na+ by TQF NMR. 
 
4.4 Uncoupling contraction with Blebbistatin. 
4.4.1 Experimental methods 
 
Blebbistatin was dissolved according to the guidelines set out by Swift et al. (2012) to 
prevent the formation of precipitates within the microvasculature which can lead to 
ischaemia.  (±)-blebbistatin (obtained from Bertin Pharma, France) was reconstituted in 
DMSO to a concentration of 17.11 mM followed by sonication and vortex mixing to 
ensure homogeneity. This stock solution was sub-aliquoted and stored at -80 °C until 
required for perfusion. Swift et al (2012) demonstrated that perfusion with 5 µM 
blebbistatin reduces contraction to negligible levels after 10 minutes in the isolated 
perfused rat heart. A 5 µM blebbistatin KH solution was prepared as follows: an aliquot 
of blebbistatin stock solution (17.11 mM) was allowed to thaw at room temperature and 




then added directly into the final volume of standard KH (Section 2.1.3). This KH had 
been pre-heated to 43-45 °C with vigorous carbogen gassing and magnetic stirring for 
five minutes to ensure complete dissolution, followed by continued gassing until the 
solution was <30°C. Blebbistatin was protected from light at all times during 
preparation and perfusion using amber glassware and aluminium foil.  
An initial bench study was performed with blebbistatin to assess function in the 
presence or absence of ouabain. Hearts were stabilised in standard KH for 20 minutes 
followed by 10 minutes of 5 µM blebbistatin KH perfusion. Hearts were then perfused 
with either 5 µM blebbistatin (bleb control group) or 5 µM blebbistatin containing 
50µM ouabain (bleb+oua group) for 20 minutes. ECG was recorded continuously 
throughout perfusion and the time from the onset of activation to 90% recovery of 
repolarization (QT90%) was used as an indicator of electrophysiological status. 
Coronary effluent was collected every five minutes for lactate efflux assessment 
(Section 2.3). LVDP, heart rate, left ventricular end diastolic pressure (LVEDP) and 
coronary flow were monitored throughout all heart perfusions. Due to loss of the 
ventricular pressure during blebbistatin perfusion, heart rate was determined using ECG 
rather than ventricular pressure. At the end of the protocol hearts were snap-frozen 
(Section 2.1.9), followed by dual-phase extraction of metabolites (Section 2.4.2) and 
high resolution 1H NMR metabolomics (Section 2.4.3). 
Following the bench study a dose-response study of 50-155µM ouabain was then 
performed in the presence of blebbistatin using the 23Na NMR perfusion setup (Section 
2.2.2). All hearts were stabilised for 20 minutes with perfusion of standard KH (Section 
2.1.3) followed by 12 minutes of perfusion with 5µM blebbistatin KH. Hearts were 




subsequently perfused for 25 minutes with KH containing 5µM blebbistatin alone or 
5µM blebbistatin containing 50, 75, 100 or 155 µM ouabain. TQF and DQF 23Na 
measurements were performed throughout perfusion in an interleaved fashion (Section 
2.2.3). LVDP, heart rate and coronary flow were monitored throughout all heart 
perfusions. Ventricular pressure was used for heart rate determination as ECG wires 
could not be used in conjunction with the NMR setup due to the introduction of external 
radiofrequencies that destroy the NMR signal. 
The influence of DMSO as an additional vehicle was assessed in the absence of 
blebbistatin. The protocol was identical to that used for the Bleb+50µM group other 
than that blebbistatin was not added to the perfusate. Hence, the perfusate was 0.029% 
v/v DMSO KH between 20 and 32 minutes and 0.029% v/v DMSO KH + 50 µM 
ouabain between 32 and 55 minutes. 
To assess any direct interaction between ouabain and blebbistatin, an Agilent 1200 LC 
and Agilent 6510 Q-TOF mass spectrometer with electrospray ionisation source 
(positive mode) was used to assess whether mixing blebbistatin (DMSO) and ouabain 
together in aqueous solution leads to the production of any new chemical entities or 
binding between the two drugs. The mobile phase was 0.1% formic acid (aq) : methanol 
(1:1). Three solutions were analysed via direct infusion: 5 µM blebbistatin (0.029% v/v 
DMSO) in water, 50 µM ouabain in water and 5 µM blebbistatin (0.029% v/v DMSO) + 
50 µM ouabain in water. Data acquisition was kindly performed by Cinzia Imberti 
(Imaging Chemistry & Biology department, The Rayne Institute, KCL). 
  




4.4.2 Results – Impact of blebbistatin on functional parameters, 
electrophysiology and metabolism in the isolated perfused rat heart. 
 
Functional parameters were constant during the stabilisation period, according to 
predefined exclusion criteria (detailed in Section 2.1.6) and were not different (P>0.05) 
between the bleb control and bleb+oua group at any point of the perfusion protocol (0-
50 minutes). Mean baseline values in the bleb control group of LVDP (Figure 4.5A), 
heart rate (Figure 4.5B), coronary flow (Figure 4.5C) and LVEDP (Figure 4.5D) were 
133±4 mmHg, 283±9 BPM, 12±2 mL/min and 6±1 mmHg, respectively. LVDP (Figure 
4.5A) decreased immediately and significantly (p<0.0001) following 5 µM blebbistatin 
perfusion at 20 minutes and was 9±1 mmHg in the bleb control group at 30 minutes 
(rate of decline during this ‘5µM bleb’ period = 12±2 mmHg/min). The rate of decline 
during the 5µM ‘bleb + treatment’ period (0.4± 0.1 mmHg/min) was considerably lower 
(p<0.0001; paired t-test) than that during the ‘5µM bleb’ period. At the end of the 
perfusion, LVDP was 1±0.8 mmHg in the bleb control group. Blebbistatin perfusion 
appeared to have no effect on heart rate (Figure 4.5B) as measured by ECG. However, 
coronary flow (Figure 4.5C) was similar to the LVDP profile, declining rapidly during 
the ‘5µM bleb’ period and then appeared to reach a new steady-state value (4.7±0.9 
mL/min in the bleb control group) at 35 minutes that was significantly different 
(p<0.05; paired t-test) to baseline. LVEDP (Figure 4.5D) was significantly elevated by 
blebbistatin at the end of perfusion (19±2 mmHg in the bleb control group; p<0.001; 
paired t-test) versus baseline. There were no differences in functional parameters 
between bleb control and bleb+oua. The lactate efflux profile (Figure 4.5E) was similar 
to the LVDP and coronary flow profiles. There was a sharp and significant reduction 




(p<0.01; paired t-test) from a baseline of 310±55 nmol/min/g at 20 minutes to 162±33 
after five minutes of perfusion with blebbistatin, followed by a slower decrease during 
the ‘5µM bleb + treatment’ period with a value of 111±26 nmol/min/g at the end of 
perfusion in the bleb control group (p<0.01 vs baseline; paired t-test). There were no 
differences (P>0.05) in lactate efflux between bleb control and bleb+oua at any point of 
perfusion. 
Perfusion of 5 µM blebbistatin had no notable effects on the shape of the ECG trace 
(Figure 4.6A) despite cessation of contractility. QT90% (Figure 4.6B) was not 
significantly different (P>0.05) between baseline and 5µM blebbistatin measurements. 
  













Figure 4.5  Effect of 5 μM blebbistatin and 50 μM ouabain on functional measurements 
and lactate efflux.  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary flow. (D) Left 
ventricular end diastolic pressure (LVEDP). (E) Lactate efflux. Symbols and error bars represent 



















































































































Figure 4.6  Blebbistatin does not significantly affect electrophysiology.  
(A) Representative left ventricular developed pressure (LVDP) traces and corresponding 
ECG traces before blebbistatin (baseline) and following 30 minutes of 5 µM blebbistatin in 
the same heart. (B) QT90% at baseline (‘stabilisation’ period) and following 30 minutes of 
perfusion with 5 µM blebbistatin (‘bleb + treatment’ period). Data correspond to mean±SEM 
of five ECG complexes at the end of the perfusion period with n=6 hearts/group, i.e, 30 




Hearts were snap frozen at the end of the protocol in Figure 4.5 and metabolites were 
extracted for high resolution 1H NMR metabolomics (Figure 4.7). In the two non-
contracting groups of hearts, treatment with 50 µM ouabain resulted in decreases in 
fumarate (-36%; P<0.05), glutamate (-22%; P<0.001) and glutamine (-14%; P<0.05) 
whereas acetate was increased (6%; P<0.001) under these conditions. Full details of the 
non-contracting metabolomics dataset is shown in Appendix 8.4. 
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Figure 4.7  1H NMR metabolomic profile for 5 µM Blebbistatin alone vs 5 µM blebbistatin 
+ 50 µM ouabain.  
Data represent mean fold change ± propagated SEM (n=4-6/metabolite/group). A fold change 
of ‘1.0’ represents zero change vs control. *p<0.05; **p<0.01; ***p<0.001; #p<0.0001. 
 
4.4.3 Results - Ouabain induces a dose dependent elevation of [Na]i but is 
attenuated in the presence of blebbistatin. 
The dose-response relationship between ouabain concentration and [Na]i in the presence 
of 5 µM blebbistatin was investigated using TQF 23Na NMR. Functional parameters 
(Figure 4.8) were constant throughout the stabilisation period according to predefined 
acceptance criteria (Section 2.1.6). Mean LVDP values (Figure 4.8A) of greater than 70 
mmHg were considered acceptable during this period to account for trace levels of 
blebbistatin present in the perfusion rig from preceding experiments. There were no 
differences in LVDP (P>0.05) between the bleb control, bleb+50 µM ouabain, bleb+75 
µM ouabain and bleb+100 µM ouabain groups during stabilisation. Baseline LVDP was 
significantly higher in the bleb+155µM oua group compared with the bleb control and 
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bleb+75µM oua groups. However, as baseline levels of derived [Na]i (Figure 4.9), heart 
rate (Figure 4.8B) and coronary flow (Figure 4.8C) in the bleb+155µM oua group were 
not different to the other groups and because [Na]i was the main focus of the study, the 
bleb+155µM oua was included. Blebbistatin significantly reduced LVDP (Figure 4.8A) 
in all groups to <30 mmHg after 10 minutes perfusion (P<0.01 versus baseline; paired t-
test). In the bleb control and bleb+50µM oua groups, LVDP continued to fall slowly 
during the bleb+treatment period with end-point values of 1.6±0.2 mmHg and 2.3±0.2 
mmHg respectively. These were not significantly different (P>0.05; one-way ANOVA) 
to end-point LVDP values for bleb+75µM oua (5.0±0.9 mmHg) and bleb+100µM oua 
(4.6±0.5 mmHg). However, a small, transient positive inotropy occurred in the 
bleb+75µM oua and bleb+100µM oua groups which peaked at 40 minutes with values 
of 12±2 mmHg and 10±2 mmHg (p<0.05 vs bleb control group at 40 minutes). A large 
positive inotropic effect occurred in Bleb+155µM oua with a maximum value of 67±3 
mmHg at 40 minutes that was significantly higher than all other groups (P<0.0001; one-
way ANOVA) at this time point. End-point LVDP in Bleb+155µM oua was also 
significantly higher (P<0.0001; one-way ANOVA) in this group (22±2 mmHg) 
compared with all other groups. There were no significant deviations (P>0.05; paired t-
test) from baseline heart rate in any of the groups at any stage of the perfusion protocol 
(Figure 4.8B). Coronary flow (Figure 4.8C) mimicked the general LVDP profile with 
significantly reduced flow due to blebbistatin at 35 minutes (p<0.05 vs baseline, paired 
t-test). End-point coronary flow was significantly higher (P<0.05) in the bleb+155µM 
oua group versus the bleb+50µM oua group. There were no other differences in end-
point coronary flow between the groups (P>0.05; one-way ANOVA). 









Figure 4.8  Effect of 5 μM blebbistatin (bleb) and 50, 75, 100 and 155 μM ouabain on 
functional measurements and lactate efflux.  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary flow. (D) Lactate 
efflux (during ‘5 μM Bleb + Treatment’ period). Symbols and error bars represent mean±SEM 
(n=6/group). 
 
Pooled coronary effluent was collected throughout the ‘bleb+oua period’ (32-55 
minutes) and lactate efflux was determined (Figure 4.8D). Values were 288±63 
nmol/min/g (bleb control), 328±84 nmol/min/g (bleb+50µM oua), 264±100 nmol/min/g 
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(bleb+155µM oua). There were no significant differences between any of the groups 
(P>0.05; one-way ANOVA). 
[Na]i measured by TQF 23Na NMR (Figure 4.9A) was constant throughout the 
stabilisation period (0-20 minutes) in all groups and there were no differences between 
the groups (P>0.05; one-way ANOVA). Normalised DQF (Figure 4.9B) did not 
markedly deviate from baseline (1.0±0.2; P>0.05; paired t-test) at any point of perfusion 
in any of the groups. In the bleb control group, there appeared to be a trend towards 
decreased [Na]i after 10 minutes of perfusion with 5µM blebbistatin which seemed to 
reach a new steady-state at 15±1.6 mM. However, this was not significantly different 
(P<0.05) to the bleb-free/oua-free control value from Chapter 3 (Figure 4.10A). 
Perfusion with bleb+50µM oua did not induce a significant elevation (P>0.05) in end-
point derived [Na]i (20±0.6 mM) versus bleb control and was significantly lower 
(P<0.0001) than the corresponding bleb-free 50 µM ouabain value (31±1.5 mM) 
ascertained in Chapter 3 (Figure 4.10).  
End-point derived [Na]i values in bleb+75 µM oua (23±1.1 mM) and bleb+100 µM 
(28±1.0 mM) were significantly elevated compared to the bleb control group. Derived 
[Na]i in the bleb+75 µM ouabain and bleb+100 µM ouabain was significantly lower 
(P<0.05) than their bleb-free counterparts (39±3.5 mM and 38±3.5 mM respectively). In 
the presence of 5 µM blebbistatin, the concentration of ouabain required to induce an 
equivalent end-point derived [Na]i to that of bleb-free 75 µM oua and bleb-free 100 µM 
was 155 µM ([Na]i = 42±3 mM). A comparison of the dose-response curves (Figure 
4.10B) for ouabain in the absence (Chapter 3) and presence (Chapter 4) of blebbistatin 




reveals that blebbistatin significantly altered the dose response relationship between 





                   
 
Figure 4.9 Dose-response of ouabain and derived [Na]i in the presence of 
blebbistatin.  
(A) Normalised TQF signal as a function of time (left axis) and corresponding derived 
[Na]i (right hand axis). (B) Normalised DQF signal as a function of time. Data are 
displayed as mean±SEM (n=6/group). 
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Figure 4.10  Ouabain concentration versus end-point derived intracellular sodium 
concentration ([Na]i) in the absence and presence of 5µM blebbistatin (bleb).  
(A) Dose-response histogram. P-values above columns represent comparisons between 
bleb-free and 5µM bleb values at the same ouabain concentration. Stars above columns 
represent comparisons between ouabain concentration and corresponding ouabain-free 
control at the same bleb concentration (*P<0.05, **P<0.01, ***P<0.001; one-way ANOVA with 
Dunnet’s post-hoc test). (B) Dose-response curves. Bleb-free was constrained 
(bottom=17.71; top=38.59; slope=0.05). Data plotted as mean±SEM at the end of perfusion 
(55 minutes). Bleb-free data was from Section 3.3.2. See Figures 3.1A (bleb-free) and 4.9A 
(with 5µM bleb) for full [Na]i time profiles.  
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Perfusion with 0.029% v/v DMSO KH (n=1) in the absence of blebbistatin had no effect 
on baseline derived [Na]i (17.4 mM) and subsequent perfusion for 25 minutes with 
0.029% v/v DMSO KH + 50 µM ouabain increased derived [Na]i to an end-point value 
of 36.4 mM. DMSO had no effect on normalised DQF signal which was stable 
throughout perfusion. LVDP, HR and coronary flow were within normal ranges during 
stabilisation (according to pre-defined exclusion criteria described in Section 2.1.6) and 
were not altered by perfusion with DMSO. A small, transient positive inotropic effect 
occurred following subsequent perfusion with 50 µM ouabain. 
 
4.4.4 Does blebbistatin attenuate ouabain inhibition of NKA in ventricular 
cardiac myocytes? 
In vitro experiments were carried out in order to investigate possible mechanisms by 
which blebbistatin attenuates ouabain action. A whole-cell voltage-clamp study was 
kindly performed by Dr Sergiy Tokar (Cardiovascular Division, KCL) to assess whether 
blebbistatin attenuates ouabain inhibition of NKA.  The objective was to determine 
whether blebbistatin (5mM) interferes with the ability of ouabain (50µM) to inhibit the 
Na+/K+ pump. 
The activity of electrogenic sarcolemmal ion transporters in isolated cardiomyocytes 
can be ascertained using the whole-cell voltage-clamp technique (reviewed by 
Bebarova, 2012). In brief, a micropipette is used to form a tight seal between the 
electrode glass and the cell surface. The membrane under the tip of the pipette is 
ruptured allowing the electrode electrical access to the cell interior. Current flow across 
the entire cell membrane can then be measured with respect to an extracellular  






Figure 4.11  Whole-cell patch-clamp measurements with 5 µM blebbistatin and 50 µM 
ouabain.  
These experiments were kindly performed by Dr Sergiy Tokar (Cardiovascular Division, The 
Rayne Institute, KCL) using the method described in Pavlovic et al (2007) with solutions slightly 
modified as follows: pipette solution contained (in mM): CsCH3O3S (95), NaCH3O3S (25), CsCl 
(20), Hepes (10), EGTA (5), MgATP (5), sodium creatine triphosphate (5), CaCl2 (1), MgCl2 (1). 
External solution contained (in mM): NaCl (140), KCL (5), Hepes (10), NiCl2 (2), MgCl2 (1), 
BaCl2 (1) (in K+ free solution 5 mM of KCl were replaced with same amount of NaCl). (A) 
Representative raw current trace of a rat left ventricular cardiomyocyte. (B) Mean inhibition of 
Na+/K+ ATPase by ouabain with and without blebbistatin plotted as % of current during K+-free 
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reference. The pipette and extracellular solutions are formulated to isolate the 
electrogenic current of interest (in this case the Na+/K+ pump current) and the cell 
membrane is clamped to 0mV to inactivate Na+ channels.  Under these conditions, the 
Na+/K+ pump current is defined as that sensitive to removal of extracellular K+. Cells 
were exposed to ouabain (50µM) and ouabain (50µM) + blebbistatin (5mM). 
 
4.4.5 Results - Patch clamp 
The control membrane current values (Figure 4.11A) were similar to those obtained 
previously (Shattock and Matsuura, 1993, Silverman et al., 2005). The extent of NKA 
inhibition by 50 µM ouabain (37±2 % of the maximally available pump current as 
defined by the K+ sensitive current) was not significantly altered by the presence of 5 
µM blebbistatin (32±2 %, P>0.05) (Figure 4.11B). 
 
4.4.6 Results – Blebbistatin does not sequester ouabain or Na+. 
Mass spectrometry data acquired of a mixed solution of blebbistatin and ouabain 
revealed that the molecular ions of blebbistatin (292 g/mol) at 293 m/z and DMSO (78 
g/mol) at 79 m/z and its corresponding Na+ adduct at 101 m/z were present as well as 
the molecular ion of ouabain (585 m/z) and the corresponding Na+ adduct at 607 m/z. 
However there were no new peaks of any notable abundance. No new chemical entities 
were formed after mixing 5 µM blebbistatin with 50 µM ouabain according to mass 
spectrometry analysis and it can therefore be concluded that blebbistatin does not 
sequester ouabain. Mass spectra for these analyses are shown in Appendix 8.5.  




A Vetscan® i-STAT®1 analyser with CG8+ cartridge (Abaxis UK) was used to 
determine the concentrations of Na+, K+ and iCa in 5 µM blebbistatin KH and were 
unchanged with respect to standard KH composition (145, 4.5 and 1.3 mM 
respectively). 
 
4.4.7 Results - Does contractile motion affect the observability of [Na]i by TQF 
23Na NMR? 
Changes in contractility and cardiac motion have the potential to change the 
observability of 23Na by NMR due to changes in magnetic field homogeneity. Peak line-
width is a reflection of field homogeneity and therefore the detectability of an analyte 
using NMR. 
Removal of contractility using either 5 µM blebbistatin or 20 mM BDM did not change 
the shape (Figures 4.12A & 4.12B) or line-width (Figures 4.12C & 4.12D) of the 
TQF/DQF 23Na peak compared with time-matched contracting control hearts.  
 
4.5 Discussion 
4.5.1 BDM inhibits contraction and significantly attenuates the dose response of 
ouabain observed by TQF NMR. 
In agreement with previous reports, BDM significantly reduced inotropy (Figure 4.2A) 
(Kettlewell et al., 2004, Daly et al., 1987, Sill et al., 2009, Doumen et al., 1995, Hebisch 
et al., 1993, Yaku et al., 1993) but was associated with significant bradycardia (Figure 
4.2B). BDM also resulted in a significant reduction in derived end-point baseline  




                
 
               
 
Figure 4.12  Contractile motion does not alter 23Na NMR measurements in 
isolated perfused rat hearts. 
(A) Triple quantum filtered (TQF) signal and (B) double quantum filtered (DQF) signal. 
Peaks are time-matched representative spectra at end of perfusion in contracting 
vehicle (DMSO, blue), non-contracting blebbistatin (‘bleb’, red) and non-contracting 2,3-
butanedione monoxime (BDM, green). Linewidths (width at half peak height) of TQF 
signal (C) and DQF signal (D) were plotted for each group (n=5-6). *P<0.05 (one-way 
ANOVA). 
 
(Control) [Na]i by 31% (Figure 4.3C) as measured by TQF NMR and also attenuated 
the apparent [Na]i elevation due to 100 μM ouabain by 56% (Figure 4.3C). Despite this 
attenuation, [Na]i was significantly higher in the BDM+100 μM oua group versus the 
BDM control group. Addition of 100 μM ouabain to 20 mM BDM led to a significant 



















































effect in future studies. However, 30 mM BDM was associated with even greater 
reductions in heart rate and baseline [Na]i which may further confound metabolic 
measurements compared with 20 mM BDM. 
 
4.5.2 BDM sequesters Na+ in vitro. 
The reduction in baseline apparent [Na]i in the perfused heart could be a result of BDM 
sequestering [Na]i. In vitro investigations demonstrated that BDM reduced free-Na+ by 
approximately one-third and prevented the measurement of Ca2+ using the iSTAT 
instrument (Table 4.1) presumably due to interference with the Ca2+-sensitive 
electrochemical detector. Increasing the concentration of Ca2+ in this BDM solution did 
not overcome this issue and so it was not possible to confirm the work of Daly et al. 
(1987) showing that BDM is a chelator of Ca2+. Nonetheless, this study demonstrated 
that BDM sequesters Na+ with an apparent stoichiometry of 2xNa per BDM molecule 
and may explain the reduction in baseline TQF observability of [Na]i following 
perfusion of rat hearts with 20 mM BDM (Figure 4.3C).  
Furthermore, the reduction in the normalised TQF signal in the presence of protein in 
vitro (Figure 4.4) indicates that BDM binds competitively to Na+ (given that the TQF 
signal is dependent upon Na+-protein interactions). This is in agreement with the BDM-
Na+ sequestration data as well as the BDM-induced reduction in baseline [Na]i in 
perfused hearts. Although the BDM-induced reduction in TQF signal in vitro was very 
large (75% decrease), it should be noted that a relatively high [Na] (145 mM) was used 
with a relatively low concentration of protein (10 mg/mL) in order to amplify any 




effects of BDM. In vivo, the concentrations of [Na]i and protein are closer to 10 mM 
and 100 mg/mL respectively, which may explain why the BDM-induced reduction in 
normalised TQF intensity in the perfused heart experiments (by ~33%) was more 
modest than that in the in vitro experiment. 
 
4.5.3 Blebbistatin inhibits contraction in the absence of altered electrophysiology. 
Perfusion of hearts with 5 µM blebbistatin rapidly decreased contractile function to 
negligible levels (Figures 4.5A and 4.8A). This is in agreement with Swift et al. (2012) 
and Brack et al. (2013). The concomitant decreases in coronary flow (Figures 4.5C and 
4.8C) and lactate efflux (Figures 4.5E and 4.8D) are most probably due to reduced 
oxygen consumption. The reason for LVEDP elevation following blebbistatin perfusion 
(Figure 4.5E) could be due to increased ventricular stiffness as a consequence of 
conformational changes in the myofilament proteins. Elevated LVEDP due to 
blebbistatin perfusion was also reported by Brack et al. (2013). 
Despite elimination of LVDP, blebbistatin had no effect on QT90% (Figure 4.6B). The 
strong agreement between values of QT90% for control rat hearts obtained in this 
chapter (~60 ms) with those obtained elsewhere (Clements-Jewery et al., 2002, Dhanjal 
et al., 2013, Rees and Curtis, 1993). Furthermore, Fedorov et al. (2007) demonstrated 
that blebbistatin does not significantly alter pacemaker activity, conduction, 
repolarization or [Ca]i cycling in both the rat and rabbit heart.  
The ouabain-dose response study using TQF 23Na NMR described in Chapter 3 was 
repeated in this chapter except with the addition of blebbistatin. Perfusion with 




blebbistatin alone did not have any significant impact upon baseline derived [Na]i 
(Figure 4.10A) which aligns with its lack of electrophysiological effects. Interestingly, 
blebbistatin appeared to both attenuate, and change the shape of, the dose-response 
curve from a sigmoidal relationship to a more linear relationship between [ouabain] and 
derived [Na]i (Figure 4.10B). The mechanism by which blebbistatin attenuates ouabain 
action has not been previously reported. Mass spectrometry data acquired of a mixture 
of ouabain and blebbistatin revealed no binding between the two drugs suggesting that 
blebbistatin does not sequester ouabain. Furthermore, iSTAT analysis revealed that 
blebbistatin does not sequester Na+ and patch clamp experiments (Figure 4.11B) using 
isolated cardiomyocytes suggested that blebbistatin does not attenuate the ability of 
ouabain to inhibit NKA. In the blebbistatin protocols there is potential for interference 
of the DMSO vehicle on the derived [Na]i, particularly as there is evidence to suggest 
that DMSO is a Na+-channel antagonist (Jacob and de la Torre, 2009). DMSO had no 
effect on baseline derived [Na]i or ouabain-induced [Na]i elevation in the perfused rat 
heart, and therefore the probability of this having any impact on the blebbistatin-
induced attenuation of ouabain in this model seems low. Also, a Na+ channel agonism 
by either blebbi or DMSO would alter the QRS duration of the ECG and also QT90 
(Suzuki et al., 1991). 
  
4.5.4 Contractile motion does not affect the measurement of [Na]i by TQF 23Na 
NMR. 
Figure 4.12 demonstrates that removal of contraction using either blebbistatin or BDM 
did not alter the linewidth of the TQF 23Na NMR peak thereby inferring that Na+ 




visibility due to changes in magnetic field homogeneity is not affected by changes in 
contractile motion in the perfused rat heart. 
 
4.5.5 Blebbistatin is more sensitive and has less impact on [Na]i than BDM. 
The perfusate concentration of BDM required for the cessation of contraction was 
10,000-fold higher than that for blebbistatin. This is in agreement with the differences in 
IC50 values for force inhibition by these compounds reported by Brixius et al. (2000), 
Shu et al. (2005) and Limouze et al. (2004). Perfusion with 100 µM ouabain in the 
presence of BDM led to a significant elevation in derived end-point [Na]i (16 mM). If 
this value is normalised for the initial BDM-induced reduction in derived [Na]i (from 18 
to 12 mM) then a corrected value of 28 mM is obtained. This value was also obtained 
for the bleb+100µM ouabain group and represents an attenuation compared with the 
BDM-free/bleb-free 100µM ouabain group in Chapter 3 (Figure 4.10A). Despite a 
significantly higher concentration of BDM used in these experiments compared with 
blebbistatin, the extent of ouabain attenuation (accounting for the differences in pre-
ouabain [Na]i) appears to be very similar between these electromechnical uncouplers. In 
contrast, there was no significant reduction in [Na]i following perfusion with ouabain-
free blebbistatin but a large reduction in [Na]i with ouabain-free BDM. Taken together, 
this may infer that the effects of these compounds on [Na]i have two components: one 
that is dependent on the concentration of the electromechanical uncoupler in the absence 
of ouabain and another that is independent of the concentration of the electromechanical 
uncoupler in the presence of ouabain. These findings are suggestive of a mechanism that 
could be common to electromechanical uncouplers leading to ouabain attenuation 




although further work is necessary to elucidate this mechanism. Comparison of the 
chemical structures of blebbistatin and BDM (Figures 4.1A and 4.1B) reveals little 
similarity although they inhibit myosin II ATPase in the same uncompetitive manner 
(Kovács et al., 2004, Herrmann et al., 1992) which may be relevant to the mechanism 
by which they attenuate ouabain action. 
Blebbistatin shows substantially higher efficacy as an electromechanical uncoupler than 
BDM and has no marked effect on baseline [Na]i. Furthermore, there are several reports 
of BDM exhibiting off-target effects at concentrations required for the cessation of 
contractility including metabolic effects (Doumen et al., 1995, Hebisch et al., 1993, 
Scaduto and Grotyohann, 2000) and altered concentrations of intracellular ions 
(Kettlewell et al., 2004, Liu et al., 1993, Baker et al., 2004, Watanabe et al., 2001). 
BDM has also been shown to have reversible inhibitory effects on metabolism (Doumen 
et al., 1995, Hebisch et al., 1993, Scaduto and Grotyohann, 2000) and electrophysiology 
(Kettlewell et al., 2004). Other studies have suggested that BDM decreases Ca2+ and K+ 
currents (Liu et al., 1993), [Ca]i (Baker et al., 2004) and EC coupling including 
sarcolemmal NCX exchange (Watanabe et al., 2001). 
 
4.5.6 Ouabain does not alter metabolomic profile in blebbistatin treated non-
contracting hearts. 
None of the ouabain concentrations used in this study in the presence of blebbistatin 
significantly altered lactate efflux in non-contracting hearts (Figure 4.5E & 4.8D), in 
contrast to their contracting counterparts in Chapter 3 (Figures 3.4 and 3.7). End-point 
metabolomics in non-contracting hearts perfused with 50 µM ouabain (Figure 4.7) 




largely abolished most of the metabolic alterations observed in contracting hearts in 
Chapter 3 (Figures 3.5 & 3.8). The reduction in fumarate is in contrast to the elevation 
observed in the contracting models following ouabain perfusion in Chapter 3. The 
reason for this is unclear but may reflect its concentration being sensitive to both [Na]i 
elevation and alterations in inotropy. Furthermore, the elevations in acetylcarnitine, 
creatine and choline observed in Chapter 3 were not observed in the non-contracting 
model in this chapter. This suggests that these metabolites are inotropy dependent rather 
than [Na]i dependent. The reductions in glutamate and glutamine observed in non-
contracting hearts could potentially reflect an increase in anaplerosis following 
perturbations in ATP supply-demand matching due to [Na]i elevation. The very modest 
elevation in acetate by 6% was measured with a high degree of precision using 1H 
NMR. Despite the limited magnitude of this change, the very low error associated with 
the measurement revealed that this change was statistically significant (P<0.001). A 
small reduction in fatty acid substrate utilisation from triglyceride stores following [Na]i 
elevation is a possible explanation for this although it seems unlikely that this would 
have any significant bearing on the overall metabolic status of the heart.   
The metabolomic changes observed in the absence of a positive inotropic effect 
following ouabain perfusion under non-contracting conditions infer a modest sensitivity 
of the TCA cycle, anaplerosis and possibly substrate utilisation to [Na]i elevation. 
However, the relevance of this to contracting hearts is probably limited. The non-
contracting isolated heart model used in this chapter has made clearer which metabolites 
are sensitive to the positive inotropic effect of ouabain but is clearly unphysiological. 
Pulseless electrical activity (PEA; a type of cardiac arrest) is the only in vivo situation in 




which the heart sustains normal electrophysiology in the absence of cardiac output and 
is out of the scope of this thesis. An important difference between contracting and non-
contracting hearts is the significant reduction in ATP demand and oxygen consumption 
thus differences in intermediary metabolism are likely. For example, Peuhkurinen et al. 
(1982) found that TCA cycle flux is 42% lower in arrested hearts perfused with K+-free 
KH compared with beating hearts. It is therefore likely that any metabolic remodelling 
due to [Na]i elevation is different between contracting and non-contracting hearts.  
 
4.6 Summary 
In this chapter, two electromechanical uncouplers (BDM and blebbistatin) were 
evaluated in the perfused rat heart, in order to remove inotropy and thereby distinguish 
[Na]i-dependent from inotropy-dependent metabolic consequences of ouabain. BDM 
(20 mM) eliminated contractility but was associated with a significant reduction in 
baseline apparent [Na]i measured by real-time TQF 23Na NMR. Blebbistatin eliminated 
contractility with a higher efficacy (5 μM) than BDM and did not alter baseline [Na]i or 
electrophysiology (QT90%). Both BDM and blebbistatin appeared to attenuate the 
ability of ouabain to elevate [Na]i. This was overcome in blebbistatin-perfused hearts by 
adding additional ouabain to the perfusate (155 μM ouabain + 5 μM blebbistatin 
elevated [Na]i to the same degree as 100 μM ouabain alone). In vitro investigations 
revealed that BDM sequesters Na+ with a stoichiometry of 2xNa per BDM molecule 
and that BDM competes with protein for Na+ thereby reducing the TQF 23Na NMR 
signal. However, blebbistatin does not sequester Na+ or ouabain. Moreover, patch 




clamping experiments in isolated cardiomyocytes suggested that blebbistatin does not 
alter NKA inhibition by ouabain. In contrast to contracting hearts in Chapter 3, 50 μM 
ouabain did not alter lactate efflux in non-contracting hearts perfused with blebbistatin. 
Furthermore, blebbistatin largely abolished the metabolomic changes due to ouabain 
observed in contracting hearts in Chapter 3. Small reductions in fumarate, glutamate and 
glutamine and a small increase in acetate occurred due to [Na]i elevation in this non-
contracting preparation. However, the relevance of these alterations to the beating heart 
is questionable given the marked reduction in ATP demand in the absence of 
contraction. Due to its substantially higher efficacy and lower impact on [Na]i compared 
with BDM, blebbistatin was selected as the most suitable electromechanical uncoupler. 
This method was developed further in Chapters 5 and 6 in which the positive inotropic 








5 DISTINGUISHING [Na]i-DEPENDENT FROM 
INOTROPY-DEPENDENT ALTERATIONS IN 
ENERGETICS AND METABOLOMICS. 
5.1 Introduction 
In Chapter 4, it was concluded that co-infusion of ouabain, to elevate [Na]i, in 
combination with blebbistatin, to uncouple contraction, did not profoundly alter the 
metabolite profile in non-contracting hearts as measured using 1H NMR. However, 
removing all contractility from the heart leads to a large reduction in ATP demand, 
potentially masking metabolomic alterations that may have occurred due to [Na]i 
elevation. It was also previously highlighted the difficulty in distinguishing between 
metabolic alterations that may be due to [Na]i elevation directly from those that were 
due to the positive inotropy (and increased ATP demand) associated with [Na]i 
elevation. It is therefore necessary to assess whether metabolic alterations occur due to 
ouabain induced [Na]i elevation in hearts allowed to contract intrinsically with a more 
physiological ATP demand while removing the confounding influence of positive 
inotropy using blebbistatin. The idea is that the blebbistatin concentration can be titrated 
in to prevent a positive inotropy but not abolish contraction. That is, when ouabain is 
added, contractility should not change despite the elevation in intracellular Na+.  
Blebbistatin has slightly slower pharmacokinetics than ouabain (Figures 4.5A and 3.1A) 
therefore simply co-perfusing these compounds at fixed concentrations throughout the 
perfusion protocol would induce transient periods of inotropy. Two perfusion protocols 
were therefore developed in which ouabain and blebbistatin were co-perfused into the 




Langendorff rat heart in an opposite order to induce [Na]i overload while reversing 
inotropic effects. Perfusion initially with ouabain alone followed by a period of titration 
with blebbistatin plus ouabain initially elevated contractility which subsequently 
returned back down to baseline levels, while maintaining a sustained elevation of [Na]i. 
This is referred to as the transient positive inotropy (TPI) group. On the other hand, 
perfusing initially with blebbistatin plus ouabain followed by ouabain alone initially 
depressed contractility followed by a recovery back up to baseline but again with a 
sustained elevation of [Na]i. This is referred to as the transient negative inotropy (TNI) 
group. Taken together, the TPI and TNI protocols would assess metabolic alterations 
that are common to both studies and therefore considered [Na]i-dependent and 
contractility-independent, while those occurring in only one study would be considered 
contractility-dependent, i.e, whether the heart has “metabolic memory” for contractility. 
This may elucidate which metabolic pathways, if any, are remodelled in contracting 
hearts due to [Na]i overload. End-point metabolomic analysis by 1H NMR and targeted 
LC-MS/MS, as well as real-time cardiac energetics were assessed during the perfusion 
protocols by 31P NMR. 
 
5.2 Aim 
The aim of this chapter is to determine whether [Na]i elevation gives rise to metabolic 
alterations that are independent of inotropic changes in the contracting perfused rat 
heart. 
 




5.3 Experimental Methods 
In Chapter 3, it was shown that 100 µM ouabain elevated derived [Na]i to 
approximately 40 mM (Figure 3.2A & 3.2B) without observable toxic effects, while in 
Chapter 4, it was demonstrated that the effect of ouabain on [Na]i was attenuated by 
blebbistatin and that 155 µM ouabain was required to elevate derived [Na]i to 
approximately 40 mM (Figures 4.9A, 4.10A & 4.10B). In order to determine the 
concentrations of blebbistatin and ouabain required for the TNI and TPI protocols, 
different concentrations of these compounds were co-perfused in preliminary test hearts 
to ascertain the appropriate doses. Different concentrations were titrated in the two 
protocols to give approximately equal but opposite degrees of positive or negative 
inotropy while yielding an equivalent elevation of end-point [Na]i.   
Rat hearts were perfused in the Langendorff mode as described in Section 2.1. The TPI 
and TNI protocols were carried out in independent studies each with a vehicle 
counterpart. Hearts were perfused in a randomised-fashion. The perfusion protocols are 
summarised in Table 5.1. LVDP, heart rate, coronary flow and LVEDP were recorded 
continuously throughout each experiment. Based on initial experiments, it was 
estimated that the mean concentration of vehicle (DMSO, used for blebbistatin 
reconstitution) at 55 minutes in ‘TPI’ and ‘TNI’ hearts was approximately 800 µM and 
this concentration was therefore used in the ‘Vehicle’ groups. Separate perfusion 
reservoirs were used for each of the different perfusion solutions. Titrations were 
carried out by adding a small volume (approximately 5-10 mL every 5 minutes) of the 
appropriate stock solution into the appropriate reservoir containing the initial perfusion 
solution (pre-warmed to 39 °C and gassed vigorously with carbogen). This resulted in a 




gradual and stable return to baseline LVDP at which time no further titrant was added. 
Homogeneity of the perfusion solutions was ensured by vigorous gassing and manual 
mixing by hand using the gas distribution tube in each perfusion reservoir.  
Heart perfusions were performed within the NMR spectrometer using the perfusion 
setup as described in Section 2.2.2. Hearts were split into two sub-groups (n=6/sub-
group): one in which interleaved 23Na TQF and 23Na DQF NMR measurements were 
performed (described in Section 2.2.3) and the other in which 31P energetics were 
performed (described in Section 2.2.4). Both NMR protocols were acquired in real-time 
throughout the entirety of the perfusion protocols (0-55 minutes). Hearts were snap-
frozen at approximately 55 minutes as described in section 2.1.9. 
Aqueous metabolites were isolated as per Section 2.4.2. High resolution 1H NMR (n=5-
6/group) was performed to obtain a global insight into metabolism (Section 2.4.3) and 
TCA cycle intermediates were quantified using LCMSMS (n=10-12/group) as described 
in Section 2.4.4. 
Table 5.1  Perfusion protocols used in the TPI/TNI study 
Group 0-20 mins 20-30 mins 30-55 mins 55 mins 
Vehicle 
Stabilisation 







100μM ouabain (titrated with a 
single solution of 155μM 







100μM ouabain (titrated with 
200μM ouabain) 
 




5.4 Results – TPI and TNI protocols remove transient inotropy while sustaining 
elevated [Na]i. 
All perfusion parameters were constant during the stabilisation period, according to 
predefined exclusion criteria (detailed in Section 2.1.6) and there were no differences 
during this period between TPI or TNI compared with their corresponding vehicle. 
Baseline LVDP (Figures 5.1A and 5.1E) was 104±5 mmHg in vehicle and was not 
altered by subsequent DMSO perfusion (103±6 mmHg; P>0.05; paired t-test). In the 
TPI group, LVDP was elevated significantly (P<0.0001; paired t-test) to a maximum of 
173±8 mmHg at 30 minutes (after 10 minutes of perfusion with 100µM ouabain) but 
returned to baseline at 45 minutes (114±9 mmHg) following blebbistatin/ouabain 
titration and remained stable then until 55 minutes (104±6 mmHg). In the TNI group, 
LVDP initially increased (P<0.01) versus baseline after 5 minutes of perfusion with 
1.5µM blebbistatin + 50µM ouabain and then decreased to a minimum of 42±3 mmHg 
at 35 minutes (following 15 minutes of perfusion with 1.5µM blebbistatin + 50µM 
ouabain; P<0.0001 vs baseline; paired t-test). LVDP then returned to baseline at 50 
minutes (99±6 mmHg) following blebbistatin-free ouabain titration for 15 minutes and 
remained stable until 55 minutes (106±6 mmHg). Heart rate (Figure 5.1B and 5.1F) was 
283±10 BPM at baseline and was not altered by DMSO vehicle (284±11 BPM; P>0.05; 
paired t-test). The TPI group exhibited a significant bradychardia at 30 minutes (213±21 
BPM; P<0.01 vs vehicle) but returned to baseline levels by the end of perfusion (Figure 
5.1B).  
  







   
Figure 5.1 Functional measurements in the transient positive inotropy (TPI) and transient 
negative inotropy (TNI) protocols.  
TPI: (A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary flow. (D) Left ventricular 
end diastolic pressure (LVEDP). TNI: (E) LVDP. (F) Heart rate. (G) Coronary flow. (H) LVEDP. Symbols 
and error bars represent mean±SEM of five minute time windows (n=11-12/group). Hearts were snap-
frozen at 55 minutes. Blebbistatin (Bleb); dimethyl sulfoxide (DMSO); ouabain (Oua). See Table 5.1 for full 
protocol details. 
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No significant change in heart rate occurred at any point during the TNI protocol 
(P>0.05 vs vehicle) (Figure 5.1F). DMSO had no effect (P>0.05) on coronary flow 
(Figure 5.1C & 5.1G) which was 11±0.6 mL/min at baseline in vehicle. Ouabain caused 
a small but significant elevation in coronary flow at 25-30 minutes (13±1mL/min, 
P<0.05 vs vehicle) before returning to baseline levels at 35 minutes which was 
sustained until the end of perfusion (Figure 5.1C). In the TNI group, coronary flow 
(Figure 5.1G) was similar to the LVDP profile with a transient reduction (P>0.05 vs 
baseline) following blebbistatin+ouabain perfusion but then returned to baseline 
following perfusion with blebbistatin-free ouabain. LVEDP (Figures 5.1D and 5.1H) 
was 7.7±1.3 mmHg at baseline in vehicle and was not altered by DMSO perfusion 
(P>0.05; paired t-test). However, LVEDP was significantly higher (P<0.0001) at 30-55 
minutes in the TPI group (16±3.6 mmHg) vs vehicle (6.0±1.0 mmHg) and showed a 
trend towards an elevation during the TNI period (13±3.5 mmHg) although did not 
reach statistical significance (P>0.05). 
[Na]i derived from the TQF signal (Figures 5.2A and 5.2C) was constant throughout the 
stabilisation period in vehicle (18±0.6 mM), TPI (18±0.4 mM) and TNI (18±0.4 mM). 
DMSO vehicle had no effect on derived [Na]i (17±0.9 mM; P>0.05; paired t-test). 
Derived [Na]i was significantly higher (P<0.001) in the TPI group (29.1±1.7 mM) 
compared with its vehicle group (17.3±1.1 mM) at the end of perfusion (Figure 5.2A). 
Derived end-point [Na]i was also significantly higher (P<0.01) in the TNI group 
(30.7±2.9 mM) compared with its vehicle group (16.8±1.2 mM) at the end of perfusion 
(Figure 5.2C). DQF signal did not markedly deviate from baseline (1.0±0.1 arbitrary 
units) at any point of perfusion in both groups (Figures 5.2B and 5.2D). 




                  
aa      
 
Figure 5.2 TQF/DQF 23Na NMR measurements in transient positive 
inotropy (TPI) and transient negative inotropy (TNI).  
TPI: (A) Normalised triple quantum filtered (TQF) 23Na NMR intensity (left axis) with 
derived intracellular [Na]i (right axis). (B) Normalised double quantum filtered (DQF) 
23Na NMR intensity. TNI: (C) Normalised TQF 23Na NMR intensity (left axis) with 
derived intracellular [Na]i (right axis). (D) Normalised double quantum filtered (DQF) 
23Na NMR intensity. Symbols and error bars represent mean±SEM of 1.5 minute time 
windows (n=6/group). Hearts were snap-frozen at 55 minutes. Blebbistatin (Bleb); 
dimethyl sulfoxide (DMSO); ouabain (Oua). See Table 5.1 for full protocol details. 
 
5.5 Results - Cardiac energetics measured by 31P NMR. 
Representative 31P NMR spectra of the Pi, PCr and β-ATP peaks are shown as a 
function of time in Figure 5.3. All cardiac energetics parameters had reached a steady-
state by the end of the stabilisation period with no significant differences between TPI 
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(Figure 5.4) and TNI (Figure 5.5) groups versus their respective vehicles during this 
period. In the vehicle groups, DMSO caused no significant deviations from baseline 
levels of any of the measured parameters (P>0.05). However, ATP slowly declined in 
the TPI group (Figure 5.4A) immediately upon ouabain perfusion and plateaued at 35% 
below baseline levels at 35 minutes. Similarly, ATP slowly declined in the TNI group 
immediately upon perfusion with 1.5µM blebbistatin + 50µM ouabain (Figure 5.5A). At 
55 minutes, ATP was significantly lower in both TPI (Figure 5.6A) and TNI (by 27%, 
Figure 5.7A) compared with their vehicle groups (P<0.01). There was a strong, negative 
correlation (r = -0.9; P<0.0001) between ATP and derived [Na]i in both TPI and TNI 
(Figure 5.8).  
In TPI, PCr fell by 50% during the transient period of positive inotropy compared with 
baseline after five minutes of ouabain perfusion (Figure 5.4B) but returned to baseline 
levels by the end of perfusion following blebbistatin perfusion (Figure 5.6B). In the TNI 
group, PCr fell by approximately 20% from baseline after five minutes of blebbistatin + 
ouabain perfusion (Figure 5.5B) but then returned to baseline for 15 minutes before 
decreasing to a plateau at 50 minutes. Nonetheless, there was no difference in PCr 
between TNI and vehicle at 55 minutes (P>0.05) (Figure 5.7B). In conjunction with 
these ATP and PCr profiles, the end-point PCr:ATP ratio was almost two-fold higher 
(P<0.01) in TPI (Figure 5.6D) and almost a third higher in the TNI group (Figure 5.7D) 
versus their vehicle groups at 55 minutes. There were no significant differences 
(P>0.05) in Pi between the vehicle and TPI group (Figure 5.4C) although Pi showed a 
trend towards elevation in the TPI group vs baseline levels at the end of perfusion 
(Figure 5.6C). 






Figure 5.3 Representative 31P Nuclear Magnetic Resonance Spectra. 
(A) Vehicle. (B) Transient positive inotropy (TPI). (C) Transient negative inotropy (TNI). Each 



























Figure 5.4  Real-time 31P nuclear magnetic resonance measurements for transient 
positive inotropy (TPI).  
(A) ATP. (B) Phosphocreatine (PCr). (C) Inorganic phosphate (Pi). (D) PCr-ATP ratio. (E) pH. 
Symbols and error bars represent mean ± SEM of five minute time windows (n=6/group). Hearts 




































































































Oua + Bleb TPI
VehicleDMSOStabilisation
Stabilisation Oua
T im e  (m in )
p
H













O u a  +  B le b T P I
V e h ic leD M S OS ta b il is a t io n















Figure 5.5  Real-time 31P nuclear magnetic resonance measurements for transient negative 
inotropy (TPI). 
(A) ATP. (B) Phosphocreatine (PCr). (C) Inorganic phosphate (Pi). (D) PCr-ATP ratio. (E) pH. 
Symbols and error bars represent mean ± SEM of five minute time windows (n=6/group). Hearts 
were snap-frozen at 55 minutes. Abbreviations: blebbistatin (Bleb); dimethyl sulfoxide (DMSO); 
ouabain (Oua). 
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Figure 5.6  End-point 31P nuclear magnetic resonance measurements for 
transient positive inotropy (TPI).  
(A) ATP. (B) Phosphocreatine (PCr). (C) Inorganic phosphate (Pi). (D) PCr-ATP ratio. 
(E) pH.  Bars and error bars represent mean ± SEM of five minute time windows 
(n=6/group). Hearts were snap-frozen at 55 minutes. Abbreviations: blebbistatin (Bleb); 
dimethyl sulfoxide (DMSO); ouabain (Oua). 
  
In the TNI group (Figure 5.5C), Pi did not deviate from baseline levels following five 
minutes of blebbistatin + ouabain perfusion but then began to follow the TNI LVDP 
profile, decreasing to 71% below the corresponding vehicle value at 30 minutes 
(P<0.01). Pi then gradually increased in the TNI group and was significantly higher than 
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Figure 5.7  End-point 31P nuclear magnetic resonance measurements for 
transient negative inotropy (TNI).  
(A) ATP. (B) Phosphocreatine (PCr). (C) Inorganic phosphate (Pi). (D) PCr-ATP ratio. 
(E) pH.  Bars and error bars represent mean ± SEM of five minute time windows 
(n=6/group). Hearts were snap-frozen at 55 minutes. Abbreviations: blebbistatin (Bleb); 
dimethyl sulfoxide (DMSO); ouabain (Oua). 
 
In regard to pH, ouabain perfusion resulted in a substantial reduction from 7.11 at 20 
minutes to a minimum of 7.01 at 30 minutes (P<0.0001; paired t-test) although, similar 
to PCr, slowly returned to baseline as the positive inotropy was titrated out in TPI 
(Figure 5.4E) and was not significantly different to vehicle pH levels at 55 minutes 
(P>0.05) (Figure 5.6E). There were no differences in pH between vehicle and TNI at 
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Figure 5.8 Real-time derived [Na]i versus [ATP] in transient positive 
inotropy (TPI) and transient negative inotropy (TNI).  
Symbols and error bars represent mean ± SEM. [Na]i values were derived from 
normalised TQF signal measured every 1.5 min (Figure 5.2) and were averaged to 
correspond with the five minute ATP windows (Figure 5.4 and 5.5). 
 
 
5.6 Results - Global metabolomics in TPI and TNI by 1H NMR and LC-MS/MS 
 
Figures 5.9A and 5.9B show the metabolomic profiles obtained using 1H NMR for TPI 
and TNI respectively. The significant increase in acetylcarnitine (P<0.05) and decrease 
in carnitine (P<0.05) resulted in a highly significant increase in the acetylcarnitine-
carnitine ratio (P<0.001) in the TPI group versus vehicle. The TPI group was also 
associated with higher concentrations of alanine (P<0.05) and there was a trend towards  
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Figure 5.9 1H NMR metabolomic profiles of transient positive inotropy 
(TPI) and transient negative inotropy (TNI).  
(A) TPI. (B) TNI. Bars and error bars represent mean ± propagated SEM (n=4-



















































































































































































































































































    
  
Figure 5.10 Tricarboxylic acid profiles of transient positive inotropy (TPI) 
and transient negative inotropy (TNI) measured by LC-MS/MS.  
(A) TPI. (B) TNI. Bars and error bars represent mean ± propagated SEM (n=8-


























































































































an increase in lactate (P=0.09) although the latter metabolite did not reach statistical 
significance. There were no marked changes in metabolites associated with cardiac 
energetics in TPI. In the TNI group, the small increase in glutamine and decrease in 
glutamate resulted in a significant decrease in the glutamate-glutamine ratio (P<0.05) 
versus vehicle. The TNI group was also associated with a smaller pool of total 
ATP+ADP (P<0.05) and lower concentration of creatine (Cr) (P<0.05) which resulted 
in a significantly higher PCr:Cr ratio (P<0.05). There were no marked changes in 
metabolites associated with glycolysis or the acetylcarnitine shuttle.  
 
Quantification of pyruvate and the TCA cycle metabolites by LC-MS/MS revealed 
significant elevations in isocitrate (P<0.001) and malate (P<0.05) in the TPI group 
versus vehicle (Figure 5.10A). There was also a trend towards elevations in citrate 
(P=0.06) and fumarate (P=0.08) although these did not reach statistical significance. 
There were significant elevations in succinate (P<0.05), fumarate (P<0.05) and malate 
(P<0.01) and a significant decrease in α-ketoglutarate (P<0.05) in the TNI group versus 
vehicle (Figure 5.10B), as well as a trend towards elevation in pyruvate although this 
was not statistically significant (P=0.06). Full details of TPI and TNI metabolomics 
datasets are shown in Appendices 8.7-8.10. 
 
5.7 Discussion – TPI and TNI perfusion measurements. 
In this chapter, two studies were carried out in order to determine whether [Na]i 
elevation alters cardiac energetics and/or the intermediary metabolism irrespective of 
inotropic changes. It is important to stress that metabolic comparisons were made at a 




time when contractility had returned to 100% and Na+ was substantially elevated – 
however, while the Na+ contractility were identical at the time of metabolic assessment, 
the immediate history of the hearts differed between TNI and TPI groups. The TPI 
group had previously experienced a transient positive inotropy whilst hearts in the TNI 
group had a recent history of a transient negative inotropy.  
Significant bradycardia was observed following 100 µM ouabain in the TPI group and 
was also observed in the 100 µM ouabain group in Chapter 3 (Figure 3.1B). 
Interestingly, subsequent titration with 155 µM ouabain + 5 µM blebbistatin increased 
heart rate back to baseline. Heart rate elevation due to 5 µM blebbistatin has been 
reported previously (Brack et al., 2013) although this was not statistically significant. 
As anticipated, the coronary flow profiles were similar to the corresponding LVDP 
profiles of the TPI and TNI groups. As coronary flow is the most reliable indicator of 
oxygen demand in the isolated crystalloid perfused heart preparation (Aksentijevic et 
al., 2016), the lack of difference in coronary flow between TPI, TNI and vehicle at 55 
minutes suggests that oxygen demand, as well as oxygen delivery, were the same for all 
groups at the end of perfusion. 
LVEDP was elevated in both TPI and TNI groups upon [Na]i elevation. There are three 
possible explanations for this. Firstly, [Na]i elevation is thought to decrease NCX 
forward mode activity (Baartscheer et al., 2003a) and increase reverse mode activity 
(Barry et al., 1985) thereby increasing diastolic [Ca]i and, at the relatively high heart 
rates in the isolated rat heart, this leads to incomplete relaxation between beats. 
Secondly, the reduction in ATP (measured by 31P NMR) during both the TPI and TNI 




periods may have lowered lusitropy given that removal of Ca2+ from the cytosol during 
diastole requires approximately 15% of the total energy cost of the cardiac cycle 
(Langer and Brady, 1974). Thirdly, it was shown in Chapter 4 that blebbistatin alone 
elevates LVEDP, thus there may have been a contribution of blebbistatin to the negative 
lusitropy observed. However, this effect occurred profoundly with ouabain in the 
absence of blebbistatin during the TPI period thus [Na]i is likely to be the key driver of 
this phenomenon. 
 
5.8 Discussion- [Na]i measurements 
As observed previously in Chapters 3 and 4, the TQF 23Na NMR methodology 
permitted derivation of [Na]i in real-time. There were no changes in baseline 
measurements of derived [Na]i in any group during the stabilisation periods but 
substantial elevations in [Na]i occurred following ouabain perfusion. However, the 
maximum derived [Na]i achieved in these studies (30 mM) was lower than previous 
chapters which demonstrated that perfusion of hearts with 100 µM ouabain alone 
(Chapter 3) or 155µM ouabain+5µM blebbistatin (Chapter 4) lead to derived [Na]i 
values of 35-45mM. There were no notable differences in DQF signal during any of the 
studies giving confidence that concentrations of extracellular Na+ were stable 
throughout all perfusion protocols. Importantly, despite this unexplained discrepancy, 
derived [Na]i was identical (30 mM) at the end of perfusion in both the TPI and TNI 
groups. However, this value of [Na]i was reached approximately 10 minutes earlier in 
the TPI group than in the TNI group. TPI hearts were therefore exposed to a longer 
duration of [Na]i elevation during the treatment period. In addition, TPI hearts were at 




steady state at the end of perfusion whereas [Na]i was still on an upwards slope at this 
time in the TNI group. It was concluded from preliminary investigations that 1.5µM 
blebbistatin+50µM ouabain were the most suitable concentrations to achieve a 
significant negative inotropy concomitantly with a significant elevation in [Na]i. In 
order for the [Na]i profile of the TNI group to be identical to that of the TPI group, a 
higher concentration of ouabain would be required at the start of the TNI period. To 
overcome the inevitable positive inotropy that would arise, a higher concentration of 
blebbistatin would then also be necessary at this time. Owing to its irreversible binding, 
it is probable that the subsequent [Na]i required to elevate contractility back to baseline 
would far exceed ~30mM. Further work is required to identify whether it is practically 
feasible to obtain identical [Na]i profiles in the TPI and TNI groups. 
 
5.9 Discussion - 31P NMR energetics measurements 
31P NMR permitted the real-time monitoring of ATP, PCr, Pi and pH. During the TPI 
period, PCr was transiently decreased and Pi was transiently increased. A close 
relationship between LVDP and HEPs has been demonstrated previously in the isolated 
rat heart (Honda et al., 2002). That is, a transient rise in LVDP was associated with 
transient decreases in PCr and ATP and a transient increase in Pi. However, ATP did not 
return to baseline levels in either TPI or TNI in this chapter. Taken together with the 
Honda et al (2002) study, this supports the hypothesis that [Na]i elevation deranges ATP 
supply-demand matching in the isolated heart. Furthermore, the reduction in ATP upon 
[Na]i elevation is in agreement with the work of Iwai et al (2002) showing that elevating 
extra-mitochondrial sodium from 12.5 mM to 25 mM significantly reduces state 3 




respiration (oxidative phosphorylation). Strikingly, end-point PCr was not lower in the 
TPI and TNI groups versus vehicle and PCr:ATP was elevated with increasing [Na]i 
reflecting the drop in ATP. There is widespread literature reporting a reduced PCr:ATP 
under pathophysiological conditions associated with elevated [Na]i, for example, dilated 
cardiomyopathy (Neubauer et al., 1997), cardiac hypertrophy (Perings et al., 2000) and 
myocardial infarction (Naumova et al., 2006). There are, however, substantially fewer 
reports of elevated PCr:ATP under pathophysiological conditions. For instance, 
Consolini et al (2004) reported an increased PCr:ATP following an 
ischaemia/reperfusion protocol in the Langendorff rat heart, although PCr and ATP both 
declined under these conditions whereas ATP declined but PCr was unaltered at the 
end-point in the TPI/TNI studies in this chapter. Weiss et al (2002) demonstrated an 
increased PCr:ATP in GLUT4 null mice but this was driven by elevations in creatine 
and PCr in the absence of changes in ATP. Indeed, caution should be taken when 
comparing the findings of these pathophysiological studies with those of the TPI/TNI 
studies, as [Na]i elevation is just one of several maladaptations within the former studies 
that could potentially alter cardiac energetics. However, these comparisons may shed 
light upon the unexpected observation that PCr:ATP appears to be dependent upon [Na]i 
irrespective of inotropic alterations.  
A crucial aspect of the TPI/TNI studies was that contractility (the primary ATP sink in 
the heart) was identical for all groups at end-point. Thus, the reduction in ATP in both 
TPI and TNI groups upon [Na]i elevation cannot be attributed to increased ATP demand 
but instead to decreased ATP synthesis. This supports the hypothesis that [Na]i 
elevation perturbs ATP supply-demand matching in the heart. However, as cardiac ATP 




levels are known to be very tightly buffered by creatine kinase (CK), these findings 
suggest that [Na]i elevation may reduce creatine kinase activity (specifically 
myofilament CK rather than mitochondrial CK as the latter resides in the inter-
membrane and cristae spaces (Wegmann et al., 1991) and therefore is not in contact 
with [Na]m). Szasz et al (1976) showed that elevating Na+ in blood serum decreases CK 
activity although the relevance of this to the perfused heart is equivocal. It has been 
shown previously that incubation of rat heart mitochondria in high Na+ media (83mM 
Na+ phosphate or 100 mM Na+ acetate) causes the mitochondria to swell and release CK 
from their membranes in the soluble form (Jacobus and Lehninge.Al, 1973). 
It is improbable that blebbistatin is responsible for the elevated PCr:ATP as ATP 
declines rapidly with blebbistatin-free ouabain (during the intial stages of the TPI 
period) despite PCr levels falling concomitantly. In the healthy heart, CK sustains 
normal ATP over a wide range of contractile demand (Wu and Beard, 2009) suggesting 
a reduced capacity of CK to maintain normal ATP during the TPI period in which [Na]i 
was high. There is no evidence in the literature to suggest that blebbistatin inhibits CK 
whereas it has been shown to stimulate CK activity in fully relaxed permeabilised 
skinned fibres in which the ATP demand was low (Perry et al., 2012). 
Alternatively, rather than CK activity being directly affected by [Na]i, it may be an 
associated elevation in [Ca]i that is responsible for the increased PCr:ATP. Cerebellum 
is known to contain CK-MM (Hemmer et al., 1994) which is the predominant cytosolic 
isoform in the mammalian heart (Eppenberger et al., 1967) and high Ca2+ (20 mM) has 
been shown to inhibit CK activity in the cerebellum (Khan, 1976). Although 20mM is 
substantially higher than myocardial [Ca]i (typically in the nanomolar range) (Jansen et 




al., 2000), “[Ca]i sparks” significantly elevate this value (Cheng et al., 1996) and occur 
in close proximity to sarcolemmal- (Saks et al., 1977) and SR- (Rossi et al., 1989) 
localised CK. 
As anticipated, there was an increase and decrease in Pi upon LVDP elevation in the 
TPI group and upon LVDP reduction in the TNI group, respectively. The Pi profiles 
were the inverse of their respective PCr profiles which corresponds with the strong 
positive correlation between cardiac workload and CK activity (PCrATP then 
hydrolysis by ATPases to give Pi) (Dawson et al., 1980). In contrast to end-point PCr, 
there were substantial elevations in end-point Pi in both TPI and TNI groups compared 
with vehicle. In the absence of changes in PCr, this adds weight to the possibility that 
CK activity is altered by [Na]i elevation. However, the elevated Pi in the TPI group 
versus vehicle did not reach statistical significance (perhaps owing to the low 
signal:noise and higher associated error compared with PCr and ATP) hence greater n 
numbers are required to substantiate this. 
The transient reduction in pH observed in the TPI period reflects a greater release of 
protons from the hydrolysis of ATP. However, end-point pH was not altered by 
increased [Na]i. Taken together with the Pi data, this is in favour of the TPI and TNI 
hearts being in a state of reduced ATP synthesis rather than increased ATP hydrolysis at 
the end of perfusion. 
 




5.10 Discussion - Metabolomics measurements. 
Several of the identified alterations in energetics and intermediary metabolism were 
common to both the TPI study and the TNI study. These are summarised in Table 5.2.  
As discussed in previous chapters in this thesis, 1H NMR and LC-MS/MS permitted the 
quantification of several aqueous metabolites involved in energy homeostasis in heart 
extracts. 
 
Table 5.2  Summary of alterations common to both TPI and TNI groups. 
Analyte 
TPI TNI 
% change  P-value % change P-value 
Fumarate  150 0.076  128 0.013 
Malate  51 0.038  54 0.002 
ATP  41 0.001  25 0.007 
PCr:ATP  44 0.003  28 0.048 
 
 
% changes are for Transient Positive Inotropy group (TPI) or Transient Negative 
Inotropy group (TNI) vs vehicle at 55 minutes where ‘0%’ change represents zero 
fold-change. Fumarate and malate were acquired using LC-MS/MS of dual-phase 
extracts. ATP and PCr:ATP were acquired using real-time 31P NMR of perfused 
hearts. 
 
Elevated acetylcarnitine:carnitine was observed in the TPI profile but not the TNI 
profile and was also elevated in both paced and unpaced contracting hearts perfused 




with blebbistatin-free ouabain (discussed in Chapter 3). This suggests that the 
acetylcarnitine shuttle is altered due to positive inotropy but also that it remains altered 
once the positive inotropy has waned. Acetylcarnitine has been shown to increase in 
skeletal muscle upon prolongued exercise in humans (Sahlin et al., 1990). 
Alanine also appeared to be elevated by TPI but not TNI. As high levels of lactate 
(which was also markedly higher than vehicle in TPI) inhibit glycolysis (Rovetto et al., 
1975), alanine transaminase activity is stimulated following elevated contractile work 
(Felig and Wahren, 1971) thereby converting more pyruvate into alanine and less into 
lactate. Alanine elevation was not observed previously in the blebbistatin-free ouabain-
perfused hearts (Chapter 3).  
TPI also elevated isocitrate (and possibly citrate). This is supported by the work of 
Stuewe et al (2000) which highlighted increased citrate synthase (but not malate 
dehydrogenase or α-ketoglutarate dehydrogenase) activity and expression in the left 
ventricle of dogs with exercise-induced increases in contractile work. This infers 
increased TCA cycle activity with elevated contractile demand. However, this disagrees 
with the findings of Sharma et al (2005) that 4-carbon intermediates (succinate, 
fumarate and malate), but not 6-carbon intermediates, are elevated by high cardiac 
work. The authors used the β-agonist, dobutamine, to elevate contractile work thus non-
contractile effects of this drug may have contributed to their metabolomic profile.  
The significant reductions in glutamate:glutamine and α-ketoglutarate in the TNI profile 
are consistent with reduced anaplerosis into the TCA cycle via glutamate 
dehydrogenase. However, this is opposed by the 13C flux assessment of KCl-arrested 




perfused hearts (Lewandowski, 1992) which, when compared with normally contracting 
controls, exhibited no change in the total size of the glutamate pool and an elevation in 
contribution of carbons into the TCA cycle via anaplerosis relative to citrate synthase. 
However fully-arrested hearts have a vastly different ATP demand to those contracting 
but with a history of TNI. 
There were also changes in energetics that were exclusive to the TNI study including 
reductions in the total ATP+ADP pool and creatine. Combined with the 31P NMR 
measurements, it is likely that the reduced adenylate pool size reflects reduced ATP 
upon [Na]i elevation. Interestingly, the ATP+ADP pool was also decreased in the TPI 
group (versus vehicle) but was more subtle than the TNI profile and did not reach 
statistical significance. The reason for the lowered creatine level is less clear given that 
end-point PCr in the TNI group was not different to vehicle. 
The increased succinate in the TNI group may be due to its accumulation following the 
transient reduction in ATP demand and subsequent downregulation of complex II and 
oxidative phosphorylation. Further work would be required to substantiate this. 
Perfused hearts exhibiting 60mmHg systolic pressure were shown to contain 38% more 
pyruvate than those exhibiting 120mmHg systolic pressure (Kobayashi and Neely, 
1983). The authors suggested that this was due to increased pyruvate dehydrogenase 
activity upon elevated contractile demand. This aligns with the observation that 
pyruvate is significantly higher than vehicle in the TNI study but not in the TPI study. 
The identification of metabolomic changes that were exclusive to either the TPI study or 
the TNI study supports the hypothesis that the heart has “metabolic memory” for 




contractility. That is, it is possible for certain metabolomic alterations induced by brief 
changes in inotropy were sustained for some time after the waning of that inotropy.  
The concentrations of malate and fumarate were elevated in an almost identical fashion 
in both the TPI and TNI studies (although fumarate did not reach statistical significance 
in the TPI study, it was elevated by 150% and was approaching significance). Similar to 
ATP, these TCA cycle intermediates may therefore potentially be considered to be 
[Na]i-dependent irrespective of alterations in inotropy. Accumulations in malate and 
fumarate are indicative of reduced malate dehydrogenase activity. The apparent Km and 
Vmax of this enzyme have been shown to decrease and increase in vitro with increasing 
[Na+], respectively (Kelavkar and Chhatpar, 1993). Malate dehydrogenase is a key 
producer of NADH in the myocyte and Maack et al (2006) have shown that 
NAD+:NADH rises upon [Na]i elevation.  
The interpretation of the metabolic aspects of the TPI/TNI studies is very complex 
given the strong association between contractile state, ATP demand and intermediary 
metabolism. Metabolites were categorised as ‘TPI-dependent’, ‘TNI-dependent’ or 
‘[Na]i-dependent’ but this is probably an oversimplification. It is likely that all 
metabolic enzymes are regulated by contractile demand (either directly or indirectly and 
to different extents) and the linearity of this relationship for each metabolite 
concentration is not known. Large changes in metabolite concentrations due to TPI or 
TNI may mask smaller metabolite changes due to regulation by [Ca2+] or [Na+]. It may 
also be the case that regulation of metabolism by [Ca2+] and/or [Na+] becomes 
increasingly important with increasing contractile demand. The TPI and TNI protocols 




could be repeated under conditions of high workload, for example, by using high rates 
of electrical pacing or increased extracellular [Ca]. 
 
5.11 Summary 
In this chapter, it has been shown using a combination of NMR and LC-MS/MS 
approaches that, in normally-contracting perfused hearts, a transient increase or 
decrease in inotropy with a sustained elevation of [Na]i resulted in an elevated PCr:ATP 
ratio due to a decrease in ATP. This showed a strong inverse correlation with [Na]i 
elevation (despite no change in PCr), indicating a possible role for [Na]i in the 
regulation ATP synthesis, TCA cycle activity or creatine kinase. 
In the TPI group, increases were observed in acetylcarnitine as well as the 
concentrations of alanine (potentially due to increased alanine transaminase activity), 
citrate and isocitrate (suggesting increased TCA cycle activity). On the other hand, a 
transient reduction in inotropy was associated with decreases in glutamate:glutamine 
and α-ketoglutarate (potentially due to reduced glutamate anaplerosis) as well as 
decreases in the total ATP+ADP pool and creatine. These changes support the existence 
of “metabolic memory” for contractility in the heart. Malate and (more tentatively) 
fumarate increased due to [Na]i elevation, suggesting a possible link between [Na]i and 
TCA cycle activity or malate dehydrogenase activity in the perfused heart.  
 
  




6 ASSESSMENT OF TRICARBOXYLIC ACID CYCLE 
ACTIVITY IN HEARTS WITH ELEVATED [Na]i IN 
THE ABSENCE OF CHANGES IN CONTRACTILITY. 
6.1 Introduction 
In Chapter 5, it was concluded that [Na]i elevation perturbs ATP supply in the perfused 
rat heart which may have been associated with the observed increase in the TCA cycle 
intermediate, malate, as well as a trend towards elevation in fumarate. According to the 
main thesis hypothesis, [Na]i elevation would reduce the [Ca]m-driven stimulation of the 
TCA cycle potentially leading to decreased TCA cycle activity during [Na]i elevation, 
which could explain the observed increase in malate or fumarate. It is also possible that 
particular enzymes of this pathway may be more sensitive to [Na]i elevation than other 
TCA cycle enzymes in the isolated heart. 
Isotopic labelling is a powerful means by which to assess TCA cycle activity as well as 
other metabolic pathways in the Langendorff preparation. This entails perfusing a fuel-
substrate (commonly glucose, palmitate or acetate) containing an isotopic label (or 
labels). The label(s) can be located at any atomic position(s) of the molecule and is 
usually 13C, although 2H and 15N have also been utilised (Carvalho et al., 2001, Li et al., 
2015, Pisarenko et al., 1980). Mass spectrometry has been used in previous chapters in 
this thesis to quantify total concentrations of metabolites. Its ability to distinguish 
between chemical entities with a resolution as low as one Dalton makes this technique 
applicable for the detection of isotopologues (molecules that differ only in the number 
of isotopic labels) and isotopomers (molecules that that differ only in the atomic 




position of the isotopic label(s)) (McNaught and Wilkinson, 2000). As the labelled fuel-
substrate is metabolised by the cell, the label is incorporated into the resultant enzymatic 
products which can be quantified by mass spectrometry. Changes in the concentrations 
of these labelled metabolites due to an intervention, for example, perfusion of a 
pharmacological agent or elevation of [Na]i could infer altered activity of the pathway 
or pathways in which that metabolite is involved. 
There are several important factors to consider when designing isotopologue mass 
distribution studies. Firstly, the fuel-substrate must be optimal for the particular 
metabolic pathway under question, in this case, the TCA cycle. Universally labelled 13C 
glucose ([U]-13C6-glucose) was chosen as the fuel-substrate for the study described in 
this chapter as its isotopic labels will be incorporated into glycolytic intermediates and 
end products as well as the TCA cycle. Secondly, the heart must be at metabolic steady-
state, that is, the pool sizes of all metabolites and also cardiac function should be 
constant and at equilibrium during the infusion. As contractile demand is known to be a 
key driver of metabolic change (discussed in previous chapters) it is crucial that the [U]-
13C6-glucose is perfused during a period of stable LVDP and coronary flow. 
Analogously, the label must be perfused during a period of stable [Na]i given the main 
thesis hypothesis that elevated [Na]i alters metabolism. Thirdly, the heart must be at an 
isotopic steady-state at the point of snap-freezing. This has been defined by Buescher et 
al (2015) as the point at which “13C enrichment into a given metabolite is stable over 
time relative to experimental error and/or the desired measurement accuracy [and is 
governed] by both the fluxes and the pool sizes [of all metabolites involved in this 
enrichment]”. Comte et al (1997) showed that glycolytic (glucose to 




pyruvate/lactate/acetyl CoA) and TCA cycle (pyruvate to TCA cycle intermediates) 
pools reach isotopic steady-state in approximately 15 minutes and 10-15 minutes, 
respectively. Furthermore, Jeffrey et al. (1995) showed that [U]-13C-glucose achieves 
isotopic steady-state with respect to TCA cycle pools after ~20 minutes perfusion in the 
perfused rat heart. As the TCA cycle is tightly coupled to glycolysis and anaplerosis 
(Figure 1.6) the presence of 13C label was assessed in all three pathways in this chapter. 
The analysis and interpretation of 13C isotopomer datasets is challenging for two key 
reasons. Firstly, numerous labelling patterns are possible for each metabolite. This is 
because metabolites can participate in unidirectional and/or reversible enzymatic 
reactions as a substrate and/or a product and those reactions can be linear or cyclic. The 
incorporation of 13C into the TCA cycle from [U]-13C6-glucose is displayed in Figure 
6.1. Secondly, the process of “deisotoping” must be performed prior to drawing any 
reliable conclusions from isotopomer datasets. This entails correcting for the 
contribution of naturally occurring isotopes (for example, 13C, 15N, 17O and 18O) to the 
acquired isotopomer signals. At present, there are several means by which to do this 
including numerous algorithms (Moseley, 2010, Lee et al., 1991) and software, for 
instance, LS-MIDA (Ahmed et al., 2013) and IsoCor (Millard et al., 2012). IsoCor was 
used in this chapter as it is capable of rapidly processing large quantities of data 
encompassing different metabolites. It also has a feature which corrects for isotopic 
purity of the tracer. 





Figure 6.1  Pathway map of 13C incorporation into the TCA cycle.  
13C6-(universally-labelled) glucose is converted into 13C3-pyruvate following glycolysis. This 
pyruvate is then decarboxylated to form 13C2-acetyl CoA which undergoes condensation with 
unlabelled (white-filled circles)-oxaloacetate forming 13C2-citrate thereby feeding two 13C 
labels (black-filled circles) into the first turn of the TCA cycle. These labels are passed around 
the cycle following numerous oxidative reactions to form 13C2-oxaloacetate which can then be 
condensed with a second molecule of 13C2-acetyl CoA. This therefore initiates a second turn of 
the TCA cycle which increases the abundance of 13C label in the TCA cycle intermediates. 
After four turns of the TCA cycle, 13C universally-labelled forms of all TCA cycle intermediates 
are present in the heart. The abundance of 13C-labelled TCA metabolites is therefore directly 
proportional to TCA cycle activity. Furthermore, the presence of 13C1 and 13C2 isotopologues of 
pyruvate and lactate is suggestive of malate-pyruvate cycling (note that not all isotopomers 
are shown). Dihydroxyacetone phosphate (DHAP, not shown) is a branch point of glycolysis 
and is interconverted to glyceraldehyde-3-phosphate via triosephosphate isomerase. Alanine 
(not shown) is interconverted to pyruvate via alanine transaminase, aspartate (not shown) is 
interconverted to oxaloacetate via aspartate transaminase and glutamate (not shown) is 
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The aims of this chapter are: 
1. To determine whether [Na]i elevation, in the absence of altered contractility, 
alters the activity of the TCA cycle using isotopic incorporation of [U]-13C6-
glucose. 
 
2. To determine whether any observed alterations in fluxes can infer whether 
the TCA cycle activity is increased or decreased in response to elevated 
[Na]i. 
 
6.3 Experimental Methods. 
6.3.1 Perfusion protocols and measurements. 
Rat hearts were perfused in the Langendorff mode as described in Section 2.1. The 
study included a vehicle group and a high [Na]i group (n=6/group). These groups were 
identical to the vehicle and TPI groups in Chapter 5, respectively, other than the 
presence of [U]-13C-glucose (Cambridge Isotope Laboratories, USA) and an extension 
of each treatment period by 25 minutes to ensure that metabolic and isotopic steady-
states had been achieved at that point of snap-freezing. Hearts were perfused in a 
randomised-fashion and the perfusion protocols are summarised in Table 6.1. Separate 
perfusion reservoirs were used for the different perfusion solutions. [Na]i elevation was 
induced by carefully pouring a small volume (approximately 5-10mL every 5 minutes) 
of 5µM blebbistatin+155µM ouabain KH into the titration reservoir initially containing 





Table 6.1  Perfusion protocols used in the 13C isotopologue study. 
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250 mL 100 µM ouabain KH (pre-warmed to 39°C and gassed vigorously with 
carbogen). This resulted in a gradual and stable return to baseline LVDP at which time 
no further titrant was added. Homogeneity of the perfusion solutions was ensured by 
vigorous gassing and manual mixing by hand using the gas distribution tube in each 
perfusion reservoir. It was important to minimise changes in cardiac function upon 
switching from [U]-12C-glucose blebbistatin+ouabain KH to [U]-13C-glucose 
blebbistatin+ouabain KH at 55 minutes in the high [Na]i group. This was accomplished 
by having the same initial volume (250 mL) of 100µM ouabain in each of these 
perfusion reservoirs from the start of the perfusion protocol and by adding the same 
volume of 155µM ouabain + 5µM titrant to both reservoirs during the titration period 
(the volume required varied slightly between experiments). LVDP, heart rate, coronary 




flow and LVEDP were recorded continuously throughout each experiment. Hearts were 
removed from the NMR spectrometer at 80 minutes and snap-frozen as described in 
section 2.1.9. 
 
6.3.2 23Na NMR protocols. 
Heart perfusions were performed within the NMR spectrometer using the in-house 
NMR perfusion setup as described in Section 2.2.2. 23Na TQF NMR measurements 
were performed from 0 to 80 minutes and 23Na DQF NMR measurements were 
performed from 0 to 55 minutes. 
 
6.3.3 13C isotopologue measurements of myocardial tissue by GC-MS. 
Aqueous metabolites were isolated using methanol extraction (Section 2.4.5) and 
isotopologue patterns of the TCA cycle (oxaloacetate, citrate, isocitrate, αKG, succinate, 
fumarate and malate), anaplerosis (alanine, aspartate and glutamate) and glycolysis 
(DHAP, pyruvate and lactate) were measured using GC-MS in single ion monitoring 
mode (described in Section 2.4.5). 
 
6.3.4 13C isotopologue measurements of myocardial tissue by LC-MS/MS. 
Aqueous metabolites were isolated using dual-phase extraction (Section 2.4.2) and 13C 
isotopomer analysis was subsequently carried out using LC-MS/MS. The setup and 
acquisition parameters were as described in Section 2.4.4 other than that different 




chemical transitions were programmed into the Analyst software in order to detect 13C 
isotopomers of metabolites in addition to 12C (unlabelled) metabolites. Individual 
isotopomer intensities were pooled into their appropriate isotopologue groups to permit 
correction of natural abundance by IsoCor. For instance, the raw intensities of the two 
m+1 isotopomers of fumarate were added together to give the total intensity of the m+1 
isotopologue of fumarate.  
 
6.3.5 Correction of 13C isotopologue measurements for natural isotopic 
abundance using IsoCor software. 
13C isotopologue intensities were compiled in a text-delimited input file and processed 
using IsoCor software (Version 1.0). This corrected for the natural abundance of the 
isotopic tracer (13C) as well as the isotopic purity (99%) of the [U]-13C-glucose used in 
the experiments. The elemental formulas for isocitrate, lactate, pyruvate, DHAP, alanine 
and glutamate were not present in the original ‘Metabolites.dat’ file and thus were 
added manually. As chemical derivatisation of extracted metabolites was not used in the 
LC-MS/MS study, the ‘Derivatives.dat’ file was not used and this column was left 
empty in the input file. The output (result) file included mass distribution vector values 
for each isotopologue as well as mean enrichment of each metabolite. 
 
6.4 Results - Perfusion measurements. 
All perfusion parameters were stable, within acceptable ranges according to previously 
defined exclusion criteria (detailed in Section 2.1.6) and were not different between the   




   
       
       
       
Figure 6.2  Functional measurements in the vehicle and high [Na]i groups (13C study).  
(A) Left ventricular developed pressure (LVDP). (B) Heart rate. (C) Coronary flow. (D) Left 
ventricular end diastolic pressure (LVEDP). Symbols and error bars represent mean±SEM of 
five minute time windows (n=5-6/group). Hearts were snap-frozen at 80 minutes. Blebbistatin 
(Bleb); dimethyl sulfoxide (DMSO); ouabain (Oua). 
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vehicle and high [Na]i group during the stabilisation period. Baseline LVDP (Figure 
6.2A) was 110±7 mmHg in the vehicle group and was not altered (P>0.05) by 
subsequent DMSO perfusion (98±7 mmHg; P>0.05; paired t-test). In the high [Na]i 
group, LVDP was elevated to a maximum of 185±8mmHg at 30 minutes (after 10 
minutes of perfusion with 100µM ouabain; P<0.0001 vs vehicle) but returned to 
baseline at 50 minutes (118±19 mmHg) following blebbistatin/ouabain titration and 
remained stable then until 80 minutes (109±10 mmHg). Heart rate (Figure 6.2B) was 
308±18 BPM at baseline and was not altered by DMSO (328±21 BPM; P>0.05; paired 
t-test) in the vehicle group. The high [Na]i group exhibited a significant bradychardia at 
30 minutes (268±15 BPM; P<0.05 vs vehicle) but returned to baseline levels by the end 
of perfusion. 
Coronary flow (Figure 6.2C) was 12±1 mL/min at baseline in the vehicle groups and 
DMSO perfusion had no effect (13±2 mL/min). There was no difference in coronary 
flow between vehicle or high [Na]i throughout the entirety of the experiment (P>0.05). 
LVEDP (Figure 6.2D) was 6.6±1.3 mmHg in the vehicle group at baseline and did not 
change upon vehicle DMSO perfusion (6.6±1.3 mmHg; P>0.05; paired t-test). 
Furthermore, there was no difference in LVEDP between vehicle and high [Na]i at any 
point in the protocol (P>0.05), despite a larger error associated with the latter group. 
 
6.5 Results- [Na]i and DQF measurements. 
[Na]i (Figure 6.3A) remained constant throughout the stabilisation period in both 
vehicle (17±0.6 mM) and TPI (18±0.5 mM). The vehicle DMSO had no effect on  









Figure 6.3  TQF/DQF 23Na NMR measurements (13C study). 
(A) Normalised triple quantum filtered (TQF) 23Na NMR intensity (left axis) with derived 
intracellular [Na]i (right axis). (B) Normalised double quantum filtered (DQF) 23Na NMR intensity. 
Symbols and error bars represent mean±SEM of 1.5 minute time windows (n=5-6/group). Hearts 
were snap-frozen at 80 minutes. See Table 6.1 for details of protocol. Blebbistatin (Bleb); 
dimethyl sulfoxide (DMSO); ouabain (Oua). 
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derived [Na]i during the treatment period (18±1.0 mM). [Na]i was significantly higher 
(P<0.05) in the high [Na]i group (31.0±.3.4 mM) compared with the vehicle group 
(18.7±1.9 mM) at the end of perfusion and was stable during the period of [U]-13C-
glucose infusion. DQF signal did not markedly deviate from baseline (1.0±0.1 arbitrary 
units) at any point between 0 and 55 minutes (Figure 6.3B). 
 
6.6 Results - 13C isotopologue measurements of myocardial tissue by GC-MS. 
 
The GC-MS method permitted the measurement of seven TCA cycle intermediates, 
three anaplerotic metabolites and three glycolytic metabolites. 
The total extent of enrichment of these metabolites with 13C label is shown in Figure 
6.4. Significant increases in mean enrichment of citrate (25%; P<0.01), α-ketoglutarate 
(6%; P<0.05), fumarate (25%; P<0.01), malate (21%; P<0.05) and alanine (23%; 
P<0.01) were observed in the high [Na]i group versus vehicle. 
With respect to the mass distribution vectors of the glycolytic metabolites, the m+3 
isotopologue of DHAP (Figure 6.5A) was elevated in the high [Na]i group compared 
with vehicle (53%; P<0.05). However no changes were observed in the isotopologues of 
pyruvate or lactate. The m+0 (-28%; P<0.01) and m+1 (-20%; P<0.05) isotopologues of 
alanine were significantly lower in the high [Na]i group versus vehicle whereas the m+3 
form was significantly higher in the high [Na]i group (25%; P<0.01) (Figure 6.5D). In 
addition, m+1 aspartate (-16%; P<0.01), m+1 glutamate (-22%; P<0.05) and m+2 
glutamate (-25%; P<0.01) were significantly lower in the high [Na]i group (Figure   





Figure 6.4  13C mean enrichment of metabolites involved in glycolysis, 
tricarboxylic acid (TCA) cycle and anaplerosis by GC-MS. 
Columns and error bars represent mean±SEM (n=3-6/metabolite/group). ‘0’ and ‘1’ 
represent 0% and 100% isotopic labelling of the metabolite pool respectively. *P<0.05; 
**P<0.01. 
 
6.5E&F). There was also a trend towards reduced levels of m+0 and m+2 aspartate 
(Figure 6.5E) as well as m+0 and m+3 glutamate (Figure 6.5F) in the high [Na]i group 
versus vehicle but were not significantly different (P>0.05). Furthermore, the m+5 
isotopologue of glutamate was substantially higher in the high [Na]i group compared 
with vehicle (42%; P<0.05). In regard to the TCA cycle intermediates, oxaloacetate 
(Figure 6.6A) displayed no marked differences between the treatment groups. There 
was a lower abundance of m+0 citrate (-23%; P<0.05) and m+2 citrate (-9%; P<0.05) in 
the high [Na]i group compared with vehicle whereas m+5 citrate (28%; P<0.05) was 
more abundant in the former group (Figure 6.6B). A trend towards an elevation was 
observed in m+6 citrate (40%; P=0.082) in the high [Na]i group versus vehicle however 
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Figure 6.5 13C isotopologue mass distribution vectors (MDVs) of glycolytic and 
anaplerotic metabolites by GC-MS. 
(A) Dihydroxyacetone phosphate (DHAP). (B) Pyruvate. (C) Lactate. (D) Alanine. (E) 
Aspartate. (F) Glutamate. Columns and error bars represent mean±SEM (n=3-
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Figure 6.6 13C isotopologue mass distribution vectors (MDVs) of TCA cycle 
intermediates by GC-MS. 
(A) Oxaloacetate. (B) Citrate. (C) Isocitrate. (D) α-ketoglutarate. (E) Succinate. (F) Fumarate. 




































































































































































high [Na]i group versus vehicle (-48%; P<0.01) and the m+4 isotopologue exhibited a 
trend towards elevation in the high [Na]i group but was not statistically significant 
(30%; P=0.065). There was also a trend toward reductions in the m+0 and m+1 
isotopologues of α-KG (Figure 6.6D) in the high [Na]i group versus vehicle (-21% and -
27% respectively) although these values were not statistically significant. M+2 
succinate and m+4 succinate were 27% lower and 39% higher respectively in the high 
[Na]i group compared with vehicle (P<0.05) (Figure 6.6E). Multiple isotopologue 
changes were observed in fumarate (Figure 6.6F) with reductions in m+0 (18%; P<0.05) 
and m+1 (10%; P<0.05) and elevations in m+3 (15%; P<0.01) and m+4 (40%; P<0.05) 
in the high [Na]i group compared with vehicle. Malate exhibited a similar pattern of 13C 
label distribution to fumarate. M+0 malate was 26% higher (P<0.05) in the high [Na]i 
group versus vehicle and m+4 malate was 38% lower (P<0.05) in the former versus the 
latter. There was a trend towards a reduction in m+1 and m+2 malate in the high [Na]i 
group compared with vehicle but did not reach statistical significance (P>0.05). Full 
details of the 13C GC-MS datasets are shown in Appendices 8.11-8.12. 
 
6.7 Results - 13C isotopologue measurements of myocardial tissue by LC-MS/MS. 
13C labelling of pyruvate, lactate and TCA cycle intermediates in the myocardial tissue 
samples was also assessed by LC-MS/MS. Isotopologues were detected for all eight of 
the metabolites targeted by this technique (pyruvate, lactate, citrate, isocitrate, α-
ketoglutarate, succinate, fumarate and malate) in the heart tissue extracts. Figure 6.7 
summarise the mean enrichments of three of these metabolites. Due to technical issues 
with the mass spectrometer, it was not possible to calculate mean enrichment for the 




   
Figure 6.7  13C mean enrichment of tricarboxylic acid (TCA) cycle intermediates. 
Columns and error bars represent mean±SEM (n=5-6/group). ‘0’ and ‘1’ represent 0% 
and 100% isotopic labelling of the metabolite pool respectively.  Mean enrichment of 
the other TCA cycle intermediates as well as pyruvate and lactate could not be 
calculated due to a technical issue. *P<0.05; **P<0.01. 
 
other five targeted metabolites as not all of their isotopomers were detected. Isocitrate, 
fumarate and malate were all enriched by >40% in both groups and isocitrate 
enrichment was significantly higher in the high [Na]i group compared with the vehicle 
group (P<0.05). Enrichment of fumarate and malate also showed a trend towards higher 
enrichment in the high [Na]i group although did not reach statistical significance. Figure 
6.8 displays the relative abundances of the isotopologues, i.e., ‘mass distribution 
vectors’ (MDVs) for isocitrate, fumarate and malate. As the isotopologue sets were 
incomplete for the other metabolites, it was not possible to plot MDVs for these. 
Therefore, the mean raw LC-MS/MS intensity of the m+0 isotopologue signals of these 
metabolites (Figure 6.9) were compared between vehicle and high [Na]i to give an 
alternative indication as to whether there was a difference in the concentration of the 
unlabelled forms of these metabolites at the end of perfusion. There was a consistent 
























     
 
Figure 6.8 13C Isotopologue Mass Distribution Vectors (MDVs). 




Figure 6.9 M+0 (unlabelled) raw LC-MS/MS counts. 
(A) Pyruvate. (B) Lactate. (C) Citrate. (D) Succinate. (E) α-ketoglutarate. Columns and 
error bars represent mean±SEM (n=5-6/group). 
Isocitrate
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fumarate (Figure 6.8B) and malate (Figure 6.8C) and succinate (Figure 6.9D) in the 
high [Na]i group versus vehicle. Both malate (P<0.05) and fumarate (P<0.001) reached 
statistical significance although isocitrate and succinate did not. The m+1 isotopologues 
of isocitrate and fumarate, as well as the m+2 isotopologues of isocitrate and malate, 
also displayed a tendency to lower abundances in the high [Na]i group compared with 
vehicle but were not statistically significant (P>0.05). There were no clear trends for the 
m+3 (P<0.05) isotopologues of the TCA cycle. However, the m+4 isotopologue profiles 
of fumarate and malate were inverse to those of the m+0, m+1 and m+2 isotopologues. 
That is, m+4 exhibited a higher abundance in the high [Na]i group versus the vehicle 
counterparts which was statistically significant. There was also a similar trend in the 
m+5 and m+6 isotopologues of isocitrate although were not statistically significant 
(P>0.05). There was a high degree of similarity between the overall isotopologue 
profiles of fumarate and malate. There were no differences (P>0.05) between the 
perfusion groups with respect to the raw intensities of the m+0 isotopologues of 
pyruvate (Figure 6.9A), lactate (Figure 6.9B), citrate (Figure 6.9C), α-ketoglutarate 
(Figure 6.9D) and succinate (Figure 6.9E). Full details of the 13C LC-MS/MS datasets 




In this chapter, a vehicle group and a high [Na]i group were perfused with 13C-labelled 
glucose to assess whether TCA cycle activity is altered by [Na]i elevation. As the 
groups exhibited the same LVDP during the labelling period, increased 13C 




incorporation (measured by GC-MS and LC-MS/MS) in the high [Na]i group were 
indicative of altered TCA cycle activity that were independent of contractile demand. 
 
6.8.1 Perfusion measurements 
As anticipated, 100µM ouabain resulted in a significant TPI that resembled the LVDP 
profile of the TPI group in Chapter 5 (Figure 5.1). LVDP was at steady-state during the 
13C labelling period in both groups. In agreement with Figure 3.1 and Figure 5.1 in 
previous studies, perfusion with 100 µM ouabain gave rise to a significant bradycardia 
(Figure 7.2) which had waned prior to the infusion of 13C label at 55 minutes. Increases 
in coronary flow (Figure 6.2) and LVEDP (Figure 6.2) upon 100 µM ouabain perfusion 
were characteristic of the profiles discussed in previous chapters (Figures 3.1 & 5.1). 
However, importantly when the inotropy had been titrated back to baseline there was 
then no significant difference in coronary flow between control and treated groups. 
 
6.8.2 [Na]i measurements 
There were no changes in baseline measurements of [Na]i in either group during the 
stabilisation periods but significant elevations in TQF and therefore in the derived [Na]i 
occurred following ouabain perfusion (Figure 6.3). The [Na]i profiles between 0 and 55 
minutes for the vehicle and high [Na]i groups exhibited a high degree of similarity with 
those of the vehicle and TPI groups in Chapter 5 (Figure 5.1), respectively. In 
concurrence with the studies detailed in Chapter 5, neither group described in this 
chapter exhibited alterations in DQF signal between 0 and 55 minutes. Although DQF 




was not measured between 55 and 80 minutes (the 13C labelling period) due to a 
technical issue, there is no difference between hearts perfused with 13C6-glucose to 
those perfused with 12C-glucose. Importantly, TQF and therefore derived [Na]i was at 
steady-state in both groups throughout the entirety of the 13C labelling period (55-80 
minutes). 
 
6.8.3 13C isotopologue measurements 
13C incorporation into the TCA cycle was assessed by both GC-MS and LC-MS/MS. 
There was good agreement between the control (vehicle) values in these datasets 
compared with those obtained by Chouchani et al. (2014) using the isolated mouse 
heart. Tables 6.2 and 6.3 summarise the alterations in mean enrichment and mass 
distribution vectors measured by GC-MS and LC-MS/MS in this thesis. There was 
strong agreement between these techniques in terms of elevated mean enrichment of 
fumarate (GC-MS: 25%; LC-MS/MS: 22%) and malate (GC-MS: 21%; LC-MS/MS: 
19%) in the high [Na]i group versus vehicle although the GC-MS values did not reach 
statistical significance. In the GC-MS method, citrate was also significantly enriched 
during [Na]i elevation (Figure 6.4). Given that citrate and isocitrate exist in equilibrium 
(Costello et al., 2000) this aligns with the increased enrichment of isoctrate measured by 
LC-MS/MS (Figure 6.7) following a period of high [Na]i. Based on the simple model of 
carbon fluxes shown in Figure 6.1, the greater abundance of m+3 fumarate and m+4 
fumarate in the high [Na]i group versus vehicle (Table 6.3) indicate that these 
isotopologues had been subject to more turns of the TCA cycle with high [Na]i. 
  




 Table 6.2  13C Mean enrichment summary (GC-MS & LC-MS/MS) 
Analyte 
GC-MS LC-MS/MS 
% change  P-value % change P-value 
Fumarate 25  0.006 22  0.068 
Malate 21  0.020 19  0.071 
 
% changes are for High [Na]i group vs vehicle at 80 minutes where ‘0 %’ change 
represents zero fold-change. Only metabolites that were significantly altered and/or 
gave similar values from GC-MS and LC-MS/MS were included. 
 
 Table 6.3  13C Mass distribution vector summary (GC-MS & LC-MS/MS) 
Analyte 
GC-MS LC-MS/MS 
% change P-value % change P-value 
Isocitrate 
m+1 
48  0.001 45  0.017 
Fumarate 
m+0 
18  0.015 32  0.017 
Fumarate 
m+3 
15  0.004 18  0.040 
Fumarate 
m+4 
40  0.029 25 0.045 
Malate 
m+0 
26  0.041 30 0.028 
 
% changes are for High [Na]i group vs vehicle at 80 minutes where ‘0 %’ change 
represents zero fold-change. Only isotopologues that were significantly altered 
and/or gave similar values from both GC-MS and LC-MS/MS were included.  




Furthermore, unlabelled fumarate and malate as well as m+1 isocitrate isotopologues 
(which all underwent zero turns of the TCA cycle during the 13C labelling period 
according to Figure 6.1) were more abundant in the vehicle group than in the high [Na]i 
group. There was a high level of agreement between the two mass spectrometry 
techniques with respect to these data (Table 6.3). There were also several other 
isotopologue differences observed by GC-MS (Figure 6.6) that were suggestive of 
greater TCA cycle activity in the high [Na]i group versus vehicle including m+0 citrate, 
m+2 citrate, m+2 succinate and m+1 fumarate (all significantly lower in high [Na]i 
group versus vehicle) as well as m+5 citrate, m+4 succinate, m+4 fumarate and m+4 
malate (all significantly higher in the high [Na]i group versus vehicle). Overall, the 
mean enrichment datasets are suggestive of greater incorporation of 13C label into TCA 
cycle intermediates during [Na]i elevation. 
This finding was unanticipated. It was hypothesised that [Na]i elevation leads to 
decreased stimulation of the TCA cycle following a reduction in [Ca]m. However, 
increased TCA cycle activity may be a consequence of the ATP depletion that was 
associated with [Na]i elevation (Figures 5.8). Direct interaction between ATP synthase 
and Ca2+ has been reported (Hubbard and McHugh, 1996) as has indirect interaction via 
calcium binding ATPase inhibitor (CaBI) (Yamada and Huzel, 1989), protein kinase Cδ 
(Nguyen et al., 2010) and S100A1 (Boerries et al., 2007), which are all postulated to 
have stimulatory effects on ATP synthase. It is possible that the heart would use the 
same entity (Ca2+) to directly stimulate both the primary sites of ATP utilisation (the 
myofilament) and ATP production (ATP synthase). Furthermore, there has been no 
study thus far investigating the importance of Ca2+ in its regulation of PDH, αKDH and 




IDH relative to its regulation of ATP synthase. It is plausible that the primary metabolic 
consequence of [Na]i elevation is a reduction in stimulation of ATP synthase activity by 
Ca2+. Given the high ATP demand in the contracting heart, this would result in 
depletion of ATP and an increase in Pi and ADP. The latter molecule is a classic 
activator of the TCA cycle via allosteric binding to IDH (Vaughan and Newsholm, 
1969, Nichols et al., 1994) and αKDH (Nichols et al., 1994, Ostrovtsova and Strumilo, 
1990). Furthermore, Balaban (2009) has demonstrated that IDH, αKDH and MDH are 
stimulated by Pi. Increases in ADP and Pi would thereby lead to increased TCA cycle 
activity following a derangement in ATP supply-demand matching. This aligns with the 
work of Marin-Garcia et al (2001) and O’Brien et al (1990) which infer that TCA cycle 
activity is increased as a consequence of impairment of ATP generating enzymes 
following pacing-induced HF. Indeed, [Na]i elevation may be an important 
pathophysiological component of this HF model given that electrical pacing is 
associated with a rise in [Na]i in cardiomyocytes (Despa et al., 2008) 
According to LC-MS/MS, [Na]i elevation resulted in significantly higher 13C mean 
enrichment of isocitrate (and a trend toward increased mean enrichment of fumarate and 
malate) (Figure 6.7). However, the enrichment of the other targeted TCA cycle 
intermediates cannot be commented on from the LC-MS/MS data as several of their 
isotopomers were not detected due to instrumental factors. Nonetheless, it was possible 
to obtain the absolute LC-MS/MS counts of the unlabelled (m+0) form of all targeted 
metabolites for both perfusion groups (Figure 6.9). In agreement with the GC-MS 
measurements, [Na]i elevation did not alter the abundance of the unlabelled (m+0) 
forms of pyruvate, lactate, succinate and α-ketoglutarate although the m+0 citrate result 




differed between the methods. The presence of unlabelled forms of the targeted 
metabolites in the samples could be due to multiple factors. Firstly, residual [U]-12C6-
glucose (m+0) and/or its downstream metabolic products may have been present at the 
end of the perfusion protocol due to these reaching an equilibrium with their labelled 
counterparts. Secondly, the TCA cycle is fed not only by exogenous fuel substrates but 
also by endogenous fuel stores. Glycogen-derived glucose and triacylglycerol-derived 
fatty acids have been shown to each provide approximately 12-13% of the total ATP 
produced in the perfused rat heart (Henning et al., 1996) and the vast majority of this is 
TCA cycle-dependent. It is probable that a portion of the unlabelled m+0 isotopologues 
were derived from unenriched, endogenous fuel sources. The effect of [Na]i elevation 
on the utilisation of these fuel stores has not been studied here. Thirdly, [Na]i elevation 
may have increased TCA cycle activity leading to greater enrichment of TCA cycle 
intermediates and thus a lower concentration of m+0 isotopologues. 
The GC-MS technique also permitted the assessment of 13C incorporation into 
glycolytic and anaplerotic metabolites which are pathways known to be tightly linked to 
TCA cycle activity (see Section 1.3.2). M+3 DHAP was substantially increased in the 
high [Na]i group vs vehicle without differences in pyruvate and lactate labelling (Figure 
6.5). This suggests an elevation in the overall flux of 13C from hexokinase through to 
fructose-bisphosphate aldolase followed by a bypassing of 13C around the subsequent 
enzymes of the glycolytic pathway, for example, via glycerol-3-phosphate 
dehydrogenase. It should be noted that glycolysis occurs in the cytosol and therefore, in 
contrast to the TCA cycle, may be affected by elevated cytosolic Na+ rather than 
elevated mitochondrial Na+. It is unclear whether this would an adaptive or maladaptive 




process in the context of deranged ATP supply-demand matching. In terms of 
anaplerotic pathways, greater total incorporation of 13C label into alanine and α-
ketoglutarate occurred in the high [Na]i group versus vehicle (Figure 6.4) and the 
abundance of fully-labelled (m+5) glutamate was also greater in the former group 
(Figure 6.5F). Interestingly, all three of these molecules are involved in the alanine 
transaminase reaction (Figure 1.6) and may infer a potential role of this enzyme during 
[Na]i elevation in the isolated perfused heart. It is also plausible that an increase in TCA 
cycle activity (due to deranged ATP production) leads to an increased flux of carbon 
into glutamate from α-KG via glutamate dehydrogenase. It is currently unknown 
whether Ca2+ and/or Na+ have any direct stimulatory or inhibitory effects on enzymes 
involved in glycolysis or anaplerosis in the isolated perfused heart. 
The results provide evidence to support an increased activity of the TCA cycle during a 
steady-state of [Na]i elevation and baseline inotropy. This regulation appears to take 
place at several points of the TCA cycle as the 13C abundance of multiple metabolites 
was altered to similar degrees. Independent GC-MS and LC-MS/MS experiments 
suggest that these points of enzyme regulation involve isocitrate, fumarate and malate. 
Interestingly, the total pool sizes of fumarate and malate were found to be elevated by 
[Na]i elevation in Chapter 5. GC-MS also pointed towards an involvement of citrate, α-
ketoglutarate and succinate during [Na]i elevation thereby adding further weight to an 
increase in TCA cycling under these conditions. The GC-MS also revealed an increase 
in partial glycolytic flux from glucose to DHAP as well as possible enhancements in the 
activities of alanine transaminase and glutamate dehydrogenase. These alterations may 




reflect the tight coupling of glycolysis and anaplerosis to TCA cycle activity which 
appears to increase during [Na]i elevation. 
 
6.9 Summary 
It was hypothesised based on the malate and fumarate data in Chapter 5 that TCA cycle 
activity is decreased as a consequence of [Na]i elevation in the isolated perfused heart. 
However, TCA cycle measurements by GC-MS and LC-MS/MS of normally-
contracting hearts perfused with 13C-labelled glucose during a period of acutely elevated 
[Na]i by ouabain suggested an increased TCA cycle activity during high [Na]i. The 
underlying mechanisms remain unclear but may be a consequence of altered cardiac 
energetics and reduced ATP supply due to an acute rise in [Na]i and a compensatory 
increase in TCA cycle activity. This chapter adds weight to the overall hypothesis that 
[Na]i elevation gives rise to metabolic alterations in the isolated perfused heart and that 
the activity of the TCA cycle is implicated in this adaptation. 
 
  




7 GENERAL DISCUSSION AND CONCLUSIONS. 
7.1 Summary of conclusions. 
The studies presented in this thesis have investigated whether [Na]i elevation alters 
intermediary metabolism and cardiac energetics in the isolated perfused rat heart 
independently of elevated inotropy. As previously discussed, inhibition of NKA by 
ouabain induces a rise in [Na]i by blocking the only quantitatively important efflux 
pathway for Na+. However, this rise in [Na]i leads to an elevation in [Ca]i via altered 
sarcolemmal NCX activity and a subsequent increase in inotropy and therefore 
increased ATP demand. A major challenge has been to overcome this positive inotropy 
which confounds the interpretation of metabolic measurements. 
There is an abundance of literature reporting the use of ouabain to inhibit NKA in the 
Langendorff model, the majority of which use a single high concentration of ouabain 
(>100 µM) which leads to arrest, considerably reducing the physiological relevance of 
the model. Initial studies (Chapter 3) showed a dose-dependent increase in [Na]i 
between 0 and 100 µM ouabain without inducing arrest or notable arrhythmias. Hearts 
perfused with 50 µM ouabain and subject to end-point metabolomics following snap 
freezing revealed several metabolites that were significantly altered including increased 
fumarate (TCA cycle) and acetylcarnitine (shuttles carbon acetyl groups into the 
mitochondria). These altered metabolite levels were augmented by increased contractile 
demand at high electrical pacing rate (500 BPM) and gave rise to additional metabolite 
changes including elevated succinate (TCA cycle) and lactate (glycolysis). Inhibition of 




NKA with ouabain induced significant inotropy, confounding the interpretation of these 
results due to increased ATP demand. 
Perfusion protocols were developed (Chapters 4 and 5) combining blebbistatin (to 
uncouple contraction) and ouabain (to elevate Na+) to remove the inotropy-dependent 
metabolic consequences of ouabain and better distinguish any [Na]i-dependent changes. 
Perfusion with 5 µM blebbistatin completely eliminated contraction after 10 minutes of 
perfusion thus eliminating contractile ATP demand. Electrocardiogram measurements 
showed that 5 µM blebbistatin had no significant effects on heart rate, QRS duration or 
QT90% suggesting that blebbistatin does not profoundly affect electrophysiology. The 
dose-response to ouabain in the presence of 5 µM blebbistatin revealed an attenuation of 
the ability of ouabain to elevate [Na]i as measured by TQF 23Na NMR which has not 
been reported previously. In isolated cell experiments, blebbistatin did not alter the 
degree of NKA pump inhibition by ouabain measured by patch clamping. Increasing the 
concentration of ouabain in the presence of 5 µM blebbistatin normalised for this 
attenuation, allowing a sustained elevation of [Na]i in the absence of contraction. End-
point metabolomics performed in non-contracting hearts perfused with blebbistatin and 
ouabain revealed only minor changes in fumarate, glutamate, glutamine and acetate 
compared to vehicle treated controls. The changes in metabolite levels observed in the 
contracting hearts (Chapter 3) which were subject to both elevated [Na]i and increased 
ATP demand were largely absent in the non-contracting situation (Chapter 4). The 
relevance of the non-contracting model to the beating heart is therefore questionable due 
to the substantially reduced ATP demand. 




A contracting heart protocol was therefore developed (Chapter 5) to better elucidate 
[Na]i-dependent from inotropy-dependent effects on metabolism and energetics while 
maintaining contractility at baseline levels. The first protocol involved perfusing 
ouabain first followed by blebbistatin to titrate the elevated LVDP back down to 
baseline at the end of the protocol, thereby inducing a transient positive inotropy (TPI). 
The second protocol involved perfusing in reverse order with blebbistatin first followed 
by ouabain to titrate the depressed LVDP back up to baseline at the end of the protocol, 
thereby inducing a transient negative inotropy (TNI). TQF 23Na measurements revealed 
that [Na]i was significantly elevated to the same degree in both groups at the end of the 
protocol.  
Real-time 31P measurements of TPI and TNI groups showed a transient increase or 
decrease in both PCr and Pi that mirrored the transient increase or decrease in inotropy. 
PCr levels returned to baseline at the end of the protocol. However there was a strong 
negative correlation between [Na]i and [ATP] in both groups irrespective of inotropy 
induced. Although the reductions in ATP appear relatively modest they are indicative of 
a significant metabolic perturbation. Given the central importance of ATP to contractile 
function and cell survival, the heart is able to maintain its steady-state ATP levels 
during high levels of stress by buffering its concentration with PCr. For example, ATP 
levels do not appear to decline in patients with moderate HF but do so in end-stage HF 
(Neubauer et al., 1997). With respect to the Langendorff model, previous work showed 
that 30 minutes of regional ischaemia following ligation of the left ascending coronary 
artery reduced ATP by approximately 50% (Wilder et al., 2016). This is similar to the 
reduction in ATP by up to 41% due to [Na]i elevation in aerobically-perfused control 




hearts described in this thesis. Therefore, [Na]i elevation in the absence of elevated ATP 
demand appears to substantially alter energy balance in the perfused heart. Although 
ADP was not measured in the TPI and TNI studies, it can be inferred that the dramatic 
reduction in ATP would have been mirrored by a proportional fold increase in ADP. As 
contractile function was at baseline levels at the end of the TPI and TNI periods in the 
absence of arrhythmias, it appears that the preparation was able to sustain normal EC 
coupling despite a substantial reduction in [ATP] (and thereby a reduction in the 
ATP/ADP ratio). This was surprising as [ATP] is significantly reduced in HF (Starling 
et al., 1998, Nascimben et al., 1995, Liao et al., 1996). It is possible that the observed 
increase in TCA cycle activity with [Na]i elevation (Chapter 6) is an implication of 
reduced [ATP]. Furthermore, there may be other metabolic pathways that were also 
altered due to [ATP] depletion but were not assessed in this thesis, for example, 
substrate utilisation. Another potential consequence of [ATP] depletion is activation of 
K+(ATP) channels which efflux K+ from the cardiomyocyte in the absence of ATP (Craig 
et al., 2008). [Na]i elevation in the TPI and TNI groups may therefore have also been 
associated with decreased [K]i versus vehicle which could have led to metabolic and/or 
electrophysiological consequences. 
Given that PCr and CK are known to buffer ATP in muscle during periods of stress 
(Duffield et al., 2004), the finding that ATP was decreased but PCr was unaltered by 
elevated [Na]i in both TPI and TNI groups was unanticipated, suggesting a possible role 
of [Na]i in the regulation of CK or ATP supply. The explanation for the inability of CK 
to buffer ATP leading to metabolic compromise remains to be determined. Furthermore, 
the relative impact of perturbation in the CK reaction versus perturbation in ATP 




synthase during [Na]i elevation is also unclear. If demand is not elevated and CK 
activity and PCr are unaffected by [Na]i elevation, then a possible explanation for a drop 
in ATP levels would be a sustained inhibition (or reduced stimulation) of ATP synthase. 
Myocardial tissue metabolites were assessed at the end of the TPI and TNI protocols by 
high resolution 1H NMR and an LC-MS/MS method for the quantification of TCA cycle 
intermediates and pyruvate. A transient elevation in inotropy appeared to increase 
acetylcarnitine shuttling as well as the concentrations of alanine (potentially due to 
increased alanine transaminase activity), citrate and isocitrate (suggesting increased 
TCA cycle activity). On the other hand, a transient reduction in inotropy was associated 
with decreases in glutamate:glutamine and α-ketoglutarate (potentially due to reduced 
glutamate anaplerosis) as well as decreases in ATP+ADP and creatine (indicative of 
decreased energetic reserve). Given that these metabolite changes were not recapitulated 
in the two groups, the observations support the existence of a “metabolic memory” for 
the transient elevation or depression of contractility during the experiment. That is, the 
immediately preceding contractile history of a heart influences the prevailing metabolic 
status and this effect persists for at least 10-15 mins. Despite many metabolite changes 
not being common to the two groups, two metabolites, malate and (more tentatively) 
fumarate, were increased in both groups. This may infer a link between [Na]m and 
malate dehydrogenase activity or more generally a change in overall TCA cycle flux in 
the perfused heart subject to an acute elevation of [Na]i. Malate is a central component 
of the TCA cycle and thereby important for ATP generation but it is not clear whether a 
~50% elevation would have marked effects on the bioenergetic status of the heart. 
Doenst et al (2013) proposed that elevated anaplerosis of pyruvate into malate via 




increased malic enzyme activity is a maladaptive mechanism during HF. This is because 
pyruvate flux through PDH would decrease leading to energetic inefficiency of the TCA 
cycle. Interestingly, PDH is known to be stimulated by increases in [Ca]m in the 
physiological range (Denton et al., 1972, Siess, 1972) thus [Na]i-induced blunting of 
this effect may contribute to a diversion of pyruvate away from PDH and toward malic 
enzyme in order to divert carbon skeletons into the TCA cycle. Furthermore, increased 
malic enzyme activity is known to decrease the NADPH pool size which may increase 
oxidative stress (Pound et al., 2009).   
Elevations in malate and fumarate do not demonstrate whether activity of the TCA 
cycle was decreased or increased. To address this question, the TPI protocol was 
adapted by perfusing hearts for an additional 25 minutes at steady-state with [U]-13C-
glucose during which time LVDP was sustained at baseline levels and [Na]i remained 
significantly elevated. Assessment of 13C isotopologue patterns of the TCA cycle 
intermediates by LC-MS/MS and GC/MS was supportive of greater incorporation of 13C 
into TCA intermediates inferring increased TCA cycle activity in the high [Na]i group 
versus time-matched vehicle. This is in contrast to the thesis hypothesis that [Na]i 
elevation reduces TCA cycle activity leading to altered energetics.  
 
7.2 Critical assessment of methods and results in this thesis 
This thesis has made use of sophisticated experimental techniques in order to 
investigate an important biological question. These techniques have potential drawbacks 
which can confound the interpretation of the data that they generate. 




7.2.1 The isolated perfused heart model 
The primary limitation of the Langendorff perfused heart is that it is an ex vivo model 
that was perfused with glucose as its sole fuel supply. Indeed, it cannot be discounted 
that the apparent effect of [Na]i elevation on metabolism is specific to this particular 
model. It is a possibility that the hearts in this thesis were approaching metabolic 
“stress” at baseline (for example, due to lower oxygen delivery and/or substrate 
availability versus in vivo) and may therefore have been more sensitive to changes in 
LVDP or [Na]i compared with healthy hearts in vivo. Heineman and Balaban (1990) 
demonstrated in healthy dogs in vivo that an increase in workload does not alter the 
PCr-ATP ratio due to compensatory increases in mean arterial pressure and coronary 
flow. Although increases in coronary flow were observed during the TPI period in 
Chapter 5, this may not have been sufficient to compensate for the increased ATP 
demand thus giving rise to reduced [PCr]. The Langendorff preparation can be made 
more physiologically-relevant by the addition of insulin and reduction of glucose 
concentration (although insulin is known to adhere to perfusion glassware thereby 
increasing heart-to-heart variability). Under aerobic conditions, healthy hearts use FAs 
preferentially as a fuel source over carbohydrates (Gertz et al., 1988, Stanley et al., 
2005). However, the preparation of FA-containing perfusion buffers is laborious, 
necessitates specialised gassing procedures and increases the likelihood of 
contamination in the perfusion rig. The effect of [Na]i on substrate selection was not a 
focus of this thesis but may be an important factor. Indeed, perfusion of hearts with FAs 
or other metabolic substrates such as glutamate may alter the metabolic response to 
[Na]i overload in this preparation. 




To minimise heart-to-heart variability, male Wistar rats weighing approximately 300g 
were used for all experiments. Restricting studies to only one gender (Townsend et al., 
2015), minimises experimental variability due to hormonal differences between the 
genders. The rat is known to have a significantly higher baseline [Na]i compared with 
other species including man (Table 1.1). Species-differences (particularly when 
comparing rodent models with the human situation) are a common issue in medical 
research. The relationship between [Na]i and metabolism may differ qualitatively and/or 
quantitatively between the rat and humans or other species. Significant metabolic 
differences have been reported between rats and mice (reviewed by Radermacher et al., 
2013). The question remains whether the relationship between [Na]i and metabolism in 
the rat is similar to man and specifically whether this is important in the development of 
HF. Maack et al (2006) showed that [Na]i overload results in metabolic alterations in 
vitro in guinea pig myocytes. Recent work in our laboratory performed by Dr Dunja 
Aksentijevic has shown that [Na]i overload significantly alters metabolism in the ex vivo 
mouse heart (unpublished data) as well as in a mouse expressing a PLM mutation (PLM 
3SA) which has a chronic elevation in Na+ at baseline. In vivo models of [Na]i overload 
may provide justification to assess this in larger species (such as the dog or minipig) in 
the future. 
Animals were weight-matched as much as possible so that variability in heart size and 
structure was minimised as these can particularly alter 23Na NMR measurements due to 
the mass and geometry of the myocardium within the RF coil. However, relatively 
young rats were used (~8-10 weeks of age) and basal metabolism is known to alter with 
age (Villa et al., 2006). In addition, HF is more prominent with age (Townsend et al., 




2015) thus the age-dependence of the [Na]i-metabolism relationship should be 
investigated in the future. 
Due to a technical issue with the ventricular pressure transducer, it was not possible to 
measure LVEDP during NMR acquisition in Chapters 3 and 4. Therefore, the 
intraventricular balloon was inflated to a fixed volume of 150 µL for all hearts before 
the start of each perfusion experiment. Although hearts were approximately the same 
size, this may have induced an over-inflation for some hearts with a smaller left 
ventricular lumen thereby leading to regional ischemia and potentially compromised 
[Na]i handling. Notwithstanding this, 31P NMR of Langendorff hearts from rats 
weighing ~300 g (the same weight as that used in this thesis) by Abe et al (1988) 
showed that intraventicular balloon inflation from 50 µL to 150 µL leads to a small 
increase in the inorganic phosphate signal although there was no observable change in 
either the PCr or ATP signals. On the other hand, 150 µL may have been an under-
inflation and hence reduced LVDP due to less myofilament stretch (Frank-Starling 
effect) which may explain why the inotropic responses to 50-100 μM ouabain were 
lower than anticipated. Importantly, this technical issue was solved for later experiments 
in Chapters 5 and 6. 
 
7.2.2 The use of ouabain and blebbistatin 
The most effective way to induce [Na]i elevation in the Langendorff preparation is to 
inhibit NKA as it is the most quantitatively important efflux pathway of [Na]i. It was 
not investigated whether stimulating one or more of the influx pathways is a viable 




alternative. It is known that the heart is able to ramp up NKA activity to counteract any 
increases in influx (Bers and Despa, 2009) and has a large capacity for Na+ efflux 
(~32µM [Na]i is extruded by NKA during the action potential (Bers and Despa, 2009)). 
Ouabain was chosen as there is a wealth of literature reporting its use in the 
Langendorff preparation including 23Na NMR measurements in the rat (for example, 
Schepkin et al., 1998). However, as ouabain was the only agent used to elevate [Na]i in 
this thesis it should be considered that ouabain may have exerted off-target effects that 
may have altered the metabolic profile irrespective of [Na]i. There is evidence to 
suggest that ouabain activates signalling cascades via interaction with NKA. For 
example, Mohammadi et al. (2003) showed that perfusion of rat and guinea pig hearts 
with 50 µM and 1 µM respectively for 10 minutes increased the expression of Src 
kinase and extracellular signal-regulated kinases (ERK) 1 and 2. The authors did not 
perform any metabolic measurements. Longer term elevations in ERK have been shown 
to increase flux through PDH in proliferating cancer cells (Huddleston, 2011) and in 
addition ouabain alters cell cycle S-phase progression in cancer cells (Xu et al., 2015). 
However, it is ambiguous whether this bears any relevance to the ouabain-perfused 
Langendorff preparation. Indeed, it was shown in Chapter 4 that ouabain appeared to 
have minimal effects on the metabolic profile of non-contracting hearts perfused with 
blebbistatin in which [Na]i was elevated by only a small extent. Nonetheless, future 
work employing other agents to elevate [Na]i may help to distinguish any signalling 
effects of ouabain from its effect on [Na]i. It should also be taken into account that 
inhibition of NKA may decrease intracellular K+ (Browning et al., 1981) which might 
have metabolic consequences in addition to those of [Na]i. However, there are no data 
on this at present and the decrease in K+ is likely to be relatively small compared to 




basal levels. Avoiding NKA-targeted agents altogether and stimulating Na+ influx 
(reviewed by Endoh, 2004), for example, using veratridine, may be a better alternative 
to the induction of [Na]i overload in the isolated perfused heart. Given that an elevation 
in the late Na+ current is a key pathophysiological feature of HF (Gremmler and Kisters, 
2013, Noble and Noble, 2006, Sossalla et al., 2008), it is also important to assess 
whether this can lead to alterations in ATP supply-demand matching in the intact heart. 
Indeed, this also applies to other mechanisms of Na+ influx that are known to be 
elevated in HF, such as NCX (Reinecke et al., 1996) and NHE (Baartscheer et al., 
2003b, Baartscheer et al., 2008). 
The possibility of off-target effects also applies to blebbistatin although there is less 
data available on this compared with ouabain. Helfman et al (2005) demonstrated that 
blebbistatin reduces ERK activation in a dose-dependent manner and also alters cell 
morphology (Wilkinson et al., 2005) although high blebbistatin concentrations were 
used (50-200µM) in non-cardiac cells. The current consensus appears to be that its 
apparent signalling effects are due to its inhibition of contractile activity via myosin II 
ATPase rather than via other proteins. Therefore, it is unclear whether the blebbistatin-
ouabain titration protocols used in this thesis (in which contraction was the same in both 
vehicle and high [Na]i at the end of perfusion) elicited significant signalling effects in 
the high [Na]i group that may have confounded metabolic measurements. 
DMSO was used as a vehicle for blebbistatin in this thesis. In Chapter 4 (Section 4.4.3), 
TQF 23Na NMR measurements in perfused hearts suggested that DMSO does not affect 
baseline [Na]i or the ability of ouabain to elevate [Na]i. However, this experiment did 
not negate the possibility that DMSO may synergise or activate the inhibitory effect of 




blebbistatin on ouabain-induced [Na]i elevation. Future experiments involving perfusion 
with blebbistatin dissolved in a different vehicle (such as dimethyl formamide) are 
necessary to elucidate this further. 
The small inotropic responses of 75µM and 100µM ouabain, following the cessation of 
contraction in blebbistatin-perfused hearts demonstrates that sarcolemmal NCX is still 
active in these preparations. This was demonstrated further by the larger positive 
inotropy induced by 155µM ouabain in these hearts. For this response to be avoided in 
future experiments, concentrations of (±)-blebbistatin higher than 5µM should be used. 
However, caution should be taken as this would increase the probability of off-target 
effects including, for example, altered Ca2+ handling (Dou et al., 2007, Farman et al., 
2008, Brack et al., 2013). 
Despite attempts to elucidate the mechanism underlying BDM and blebbistatins’ 
attenuation of ouabain action in Chapter 4, this was unsuccessful and thus further 
studies are needed. 
 
7.2.3 NMR 
A Triple Quantum Filtered 23Na NMR method was adapted for use in the rat heart that 
allowed measurements of fold-changes in [Na]i as well as to ascertain estimates of 
absolute [Na]i. This method removes the need to use toxic shift reagents to distinguish 
intra and extra cellular Na+ in the isolated rat heart, allowing all measurements to be 
performed under more physiological conditions. A key limitation of the 23Na NMR 
measurements performed is that the reliability of the derived [Na]i values rely on the 




accuracy of the measurements performed in Schepkin et al (1997) in which the reported 
baseline [Na]i was 17.5 mM. Furthermore, the reported slope on the TQF vs [Na]i curve 
(0.35) and normalisation factor for 50% extracellular Na+ contribution to the TQF signal 
were assumed to be correct. However, fold differences in [Na]i between treatment 
groups are not affected by these assumptions and are thus more reliable. 
The reported ‘end-point’ values of [Na]i and 31P energetics measurements were 
performed ~2-3 minutes prior to snap-freezing. This is because the heart had to be 
removed from the NMR apparatus to permit snap-freezing. However, the heart 
continued to be perfused with the end-point perfusion buffer throughout the entirety of 
this process and thus error was kept to a minimum. 
In order to permit fair comparisons between cardiac energetics and [Na]i measurements 
as well as peak integration of the Pi signal by 31P NMR, all KH used was phosphate-




The LC-MS/MS method adapted in this thesis gave an insight into the relationship 
between [Na]i and the TCA cycle. An internal standard was not included in this method 
and thus the recovery of analytes was not assessed. Loss of analyte is inevitable for any 
extraction procedure due to, for example, incomplete homogenisation, sample 
concentration steps and degradation. Analyte concentrations were therefore likely 




underestimated, although fold differences can be trusted given that the samples were 
prepared in an identical fashion and all analyses were blinded and randomised. 
Other than the addition of chelex and universal indicator, the dual phase metabolite 
extraction procedure was identical for both NMR and LC-MS/MS. This increased 
throughput but an additional solid-phase extraction step (for instance, using an ion-
exchange column) preceding LC-MS/MS analysis would have removed extraneous 
matter that may have blunted detectability of the TCA cycle intermediates and pyruvate. 
A good example of extraneous matter is the high concentration of salt that may have 
been responsible for the ion suppression associated with α-ketoglutarate. 
 
7.2.5 Whole-cell voltage clamp 
In Chapter 4, it was shown that blebbistatin appears to attenuate the ability of ouabain to 
elevate [Na]i. To assess whether NKA was directly involved in this phenomenon, 
voltage clamp experiments using cardiomyocytes were kindly performed by Dr Sergiy 
Tokar. However, work by Zak (1974) and Nag (1980) that was subsequently verified by 
Banerjee et al. (2007) revealed that cardiomyocytes form only ~30% of the total cell 
count in the adult rat heart with fibroblasts accounting for 64% and the remainder 
consisting of other cells including smooth muscle cells (although more recently Pinto et 
al. (2016) showed that endothelial cells constitute >60 % of the total cell number in the 
mouse heart). Therefore, the observed attenuation of ouabain by blebbistatin in the 
isolated perfused rat heart may reflect a phenomenon that is specific to the non-myocyte 
compartments in the heart although cardiomyocytes were used in the patch clamp 




experiments. It is also important to consider that cells will behave differently in several 
ways when in isolation compared with the more physiological context of the intact 
heart, for example, the absence of paracrine signalling in the former as well as 
differences in metabolism. Nonetheless, cardiomyocytes constitute ~70-85 % of the 
total cell volume in the heart (Anversa et al., 1980, Dammrich and Pfeifer, 1983, 
Mattfeldt et al., 1986, Tang et al., 2009) so it seems likely that it is the response of these 
cells that are the main driving force for the blebbistatin attenuation of ouabain in the 
whole heart. With the data currently available, it appears that the mechanism underlying 
this attenuation does not involve NKA.  
 
7.2.6 Statistics and interpetation 
There is no gold-standard approach for statistical assessment of metabolomics datasets 
and is dependent upon the question and type of metabolomics being performed. The 
Bonferonni multiplicity correction is too conservative for targeted metabolomics and is 
susceptible to false negatives (Perneger, 1998, Rothman, 1990). In order for a 
metabolite to be deemed statistically significant following multiplicity correction, that 
metabolite would have to be profoundly different between the treatment groups with 
low biological and instrumental error as well as powered with large n numbers. 
Fulfilling these criteria is often very difficult to achieve due to the experimental 
challenges associated with Langendorff perfusions, metabolite extractions, NMR and 
LC-MS/MS. Therefore, raw p-values from unpaired t-tests for each metabolite were 
used as a guide as to whether that metabolite may be affected by [Na]i elevation. The 
likelihood of false positives was minimised by the experimental design of the TPI/TNI 




metabolomics studies (Chapters 6 and 7). That is, the probability of a metabolite 
reaching statistical significance (P<0.05 versus vehicle counterpart) in both the TPI and 
TNI groups is very low as these groups were perfused in separate studies and compared 
with their own vehicle counterpart group. The likelihood of that metabolite reaching 
statistical significance and exhibiting the same fold-change across both studies (as was 
the case for malate; Table 5.2) is smaller still. Thus, the finding that malate is elevated 
in both TPI and TNI by 50%, gives confidence that this was not a false positive. 
However, it is more difficult to discount false negatives in the metabolomics datasets. 
For metabolites that, for example, reside at high concentration but change by only a 
small extent or where changes occur within the error of the technique false negatives 
may occur. This may have been the case for oxaloacetate which gave rise to small peaks 
by LC-MS/MS and did not appear to be altered by [Na]i elevation despite increased 
incorporation of 13C into the TCA cycle under these conditions. Furthermore, there were 
metabolites that were not measured due to technical challenges such as NAD and 
NAD(H) as separate entities (the NAD(H) pool was measured by 1H NMR). 
 
7.2.7 13C enrichment experiments 
The 13C enrichment data acquired by mass spectrometry in Chapter 6 do not permit the 
elucidation of real-time enzyme kinetics of the TCA cycle during [Na]i. Although the 
methodology does not exist at present, this would be best achieved in the future by 
quantifying all TCA cycle intermediates in the Langendorff preparation in real-time. 
Future measurements using real-time hyperpolarised 13C NMR in conjunction with this 
preparation may give a time-course of changes in TCA cycle activity during [Na]i 




elevation. However, this technique involves perfusion with a supra-physiological 
concentration of pyruvate which has been shown to affect the NAD+:NADH ratio 
(Mariotti et al., 2016) and may therefore confound interpretation of the metabolic data 
generated. Alternatively, TCA cycle kinetics during [Na]i elevation could be 
investigated in vitro using the spectrophotometric method of  Goncalves et al (2010) in 
which the activities of all TCA cycle enzymes can be rapidly determined for multiple 
samples of heart homogenate. 
 
7.2.8 Discussion 
The experiments reported here suggest deranged ATP supply and increased TCA cycle 
activity in ouabain/blebbistatin treated hearts with elevated [Na]i in the absence of 
elevated inotropy. The specific mechanisms and chronology of these metabolic 
alterations is unclear. It is postulated that energetics are altered initially and TCA cycle 
activity increases as a compensatory mechanism for the reduced ATP supply. Direct 
interaction between ATP synthase and Ca2+ has been reported (Hubbard and McHugh, 
1996) as has indirect interaction via calcium binding ATPase inhibitor (CaBI) (Yamada 
and Huzel, 1989), protein kinase Cδ (Nguyen et al., 2010) and S100A1 (Boerries et al., 
2007) which are all postulated to have stimulatory effects on ATP synthase. It is 
possible that the heart uses the same entity (Ca2+) to directly stimulate both the primary 
sites of ATP utilisation (the myofilament) and ATP production (ATP synthase). This 
hypothesis is supported by Harris et al (1991). [Na]i elevation may reduce Ca2+ 
stimulation of ATP synthase leading to reduced ATP and increased ADP and Pi. 
Interestingly, there was a trend towards increased Pi with [Na]i elevation in both TPI 




and TNI groups. ADP was not measured but is a classic activator of the TCA cycle via 
allosteric binding to IDH (Vaughan and Newsholm, 1969, Nichols et al., 1994) and 
αKDH (Nichols et al., 1994, Ostrovtsova and Strumilo, 1990) and would thereby 
increase TCA cycle activity to compensate for decreased ATP supply. This aligns with 
the work of Marin-Garcia et al (2001) and O’Brien et al (1990) which showed increased 
TCA cycle activity as a consequence of impairment of ATP generating enzymes 
following pacing-induced HF.  
The apparent discrepancy between previous work suggesting decreased TCA cycle in 
HF and the findings reported in this thesis is likely due to the different models used. 
Most of the previous HF studies involved pressure-overload giving rise to a plethora of 
pathophysiological events including [Na]i elevation. Whereas, the ouabain-perfused 
heart used in this thesis is clearly not a model of HF but of [Na]i elevation (only one 
aspect of HF). Other pathophysiological events during HF may outweigh the increase in 
TCA cycle activity due to elevated [Na]i. It is also important to consider the timescale 
of these pathophysiological events. The duration of [Na]i overload in this thesis was 
approximately 30 minutes thus representing an acute situation whereas those in models 
of HF are likely to be chronic and therefore notably longer. Shorter periods of [Na]i 
elevation may lead to a transient increase of TCA cycle activity (as a compensatory 
mechanism for reduced ATP) but this activity may gradually wane with HF progression 
and lead to metabolic remodelling as a result of the more chronic [Na]i overload 
associated with heart failure. The TCA cycle is important for the catabolism of 
precursors used to generate proteins and lipids (Owen et al., 2002) and is speculated to 
be a causal factor of cardiac hypertrophy and HF (Doenst et al., 2013). Although 




chronic alterations to metabolism as a result of [Na]i elevation were not investigated in 
this thesis, the data may give an insight into the early events that may be reversed 
therapeutically and precede irreversible longer term consequences such as 
transcriptional, post-translational and structural remodelling. Pharmacological reduction 
of myocardial [Na]i may be a novel therapeutic approach for heart failure and hence the 
development of novel activators of NKA is a promising avenue currently under 
investigation. From a diagnostic standpoint, there is currently no “gold standard” for the 
clinical diagnosis of HF. Plasma BNP concentration, ultrasound imaging and 
assessment of symptoms are the main ways in which the presence of the condition is 
currently confirmed in patients (Authors/Task Force et al., 2012). These alterations are 
observed relatively late in the aetiology of HF once irreversible structural remodelling 
has occurred. [Na]i might be an earlier biomarker of HF that could potentially allow 
therapies to be assessed earlier to mitigate the severity or progression of the disease.  
The 23Na NMR methods presented have the potential to be translated clinically. A 
recent study by Qian et al. (2015) measured total and bound Na+ in patients with brain 
tumours using a 3T MRI scanner. The development of cardiac 23Na MRI is an area of 
active research. It would be challenging to implement 23Na MR routinely as a predictor 
of HF in a clinical setting and it is unclear whether [Na]i elevation is a cause or 
consequence (or both) of HF. However this could be a potential way to screen patients 
deemed to have increased risk of developing HF, for example, individuals with diabetes 
(Lambert et al., 2015) or indeed as part of clinical trials for novel therapeutics. 
The relationship between [Na]i and metabolism may also be relevant in other tissues. 
Using TQF 23Na NMR Hansen et al. (1993) showed that [Na]i is higher in cancer cells 




compared with wildtype counterparts. The role of Na+ in cancer is not well understood, 
however rewiring of metabolism is a classic hallmark in cancer progression (reviewed 
in Kee et al., 2014). Furthermore, diabetes is also associated with [Na]i elevation 
(Lambert et al., 2015, Scheuermann-Freestone et al., 2003). [Na]i has been found to be 
elevated in brain cortex biopsies from Alzheimer’s Disease (AD) patients due to 
depressed NKA activity compared with normal individuals (Vitvitsky et al., 2012), as 
well as other neurodegenerative disorders, which are highly correlated with metabolic 
dysfunction (reviewed in Cai et al., 2012). 
 
7.3 Final conclusion 
This thesis has investigated the metabolic consequences of acute [Na]i elevation in the 
isolated perfused rat heart. Ouabain was used to inhibit NKA in this model in order to 
induce [Na]i overload and measurements of lactate efflux and myocardial metabolomics 
using 1H NMR inferred several metabolic alterations with ouabain. These changes were 
potentiated by increased contractile demand (using high-rate electrical pacing), 
including altered TCA cycle intermediates. Cessation of contraction using the 
electromechanical uncoupler, blebbistatin (5 µM), negated these metabolite changes due 
to ouabain (50 µM). The dose-response relationship between ouabain and [Na]i was 
found to be sigmoidal between 0 and 100 µM using TQF 23Na NMR. This relationship 
was found to be blunted by 5 µM blebbistatin which appeared to attenuate the ability of 
ouabain to elevate [Na]i by approximately 50%. In vitro and ex vivo investigations were 
carried out in order to elucidate the mechanism underlying this phenomenon. 
Blebbistatin did not alter NKA activity nor sequester Na+ or alter the detectability of 




Na+ by NMR. The mechanism did not appear to be blebbistatin-specific as another 
electromechanical uncoupler, BDM, attenuated ouabain to the same extent. 
Titrating hearts with a combination of ouabain and blebbistatin during perfusion 
induced a significant and sustained [Na]i elevation (~2-fold baseline) with either a 
transient positive inotropy or a transient negative inotropy in contracting hearts that had 
identical end-point contractile demand. Transient changes in contraction resulted in 
several metabolic alterations including acetylcarnitine shuttling, anaplerosis and the 
TCA cycle. In both protocols, ATP levels (measured in real-time by 31P NMR) were 
reduced in the absence of a change in PCr and showed a strong inverse correlation with 
[Na]i. Malate (and more tentatively fumarate) were both elevated in both protocols 
suggesting an inotropy independent contribution of elevated [Na]i. This supports the 
hypothesis that [Na]i elevation alters cardiac energetics and intermediary metabolism in 
the isolated perfused heart. 13C isotopomer analysis demonstrated that TCA cycle 
activity was increased by acute [Na]i elevation and may reflect ATP supply-demand 
mismatch following a derangement of ATP synthesis in the absence of elevated 
demand. 
These findings add weight to the hypothesis that [Na]i elevation alters energetics and 
intermediary metabolism in the heart. However, this does not appear to be caused by 
reduced-Ca2+ stimulation of the TCA cycle. Therefore, more comprehensive 
mechanistic investigations are required to elucidate the events that occur due to [Na]i 
elevation leading to loss of ATP in this model. It is also important to assess this using 
agents that elevate [Na]i other than ouabain to strengthen the claim that these metabolic 
effects are truly a result of [Na]i derangement. 




7.4 Future work 
Taken together with the conclusions and drawbacks discussed in Sections 7.1 and 7.2, 
this thesis work provides a platform for a number of potential future studies related to 
the thesis hypothesis. In particular the following questions should be answered in future 
work: 
Given the relationship between elevated [Na]i and decreased ATP in the absence of a 
change in PCr or altered contractility: 
• Does high [Na]i (or high [Na]m) directly inhibit ATP synthase or CK activity in 
the perfused heart? 
• Does high [Na]i indirectly inhibit ATP synthase or CK activity via reduced 
stimulation by Cam?  
• Is the [Na]i induced reduction in ATP exacerbated by increased ATP demand?  
• Can the [Na]i induced reduction in ATP be reversed by inhibiting NCLX and 
normalise ATP levels during Na+ overload? 
• Is the metabolic phenotype of reduced ATP and elevated TCA cycle activity 








8.1 Unpaced metabolomics (Chapter 3) 
 
  
Unpaced Control Unpaced Ouabain Unpaced Control Unpaced Ouabain
Acetate 67.299 71.818 3.715 5.321 1.067 0.099 0.502
Acetylcarnitine 27.972 48.699 2.713 3.552 1.741 0.211 0.001
Acetylcarnitine:Carnitine 0.053 0.100 0.005 0.006 1.888 0.205 0.000
Alanine 156.147 236.322 14.028 35.486 1.513 0.265 0.084
Aspartate 1055.974 1178.542 114.339 46.597 1.116 0.129 0.350
ATP+ADP 957.359 1078.232 34.481 48.328 1.126 0.065 0.076
Carnitine 488.063 461.165 21.933 23.021 0.945 0.063 0.422
Choline 68.261 73.100 7.422 1.448 1.071 0.118 0.619
Cr 3211.962 3129.229 139.379 166.491 0.974 0.067 0.719
Formate 43.576 41.067 4.088 2.110 0.942 0.101 0.597
Fumarate 7.423 12.190 0.421 1.472 1.642 0.219 0.034
Glutamate 1040.453 1066.148 136.246 57.275 1.025 0.145 0.875
Glutamate:Glutamine 1.504 1.343 0.091 0.086 0.893 0.079 0.234
Glutamine 690.105 762.984 113.740 35.565 1.106 0.189 0.554
Glycine 178.940 183.541 13.681 8.345 1.026 0.091 0.780
Isoleucine 24.087 22.640 1.653 1.083 0.940 0.079 0.503
Lactate 324.435 304.381 37.486 29.541 0.938 0.142 0.694
NAD(H) 195.715 197.804 23.624 12.623 1.011 0.138 0.939
PCr 1420.445 1442.956 224.808 107.293 1.016 0.178 0.930
PCR:Cr 0.518 0.464 0.068 0.034 0.896 0.134 0.471
PCr+Cr 4322.756 4131.137 266.160 113.806 0.956 0.064 0.554
Phosphocholine 173.904 179.613 10.214 7.887 1.033 0.076 0.668
Succinate 17.121 15.239 2.333 0.596 0.890 0.126 0.542
Taurine 9544.995 10102.658 584.725 211.551 1.058 0.069 0.391
Valine 9.473 10.085 1.303 0.665 1.065 0.162 0.704
P-valueMetabolite
Mean (nmol/g wet wt) SEM





8.2 Paced metabolomics (Chapter 3) 
 
  
Paced Control Paced Ouabain Paced Control Paced Ouabain
Acetate 72.727 84.763 6.552 6.277 1.165 0.136 0.214
Acetylcarnitine 40.265 93.377 4.170 7.222 2.319 0.300 0.000
Acetylcarnitine:Carnitine 0.079 0.174 0.008 0.017 2.188 0.313 0.001
Alanine 317.187 340.672 59.248 18.764 1.074 0.209 0.764
Aspartate 1197.381 1170.776 50.334 77.025 0.978 0.076 0.805
ATP+ADP 1427.854 1415.684 160.420 65.196 0.991 0.120 0.949
Carnitine 469.622 493.543 64.494 34.062 1.051 0.162 0.750
Choline 93.903 138.987 10.847 10.399 1.480 0.204 0.013
Cr 2829.814 4246.493 335.490 136.499 1.501 0.184 0.003
Formate 44.066 32.443 7.934 1.014 0.736 0.135 0.177
Fumarate 3.206 9.974 1.268 1.749 3.111 1.346 0.015
Glutamate 1159.809 1277.681 118.576 76.838 1.102 0.131 0.428
Glutamate:Glutamine 2.140 2.921 0.157 0.460 1.365 0.237 0.147
Glutamine 547.577 398.057 88.085 50.369 0.727 0.149 0.198
Glycine 532.830 570.508 14.221 12.982 1.071 0.038 0.092
Isoleucine 28.804 29.889 3.062 2.367 1.038 0.138 0.785
Lactate 384.346 772.706 50.725 132.602 2.010 0.435 0.032
NAD(H) 364.445 362.017 12.538 3.780 0.993 0.036 0.873
PCr 1569.945 1679.209 269.966 120.537 1.070 0.199 0.703
PCR:Cr 0.660 0.399 0.102 0.036 0.605 0.108 0.036
PCr+Cr 4713.178 5993.180 536.436 83.835 1.272 0.146 0.061
Phosphocholine 222.208 238.752 8.342 4.240 1.074 0.045 0.095
Succinate 45.899 87.079 4.440 8.170 1.897 0.256 0.002
Taurine 10567.147 12243.694 1283.131 353.079 1.159 0.145 0.236
Valine 8.627 10.538 1.160 2.139 1.221 0.297 0.479
Metabolite
Mean (nmol/g wet wt) SEM





8.3 A ‘positive inotropy’ method using the Frank-Starling mechanism (Chapter 
4) 
This study was performed in order to assess the feasibility of inducing a positive 
inotropy in a control group of Langendorff rat hearts. This control group would have 
lower [Na]i but identical inotropy to its ouabain counterpart group thus permitting 
metabolomic comparison.  
Positive inotropy can be induced mechanically via an increase in the Frank-Starling 
(FS) stretch mechanism (Saks et al., 2006) using intraventricular balloon inflation. This 
mechanism is underpinned not by calcium (Rhodes et al., 2015) but by titin (connectin) 
geometry and thin filament “on-off” regulation (Kobirumaki-Shimozawa et al., 2014). 
Experiments were performed to investigate whether the elevated inotropy in response to 
ouabain can be mimicked in the control group by over inflation of the intraventricular 
balloon.  
 
8.3.1 Experimental methods 
Rat hearts (n=6/group for all studies) were perfused in the Langendorff mode as 
described in Sections 2.1 and 2.2.2. Ouabain octahydrate was obtained from Sigma 
(UK).  
Hearts were stabilised for 30 minutes with standard KH (Section 2.1.3) and then for a 
further 20 minutes with either ouabain or balloon over-inflation. In the FS group, 
increased inotropy was achieved by gradually increasing the volume of the 





exceeding 150 µL intraventricular balloon volume, to avoid the risk of inducing 
ischaemia due to balloon over-inflation (Abe et al., 1988). Hearts were perfused with 20 
µM ouabain between 30 and 50 minutes to achieve the same LVDP profiles for the 
ouabain group as the FS group. 23Na NMR measurements were performed with 
interleaved TQF and DQF measurements to elucidate the [Na]i profile associated with 
20µM ouabain treatment. However it became apparent that it was not feasible to 
increase intraventricular balloon volume during 23Na NMR data acquisition using the 
current NMR perfusion setup.  
 
8.3.2 Results 
LVDP, heart rate and coronary flow were constant, within predefined acceptance 
criteria (detailed in Section 2.1.6) and were not different between the control and 20 µM 
ouabain group during the stabilisation period. Baseline LVDP (Figure 8.1A) was 114±6 
mmHg (average) in the control group. The maximum increase in LVDP that could be 
achieved using intraventricular balloon inflation in the FS group during the treatment 
period was 139±5 mmHg (at 40 minutes). This increase in LVDP was matched by using 
20 µM ouabain in the ouabain group (144±8 mmHg at 40 minutes). Deflating the 
balloon slightly in the FS group after 40 minutes led to these two groups exhibiting 
almost identical inotropic profiles during the treatment period. FS and ouabain LVDP 
values were 131±3 mmHg and 137±11 mmHg at the end of perfusion respectively. 
Mean values of heart rate (Figure 8.1B) and coronary flow (Figure 8.1C) of the control 












Figure 8.1  Perfusion measurements (‘increased inotropy’ study). 
Symbols and error bars represent mean±SEM of five minute time windows (n=6/group). 
IVB (intraventricular balloon) inflation = Frank-Starling (FS) group. 
 
no significant deviations from these values in either perfusion group at any point during 




























































































LVEDP (Figure 8.1D) was constant in both groups during the stabilisation period and 
was set to an average of 7.8±1.1 mmHg in the ouabain group but 5.1±0.6 mmHg in the 
FS group. These values were significantly different (P<0.05). This was necessary in 
order to prevent LVEDP from markedly exceeding 10 mmHg (used as stabilisation 
exclusion criteria; Section 2.1.6) following balloon inflation in the FS group. There 
were no significant differences (P>0.05) in LVEDP between the two groups at any point 
during the treatment period and were highly similar at the end of perfusion (FS = 
8.5±1.0 mmHg and ouabain = 7.0±1.2 mmHg). 
TQF 23Na NMR was used to assess whether 20 µM ouabain induces a significant and 
sustained [Na]i elevation. Due to technical issues, it was not possible to include an FS 
group in the NMR study. Figure 8.2A shows that derived [Na]i was stable throughout 
the stabilisation period and averaged 17.6±0.5 mM. There was a small, significant 
elevation in derived [Na]i at 35 min (following 5 minutes of perfusion with 20 µM 
ouabain) to 20.4±0.9 mM (P<0.05 vs baseline) but this elevation gradually decreased 
and was not significant at the end of perfusion (18.2±0.9 mM, P>0.05 vs baseline). 
Mean DQF (Figure 8.2B) was 1.0±0.2 during stabilisation and did not change upon 
perfusion with 20 µM ouabain although was associated with a higher level of noise than 
the TQF measurements. Since the [Na]i elevation arising from 20 µM ouabain was very 
modest and not sustained at the end of the experiment, metabolomic analysis was not 






8.3.3 Discussion - Is it practical to use an ‘increased inotropy’ approach to 
eliminate inotropic differences between control and ouabain hearts? 
 
This study explored the potential of using the Frank-Starling (FS) mechanism using 
intraventricular balloon inflation to mimic the inotropic profile of isolated rat hearts 




Figure 8.2  23Na NMR during 20 µM ouabain perfusion. 
(A) Normalised triple quantum filtered (TQF) 23Na NMR intensity (left axis) with derived 
intracellular [Na]i (right axis). (B) Normalised double quantum filtered (DQF) 23Na NMR 
intensity. Symbols and error bars represent mean±SEM of five minute time windows 
(n=6/group). 
 
intraventricular balloon inflation was a highly effective way to increase or decrease 
LVDP so that the LVDP profile was nearly identical to the ouabain group. However, the 
maximal LVDP that could be achieved via mechanical stretching was relatively low    
(~140 mmHg). This protocol was carried out without exceeding 150 µL intraventricular 
balloon volume (≤10 mmHg LVEDP) that has been reported to cause ischaemia in the 
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isolated rat heart (Abe et al., 1988). The low LVDP achieved in the FS group meant that 
the concentration of ouabain required to induce an equivalent positive inotropic effect 
was relatively low (20 µM). The TQF 23Na NMR of hearts perfused with 20 µM 
ouabain showed a fairly modest elevation in derived [Na]i compared to the results in 
Chapter 3. Furthermore, it became apparent during the NMR study that it was not 
practically possible to modulate intraventricular balloon volume during NMR data 
acquisition. This is because the NMR perfusion rig is setup with the ventricular pressure 
transducer housed within the NMR probe close to the centre of the spectrometer during 
acquisition (Figure 2.2). Given that normalised TQF and DQF values are sensitive to the 
positioning of the heart within the RF coil, removal of the NMR probe to gain access to 
the pressure transducer during data acquisition introduces systematic error to the NMR 
measurements. Thus, 23Na NMR measurements could not be carried out for the FS 
group and it remains unclear whether [Na]i was altered by increased mechanical stretch. 
In conclusion, practical considerations precluded the use of the ‘increased inotropy’ 
approach using enhanced FS mechanism to overcome the issue of inotropy interference 
by ouabain during metabolic studies. An alternative approach to induce positive 
inotropy is the use of a myofilament sensitizer such as levosimendan. However, it is 
unknown whether this drug alters [Ca]i (Todaka et al., 1996, du Toit et al., 2001, Wilson 
et al., 2014, Yang et al., 2016) which may give rise to metabolic alterations that would 
exacerbate the issue of identifying [Na]i-dependent metabolic pathways in the heart. 
This is also the case for better understood positive inotropes such as isoprenaline, 
adrenaline and noradrenaline. Another alternative to increasing intraventricular balloon 
inflation is increasing coronary perfusion pressure (Vassallo et al., 1998). However, the 





those used at baseline (~10 mL/min) which may give rise to differences in perfusate 







8.4 Non-contracting (blebbistatin) metabolomics (Chapter 4) 
 
  
Bleb Bleb+Oua Bleb Bleb+Oua
Acetate 64.097 67.621 0.647 0.158 1.055 0.011 0.002
Acetylcarnitine 17.417 18.237 0.840 1.083 1.047 0.080 0.577
Acetylcarnitine:Carnitine 0.042 0.044 0.001 0.003 1.056 0.072 0.447
Alanine 255.972 236.152 7.948 24.772 0.923 0.101 0.502
Aspartate 799.704 875.715 59.147 41.418 1.095 0.096 0.317
ATP+ADP 1114.434 1095.347 30.736 30.585 0.983 0.039 0.673
Carnitine 445.759 412.370 29.609 18.997 0.925 0.075 0.365
Choline 50.183 56.026 1.775 5.586 1.116 0.118 0.384
Cr 2313.489 2124.984 138.548 69.291 0.919 0.063 0.252
Formate 47.882 44.792 1.170 2.309 0.935 0.053 0.260
Fumarate 5.404 3.482 0.334 0.465 0.644 0.095 0.010
Glutamate 1935.690 1515.014 83.663 74.690 0.783 0.051 0.004
Glutamate:Glutamine 2.051 2.045 0.103 0.126 0.997 0.079 0.973
Glutamine 948.464 819.354 33.579 47.149 0.864 0.058 0.048
Glycine 196.843 184.163 5.682 4.168 0.936 0.034 0.117
Isoleucine 28.973 24.967 1.720 0.912 0.862 0.060 0.067
Lactate 307.891 250.192 10.306 22.873 0.813 0.079 0.061
NAD(H) 190.106 169.848 25.103 9.602 0.893 0.128 0.468
PCr 2008.781 1994.623 130.965 45.994 0.993 0.069 0.927
PCR+Cr 4164.256 3845.399 147.892 109.444 0.923 0.042 0.114
PCr:Cr 0.812 0.956 0.066 0.041 1.177 0.108 0.103
Phosphocholine 166.932 153.116 6.880 5.462 0.917 0.050 0.147
Succinate 12.346 11.235 0.626 1.214 0.910 0.109 0.465
Taurine 9812.690 9711.723 515.550 325.285 0.990 0.062 0.878
Valine 13.023 11.777 0.693 0.459 0.904 0.060 0.165
Metabolite
Mean (nmol/g wet wt) SEM





8.5 Mass Spectra of blebbistatin and ouabain solutions (Chapter 4). 
 
 
 Figure 8.4  Mass spectra of blebbistatin (DMSO) and ouabain solutions. 
 (A) 5 µM blebbistatin (0.029 % v/v dimethylsulfoxide, DMSO) in water. (B) 50 µM 
 ouabain in water. (C) 5µM blebbistatin (0.029 % v/v DMSO) + 50µM ouabain in 
 water. The molecular ion signals for blebbistatin (293 m/z), dimethylsulphoxide (79 
 m/z) and ouabain (585 m/z) are indicated. Many of the low-level unlabelled peaks 
 were probably due to a small extent of carryover from previous analyses or trace 
 impurities in the solutions. Data  acquisition was kindly performed by Cinzia Imberti 
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8.6 Transient Negative Inotropy (TNI) method development (Chapter 4) 
 
 
Figure 8.5  LVDP and [Na]i (preliminary TNI protocol development). 
Left ventricular developed pressure (LVDP) (left axis). [Na]i derived from TQF signal 



































Vehicle TPI Vehicle TPI
Acetate 187.692 173.074 4.173 14.138 0.922 0.078 0.387
Acetylcarni tine 57.330 93.115 5.742 11.423 1.624 0.257 0.019
Acetylcarni tine:Carni tine 0.085 0.157 0.008 0.011 1.840 0.216 0.001
Alanine 184.292 346.465 11.641 51.512 1.880 0.304 0.012
Aspartate 1579.658 1085.088 229.502 164.709 0.687 0.144 0.111
ATP:ADP 2166.666 1740.753 143.017 179.089 0.803 0.098 0.093
Carni tine 727.645 588.979 24.802 47.980 0.809 0.071 0.039
Chol ine 172.336 151.675 4.305 13.677 0.880 0.082 0.218
Cr 5004.638 4566.807 253.241 350.745 0.913 0.084 0.335
Formate 56.937 46.619 4.349 5.374 0.819 0.113 0.166
Glucose 3995.005 4756.707 116.177 349.346 1.191 0.094 0.065
Glutamate 1555.795 2175.553 44.649 247.960 1.398 0.164 0.082
Glutamate:Glutamine 0.939 1.553 0.316 0.175 1.654 0.586 0.102
Glutamine 1260.025 1453.667 28.830 164.807 1.154 0.133 0.378
Glycine 241.444 244.072 11.843 15.155 1.011 0.080 0.894
Isoleucine 15.024 18.150 1.968 2.567 1.208 0.233 0.357
Lactate (NMR) 258.184 474.852 8.378 102.006 1.839 0.400 0.088
NAD(H) 360.307 350.481 16.998 25.487 0.973 0.084 0.755
PCr (1-H NMR) 1439.099 1611.598 209.440 216.570 1.120 0.222 0.580
PCr+Cr 6134.592 5877.095 285.288 396.999 0.958 0.079 0.610
PCR:Cr 0.293 0.367 0.048 0.058 1.254 0.287 0.349
Phosphochol ine 254.978 238.725 6.298 13.434 0.936 0.058 0.333
Succinate (NMR) 26.445 36.645 2.607 5.632 1.386 0.253 0.131
Taurine 13053.329 12473.683 547.440 649.724 0.956 0.064 0.511
P-valueMetabolite
Mean (nmol/g wet wt) SEM
Fold Change Propagated SEM
Vehicle TPI Vehicle TPI
Alpha ketoglutarate 0.005 0.004 0.001 0.001 0.871 0.152 0.434
Citrate 1.265 4.354 0.496 1.228 3.442 1.664 0.065
Fumarate 1.313 3.285 0.310 0.890 2.501 0.898 0.076
Isocitrate 0.529 0.925 0.051 0.076 1.749 0.222 0.001
Lactate 69.433 75.747 12.544 8.650 1.091 0.233 0.679
Malate 8.375 12.607 1.011 1.617 1.505 0.265 0.038
Pyruvate 0.064 0.065 0.012 0.013 1.012 0.268 0.966
Succinate 24.344 31.288 5.134 10.185 1.285 0.499 0.550
Metabolite P-value
Mean (nmol/g wet wt) SEM





8.9 Transient Negative Inotropy (TNI) 1H NMR metabolomics (Chapter 5) 
 
 




Vehicle TNI Vehicle TNI
Acetate 149.617 136.789 7.806 12.237 0.914 0.095 0.422
Acetylcarnitine 43.040 43.679 1.863 2.019 1.015 0.064 0.827
Acetylcarnitine:Carnitine 0.071 0.093 0.006 0.012 1.307 0.195 0.206
Alanine 205.433 251.664 34.943 30.179 1.225 0.255 0.340
Aspartate 1549.437 1934.542 133.362 388.353 1.249 0.273 0.410
ATP:ADP 1870.044 1303.840 128.734 184.904 0.697 0.110 0.036
Carnitine 597.459 528.847 23.785 51.732 0.885 0.093 0.290
Choline 146.495 119.239 14.363 10.838 0.814 0.109 0.157
Cr 4505.913 3864.794 85.948 198.289 0.858 0.047 0.031
Formate 34.368 33.514 1.957 3.153 0.975 0.107 0.832
Glucose 3081.380 3085.647 45.803 150.871 1.001 0.051 0.984
Glutamate 1217.916 1080.350 55.042 93.210 0.887 0.086 0.260
Glutamate:Glutamine 0.984 0.795 0.071 0.044 0.808 0.073 0.044
Glutamine 1248.925 1389.602 40.395 154.220 1.113 0.129 0.441
Glycine 196.262 202.019 8.822 16.533 1.029 0.096 0.799
Isoleucine 21.220 20.829 1.395 2.499 0.982 0.134 0.900
Lactate (NMR) 291.576 358.694 27.220 65.768 1.230 0.253 0.420
NAD(H) 292.474 280.282 34.057 35.935 0.958 0.166 0.814
PCr (1-H NMR) 888.006 980.132 42.090 124.098 1.104 0.149 0.547
PCr+Cr 5437.041 4637.571 197.665 224.930 0.853 0.052 0.028
PCR:Cr 0.191 0.259 0.011 0.014 1.355 0.104 0.028
Phosphocholine 203.613 191.261 8.458 15.068 0.939 0.084 0.517
Succinate (NMR) 22.111 25.024 1.286 4.406 1.132 0.210 0.575
Taurine 11710.966 9887.421 717.111 723.480 0.844 0.081 0.111
P-ValueMetabolite
Mean (nmol/g wet wt) SEM
Fold Change Propagated SEM
Vehicle TNI Vehicle TNI
Alpha ketoglutarate 0.004 0.002 0.001 0.000 0.535 0.127 0.045
Citrate 1.688 1.915 0.461 0.524 1.135 0.439 0.749
Fumarate 0.886 2.021 0.054 0.314 2.280 0.381 0.013
Isocitrate 0.363 0.279 0.044 0.033 0.768 0.130 0.165
Lactate 65.310 80.923 13.365 19.538 1.239 0.392 0.517
Malate 5.730 8.799 0.531 0.643 1.535 0.181 0.002
Pyruvate 0.392 1.562 0.252 0.449 3.986 2.806 0.062
Succinate 1.573 6.142 0.268 1.503 3.905 1.164 0.037
Metabolite P-value
Mean (nmol/g wet wt) SEM









              N values are post-outlier removal. Table continued overleaf. 
Mean MDV SEM N Mean MDV SEM N
6 0.643
0.148 0.027 6 0.314
m+4 0.107 0.003 3 0.128 0.030
0.268
m+2 0.197 0.019 5 0.158 0.030 6 0.327
0.068 6 0.455
m+1 0.126 0.057 4 0.196 0.007 4
Oxaloacetate
m+0 0.430 0.060 5 0.358
m+3 0.108 0.026 5
4 0.261
m+5 0.198 0.040 5 0.304 0.015 5 0.039
m+4 0.164 0.014 5 0.185 0.006
5 0.006
m+3 0.173 0.008 5 0.158 0.006 4 0.209
m+2 0.171 0.003 3 0.128 0.008
0.318
m+1 0.116 0.004 3 0.090 0.007 6 0.034
5 0.251
Glutamate
m+0 0.200 0.029 4 0.160 0.024 6
m+4 0.228 0.010 4 0.262 0.022
5 0.071
m+3 0.202 0.014 5 0.221 0.014 6 0.379
m+2 0.227 0.005 5 0.209 0.007
0.125
m+1 0.188 0.005 4 0.158 0.003 4 0.001
5 0.009
Aspartate
m+0 0.169 0.024 5 0.124 0.013 6
m+3 0.398 0.039 5 0.534 0.010
0.047
m+2 0.062 0.005 5 0.058 0.001 6 0.390
0.012 6 0.002
m+1 0.098 0.004 4 0.079 0.006 6
0.345 0.027 6 0.442
Alanine
m+0 0.434 0.027 5 0.314
0.345
m+2 0.076 0.002 5 0.077 0.004 6 0.865
0.016 5 0.257
m+1 0.115 0.010 5 0.104 0.003 5
Lactate
m+0 0.510 0.043 5 0.453
m+3 0.300 0.054 5
6 0.969
m+3 0.219 0.021 5 0.021 0.020 5 0.594
m+2 0.076 0.005 5 0.076 0.003
0.091
m+1 0.088 0.001 4 0.086 0.006 6 0.798
5 0.013
Pyruvate
m+0 0.640 0.007 4 0.575 0.027 6
m+3 0.085 0.017 4 0.183 0.022
6 0.807
m+2 0.093 0.065 4 0.145 0.040 6 0.493
0.083 0.009 6 0.198












     N values are post-outlier removal. 





m+4 0.158 0.023 5 0.2549 0.02077
6 0.202
m+3 0.169 0.013 5 0.189 0.01831 6 0.402
m+2 0.191 0.007 4 0.1633 0.01511
0.110
m+1 0.175 0.011 5 0.1508 0.00679 5 0.110
5 0.029
Malate
m+0 0.175 0.011 5 0.1508 0.00679 5
m+4 0.102 0.002 4 0.1687 0.0214
6 0.593
m+3 0.134 0.005 5 0.1591 0.004063 5 0.004
m+2 0.098 0.010 5 0.08953 0.01112
0.015
m+1 0.163 0.004 4 0.146 0.005385 5 0.049
6 0.046
Fumarate
m+0 0.506 0.017 5 0.4165 0.02299 6
0.1626 0.01073 6 0.873
m+4 0.163 0.028 4 0.2691 0.03132
0.334
m+2 0.261 0.018 5 0.1892 0.01141 5 0.011
0.01787 6 0.395
m+1 0.113 0.006 4 0.1057 0.004632 5
Succinate
m+0 0.242 0.010 4 0.2629
m+3 0.165 0.002 3
6 0.485
m+5 0.226 0.034 4 0.2063 0.01291 6 0.551
m+4 0.115 0.043 4 0.1493 0.02635
6 0.065
m+3 0.152 0.005 3 0.1448 0.006011 4 0.446
m+2 0.126 0.017 4 0.1799 0.01701
0.189
m+1 0.074 0.017 5 0.05355 0.005787 5 0.294
6 0.309
α-ketoglutarate
m+0 0.124 0.016 4 0.09851 0.005897 4
m+6 0.101 0.031 5 0.1396 0.01964
6 0.065
m+5 0.201 0.028 5 0.2251 0.01745 6 0.457
m+4 0.126 0.017 4 0.1799 0.01701
5 0.766
m+3 0.174 0.005 3 0.1345 0.01757 6 0.176
m+2 0.108 0.013 5 0.1081 0.004395
0.910
m+1 0.107 0.008 4 0.05547 0.002841 4 0.001
6 0.082
Isocitrate
m+0 0.139 0.017 4 0.1425 0.02434 6
m+6 0.092 0.016 5 0.1521 0.02465
6 0.643
m+5 0.123 0.018 5 0.1696 0.008289 6 0.035
m+4 0.107 0.003 3 0.1277 0.0295
5 0.025
m+3 0.108 0.026 5 0.1476 0.0266 6 0.314
m+2 0.139 0.004 4 0.1263 0.002416
0.039
m+1 0.145 0.014 5 0.1151 0.008729 6 0.101
Citrate










        N values are post-outlier removal. 
 
 
8.13 13C isotopologue mass distribution vectors by LC-MS/MS (Chapter 6). 
 
Metabolite Isotopologue 
Vehicle High [Na]i 
P value 
Mean (MDV) SEM N Mean SEM N 
Fumarate 
m+0 0.3534 0.03498 5 0.2409 0.02011 6 <0.0001 
m+1 0.1317 0.01216 5 0.09444 0.01525 6 0.1232 
m+2 0.1917 0.005102 5 0.1768 0.008075 5 0.5509 
m+3 0.162 0.01204 5 0.198 0.005085 4 0.177 
m+4 0.1884 0.006703 4 0.2486 0.0212 5 0.0271 
Isocitrate 
m+0 0.1308 0.04298 5 0.07586 0.004017 6 0.1316 
m+1 0.04724 0.007015 4 0.02604 0.003524 6 0.5818 
m+2 0.1448 0.01933 4 0.09587 0.01349 6 0.206 
m+3 0.1526 0.01248 4 0.1214 0.01706 6 0.4185 
m+4 0.2918 0.03483 4 0.2202 0.04801 6 0.0668 
m+5 0.2621 0.03992 5 0.3322 0.02597 6 0.0557 
m+6 0.06074 0.01666 4 0.09359 0.01073 5 0.4123 
Malate 
m+0 0.3723 0.0389 5 0.2616 0.02112 6 0.0148 
m+1 0.1174 0.01008 5 0.168 0.04279 6 0.2516 
m+2 0.1819 0.00717 5 0.1159 0.01663 6 0.1372 
m+3 0.1701 0.009217 4 0.1899 0.01504 6 0.6715 
m+4 0.1981 0.007252 4 0.3068 0.05892 6 0.0239 
 
   N values are post-outlier removal. 
Mean enrichment SEM N Mean enrichment SEM N
DHAP 0.414 0.023 4 0.469 0.018 5 0.098
Pyruvate 0.270 0.008 4 0.311 0.020 5 0.133
Lactate 0.384 0.052 5 0.430 0.025 6 0.421
Alanine 0.467 0.038 5 0.603 0.009 5 0.008
Aspartate 0.546 0.546 4 0.583 0.018 5 0.171
Glutamate 0.560 0.038 4 0.596 0.024 5 0.430
Citrate 0.366 0.019 4 0.488 0.026 6 0.009
Isocitrate 0.514 0.028 5 0.563 0.028 6 0.258
α-ketoglutarate 0.523 0.015 3 0.559 0.007 5 0.048
Succinate 0.500 0.018 4 0.500 0.012 5 0.980
Fumarate 0.276 0.012 5 0.366 0.021 5 0.006








8.14  13C mean enrichment by LC-MS/MS (Chapter 6). 
 
Metabolite 
Vehicle High [Na]i 
P value 
Mean SEM N Mean SEM N 
Fumarate 0.4338 0.003799 3 0.5580 0.3939 6 0.0684 
Isocitrate 0.5196 0.03949 4 0.6490 0.02229 6 0.0148 
Malate 0.4451 0.01050 4 0.5489 0.03928 6 0.0706 
   N values are post-outlier removal. 
8.15  M+0 raw LC-MS/MS counts (Chapter 6) 
 
Metabolite 
Vehicle High [Na]i 
P value 
Mean SEM N Mean SEM N 
Pyruvate 6360 1768 5 8488.0000 1763 6 0.4202 
Lactate 2.08E+06 444623 5 2462000.0000 502795 6 0.5913 
Citrate 2.47E+06 397450 4 3.39E+06 527028 6 0.2454 
Succinate 3.74E+06 1.34E+06 5 2.50E+06 668981 6 0.4039 
α-ketoglutarate 58460 12514 5 62250 8892 6 0.8059 
   N values are post-outlier removal. 
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